

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 July 2002 (04.07.2002)

PCT

(10) International Publication Number
WO 02/051831 A1

(51) International Patent Classification⁷: C07D 401/00,
213/30, 333/16, 333/58, A61K 31/38, 31/435

(21) International Application Number: PCT/EP01/14842

(22) International Filing Date:
15 December 2001 (15.12.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
00128477.7 23 December 2000 (23.12.2000) EP

(71) Applicant: AVENTIS PHARMA DEUTSCHLAND
GMBH [DE/DE]; Brüningstrasse 50, 65929 Frankfurt
(DE).

(72) Inventors: NAZARE, Marc; Schützenstrasse 7, 65817 Eppstein (DE). WILL, David, William; Kirchstrasse 21, 65830 Kriftel (DE). PEYMAN, Anuschirwan; Zeilsheimer Strasse 46, 65779 Kelkheim (DE). MATTER, Hans; Feldbergring 37, 63505 Langenselbold (DE). ZOLLER, Gerhard; Höhenstrasse 8, 61137 Schöneck (DE). GERLACH, Uwe; Im Heideck 30, 65795 Hattersheim (DE).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.



WO 02/051831 A1


(54) Title: OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS

(57) **Abstract:** The present invention relates to compounds of the formula I, R⁰-Q-X-Q'-W-U-V-G-M (I) in which R⁰; Q; X; Q'; W; U, V, G and M have the meanings indicated in the claims. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (Fxa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

Description

OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS

- 5 The present invention relates to compounds of the formula I,



in which R^0 ; Q; X; Q'; W ;U, V, G, M have the meanings indicated below. The compounds of the formula I are valuable pharmacologically active compounds. They exhibit a strong antithrombotic effect and are suitable, for example, for the therapy and prophylaxis of

10 cardiovascular disorders like thromboembolic diseases or restenoses. They are reversible inhibitors of the blood clotting enzymes factor Xa (FXa) and/or factor VIIa (FVIIa), and can in general be applied in conditions in which an undesired activity of factor Xa and/or factor VIIa is present or for the cure or prevention of which an inhibition of factor Xa and/or factor VIIa is intended. The invention furthermore relates to processes 15 for the preparation of compounds of the formula I, their use, in particular as active ingredients in pharmaceuticals, and pharmaceutical preparations comprising them.

Normal haemeostasis is the result of a complex balance between the processes of clot initiation, formation and clot dissolution. The complex interactions between blood cells, 20 specific plasma proteins and the vascular surface, maintain the fluidity of blood unless injury and blood loss occurs (EP-A-987274). Many significant disease states are related to abnormal haemeostasis. For example, local thrombus formation due to rupture of atheroslerotic plaque is a major cause of acute myocardial infarction and unstable angina. Treatment of an occlusive coronary thrombus by either thrombolytic therapy or 25 percutaneous angioplasty may be accompanied by acute thrombolytic reclosure of the affected vessel.

There continues to be a need for safe and effective therapeutic anticoagulants to limit or prevent thrombus formation. It is most desirable to develop agents that inhibit 30 coagulation without directly inhibiting thrombin but by inhibiting other steps in the coagulation cascade like factor Xa and/or factor VIIa activity. It is now believed that inhibitors of factor Xa carry a lower bleeding risk than thrombin inhibitors (A. E. P. Adang & J. B. M. Rewinkel, Drugs of the Future 2000, 25, 369-383).

Low molecular weight, factor Xa-specific blood clotting inhibitors that are effective but do not cause unwanted side effects have been described, for example, in WO-A-95/29189.

However, besides being an effective factor Xa-specific blood clotting inhibitor, it is

desirable that such inhibitors also have further advantageous properties, for instance

5 stability in plasma and liver and selectivity versus other serine proteases whose inhibition is not intended, such as thrombin. There is an ongoing need for further low molecular weight factor Xa specific blood clotting inhibitors, which are effective and have the above advantages as well.

10 Specific inhibition of the factor VIIa/tissue factor catalytic complex using monoclonal antibodies (WO-A-92/06711) or a protein such as chloromethyl ketone inactivated factor VIIa (WO-A-96/12800, WO-A-97/47651) is an extremely effective means of controlling thrombus formation caused by acute arterial injury or the thrombotic complications related to bacterial septicaemia. There is also experimental evidence suggesting that


15 inhibition of factor VIIa/tissue factor activity inhibits restenosis following balloon angioplasty. Bleeding studies have been conducted in baboons and indicate that

inhibition of the factor VIIa/tissue factor complex has the widest safety window with respect to therapeutic effectiveness and bleeding risk of any anticoagulant approach tested including thrombin, platelet and factor Xa inhibition. Certain inhibitors of factor VIIa

20 have already been described. EP-A-987274, for example discloses compounds containing a tripeptide unit, which inhibit factor VIIa. However, the property profile of these compounds is still not ideal, and there is an ongoing need for further low molecular weight factor VIIa inhibitory blood clotting inhibitors.

25 The present invention satisfies the above needs by providing novel compounds of the formula I which exhibit factor Xa and/or factor VIIa inhibitory activity and are favourable agents for inhibiting unwanted blood clotting and thrombus formation.

I) Thus, the present invention relates to compounds of the formula I,



wherein

R^0 is 1. a monocyclic or bicyclic 5- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^2 , or

2. a monocyclic or bicyclic 5- to 14-membered heteroaryl, containing zero, one, two, three or four heteroatoms chosen from nitrogen, sulphur or oxygen,

wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R²,

R² is halogen, -NO₂, -CN, -C(O)-NH₂, -OH, -NH₂, -NH-C(O), -NH-C(O)-(C₁-C₈)-alkyl, -NH-C(O)-(C₁-C₈)-alkyl, -(C₁-C₈)-alkyl, wherein alkyl in each case is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH₂, -OH or a methoxy residue, or -(C₁-C₈)-alkyloxy, wherein alkyloxy is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH₂, -OH or a methoxy residue,

Q and Q' are independently of one another identical or different and are a direct bond, -(CH₂)_r-O-CH₂_s-, wherein r and s are independently from each other the integers zero, 1, 2 or 3, -C(O)-; -O-, -NR¹⁰-, -C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -S-, -S(O)-, -SO₂-, -NR¹⁰-SO₂-, -SO₂-NR¹⁰-, -(C₁-C₆)-alkylene, wherein alkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH₂ or -OH; or -(C₃-C₆)-cycloalkylene, wherein cycloalkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -NH₂ or -OH;

X is a direct bond, a 3- to 7-membered heteroaryl, -(C₁-C₆)-alkylene, wherein alkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -NH₂ or -OH; or-(C₃-C₆)-cycloalkylene, wherein cycloalkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, -NH₂ or -OH;

provided that when Q or Q' is -(C₁-C₆)-alkylene then X is -O-, -S-, -NR¹⁰-, -C(O)-, -C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -S(O)-, -SO₂-, -NR¹⁰-SO₂- or -SO₂-NR¹⁰-; with the proviso that if X is a direct bond, the fragment -Q-X-Q'- is not O-O, O-S, S-O, S-S, SO₂-SO₂, SO-SO, SO-SO₂, SO₂-SO, SO₂-S, S-SO₂, SO-S, S-SO; with the proviso that if X is oxygen atom or sulphur atom, then Q and Q' are not oxygen atom or sulphur atom; and with the further proviso that if X is S(O) or SO₂, then Q and Q' are not oxygen atom or sulphur atom;

W is 1. a 5- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,
2. a 5- to 14-membered heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,

3. a 4-to 15 membered mono- or polycyclic group, wherein said mono- or polycyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹, or
4. a 4-to 15 membered mono- or polycyclic group, containing one, two, three or four heteroatoms, such as nitrogen, sulphur or oxygen, wherein said mono- or polycyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,

5 provided that if W is a six membered aryl or heteroaryl group, then Q' and U are not in an ortho position with respect to each other;

- 10 R¹ is 1. halogen,
2. -NO₂,
3. -CN,
4. -NR⁴R⁵, wherein R⁴ and R⁵ are defined below,
5. -O-(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or
15 trisubstituted independently of one another by R¹³,
6. -OH,
7. -SO₂-NH₂,
8. (C₁-C₈)-alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
- 20 9. (C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
- 10 (C₁-C₈)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
- 25 11. hydroxycarbonyl-(C₁-C₈)-alkylureido-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
12. (C₁-C₈)-alkyloxycarbonyl-(C₁-C₈)-alkylureido-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
- 30 13. (C₁-C₈)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
14. -NH-C(O),
15. -NH-C(O)-(C₁-C₈)-alkyl,
16. -NH-C(O)-(C₁-C₈)-alkyl,
17. -C(O)-NR⁴R⁵, wherein R⁴ and R⁵ are defined below,

18. -COOH;
 19. -C(O)-(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 20. -C(O)-O-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 21. -C(O)-NR¹¹R¹²,
 22. -C(NH)-NH₂,
 23. -NH-C(O)-NH₂,
 24. -S-(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 25. -(C₁-C₈)-alkylthio, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, or
 26. R¹¹R¹²N-, or

two R¹ residues bonded to adjacent ring carbon atoms together with the carbon atoms to which they are bonded form a dioxalane ring or an aromatic ring condensed to W, where the ring formed by the two R¹ residues is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³.

R^{11} and R^{12} together with the nitrogen atom to which they are bonded form a saturated or unsaturated 5- to 6-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R^{11} and R^{12} can contain one or two identical or different ring heteroatoms chosen from oxygen, sulphur and nitrogen, and in which

one or two of the ring carbon atoms can be substituted by oxo to form -C(O)-residue(s),

25 R¹³ is halogen, -NO₂, -CN, -OH, -(C₁-C₈)-alkyl, -(C₁-C₈)-alkyloxy, -CF₃, -C(O)-NH₂, -NH₂ or the residue V-G-M, wherein V, G and M are as defined below.

R^{10} is hydrogen atom or $-(C_1-C_4)\text{-alkyl}$.

U and **G** are independently of one another identical or different and are a direct band.

$-(\text{CH}_2)_m-$, $-(\text{CH}_2)_m-\text{O}-(\text{CH}_2)_n-$, $-(\text{CH}_2)_m-\text{C}(\text{O})-\text{NR}^{10}-$ $(\text{CH}_2)_n-$, $-(\text{CH}_2)-\text{SO}_2-(\text{CH}_2)_n-$,

30 $-(\text{CH}_2)_m-\text{NR}^{10}-\text{C}(\text{O})-\text{NR}^{10}-(\text{CH}_2)_n-$, $-(\text{CH}_2)_m-\text{NR}^{10}-\text{C}(\text{O})-(\text{CH}_2)_n-$, $-(\text{CH}_2)-\text{S}-(\text{CH}_2)_n-$,

$-(CH_2)_m-C(O)-(CH_2)_n-$, $-(CH_2)_m-SO_2-NR^{10}-(CH_2)_n-$, $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n-$,

$$-(\text{CH}_2)_m-\text{NR}^{10}-\text{SO}_2-\text{NR}^{10}-(\text{CH}_2)_n, \quad -(\text{CH}_2)_m-\text{CH(OH)}-(\text{CH}_2)_n,$$

$$-(\text{CH}_2)_m-\text{O}-\text{C}(\text{O})-\text{NR}^{10}-(\text{CH}_2)_n \text{ or } -(\text{CH}_2)_n-\text{NR}^{10}-\text{C}(\text{O})-\text{O}-(\text{CH}_2)_m-$$

$$\Sigma_{\text{m}} = \cup_{n=1}^{\infty} \Sigma_n = \cup_{m=1}^{\infty} \cup_{n=1}^{2^m} \Sigma_n = \cup_{(m,n) \in \mathbb{N}^2} \Sigma_{(m,n)}.$$

n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6, wherein the alkylene residues which are formed by -(CH₂)_m- or -(CH₂)_n- are unsubstituted or mono-, di- or trisubstituted independently of one another by -(C₁-C₄)-alkyl; -C(O)-OH, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵, -SO₂, -NR⁴R⁵ or -(C₁-C₈)-alkylsulfonyl,

5 R⁴ and R⁵ are independently of one another identical or different and are hydrogen atom; -(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or tri-substituted independently of one another by R¹³, -(C₆-C₁₄)-aryl-(C₁-C₄)-alkyl-, wherein alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, -(C₆-C₁₄)-aryl-, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -(C₆-C₁₄)-heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³ or -(C₆-C₁₄)-heteroaryl-(C₁-C₄)-alkyl-, wherein alkyl and heteroaryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, or

10 R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a saturated 5- to 7-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R⁴ and R⁵ can contain one or two identical or different ring heteroatoms chosen from oxygen, sulphur and nitrogen; wherein said heterocyclic ring is

15 unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

- V is
1. a direct bond,
 2. -(C₁-C₆)-alkylene, which is branched or unbranched and which is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, =O, -CN, -OH, -NR⁴R⁵, -C(O)-OH, -C(O)-O-(C₁-C₄)-alkyl, -SO₂-NR⁴R⁵, -C(O)-NR⁴R⁵ or -(C₁-C₈)-alkylsulfonyl,
 3. a 3- to 7-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
 4. a 6- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or
 5. a heteroaryl, wherein said heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R^{14} is R^1 , halogen, -OH, -NR⁴R⁵, =O, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkoxyl, -NO₂, -C(O)-OH, -CN, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵, -(C₁-C₈)-alkylsulfonyl, -O-heteroaryl, -NR¹⁰-C(O)-NH-(C₁-C₈)-alkyl, -NR¹⁰-C(O)-NH-[(C₁-C₈)-alkyl]₂, -SO₂-NR⁴R⁵, -SR⁴, or -SO₂, wherein R⁴, R⁵ and R¹⁰ are as defined above, and

- 5 M is 1. a hydrogen atom,
2. -(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
3. -C(O)-NR⁴R⁵,
4. -(C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
10 5. -(C₆-C₁₄)-heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
6. a 3- to 7-membered cyclic group, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
15 7. a 3- to 7-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, wherein R¹⁴ is defined above,
20 8. -NH-CH(NA¹)(NA²), wherein A¹ and A² are independently of one another identical or different and are a hydrogen atom or -(C₁-C₈)-alkyl, or A¹ and A² together with the nitrogen atom to which they are each bonded form a saturated 5- or 6-membered monocyclic heterocyclic ring, which is saturated or aromatic, or
25 9. -CH(NA¹)(NA²), wherein A¹ and A² are independently of one another identical or different and are hydrogen atom or -(C₁-C₈)-alkyl, or A² together with the nitrogen atom to which it is bonded forms a saturated 5- or 6-membered monocyclic heterocyclic ring, which contains 2 nitrogen atoms and is saturated or aromatic,
30 in all its stereoisomeric forms and mixtures thereof in any ratio, polymorph forms and mixtures thereof in any ratio and its physiologically tolerable salts.

II) Preferred are compounds of the formula I, wherein

R^0 is phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^2 ,

5 pyridyl, wherein pyridyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^2 ,

pyrimidyl, wherein pyrimidyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^2 , or

naphthyl, wherein naphthyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^2 ,

10 R^2 is as defined above and wherein the alkyl- or alkyloxy residue is unsubstituted or mono-, di- or trisubstituted independently of one another by an amino residue or a methoxy residue,

Q and Q' are as defined above and wherein the alkylene- or cycloalkylene residue is unsubstituted or mono-, di- or trisubstituted independently of one another by $-NH_2$ or $-OH$;

15 X is as defined above,

W is phenyl, pyridyl, pyrimidyl, benzoxazole, benzthiazole, indole, benzo[1,3]dioxole, or naphthyl, wherein W is unsubstituted or mono-, di- or trisubstituted independently of one another by R^1 ,

20 provided that if W is a six membered aryl or heteroaryl group, Q' and U are not in an ortho position with respect to each other;

R^1 , R^{10} , R^{11} , R^{12} and R^{13} are as defined above,

U and G are independently of one another identical or different and are a direct bond,

$-(CH_2)_m$, $-(CH_2)_m-O-(CH_2)_n-$, $-(CH_2)_m-C(O)-NR^{10}-(CH_2)_n$,

25 $-(CH_2)_m-NR^{10}-C(O)-NR^{10}-(CH_2)_n$, $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n$, $-(CH_2)_m-C(O)-(CH_2)_n$,

$-(CH_2)-S-(CH_2)_n$, $-(CH_2)_m-SO_2-NR^{10}-(CH_2)_n$, $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n$,

$-(CH_2)_m-NR^{10}-SO_2-NR^{10}-(CH_2)_n$ or $-(CH_2)_m-CH(OH)-(CH_2)_n$,

wherein n, m, R^4 and R^5 are as defined above,

V and M are as defined above,

30 in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically tolerable salts.

III) Especially preferred are compounds of the formula I, wherein

R⁰ is phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R²,

5 pyridyl, wherein pyridyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R²,

pyrimidyl, wherein pyrimidyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R², or

naphthyl, wherein naphthyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R²,

10 R² is halogen, -CN, -NH₂, -C(O)-NH₂, -(C₁-C₄)-alkyl, or -(C₁-C₄)-alkyloxy, wherein the alkyl- or alkyloxy residue is unsubstituted or mono-, di- or trisubstituted independently of one another by an amino residue or a methoxy residue,

Q and Q' are independently of one another identical or different and are a direct bond, -C(O)-; -O-, -NR¹⁰-, -C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -SO₂-, -NR¹⁰-SO₂-, -SO₂-NR¹⁰-,

15 -(C₁-C₄)-alkylene, wherein alkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen; or -(C₃-C₆)-cycloalkylene, wherein cycloalkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen;

X is a direct bond, -(C₁-C₃)-alkylene, wherein alkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen; or -(C₃-C₆)-cycloalkylene, wherein cycloalkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen;

provided that when Q or Q' is -(C₁-C₃)-alkylene then X is -O-, -NR¹⁰-, -C(O)-, -C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -SO₂-, -NR¹⁰-SO₂- or -SO₂-NR¹⁰-;

25 with the proviso that if X is a direct bond, the fragment -Q-X-Q'- is not O-O, SO₂-SO₂, or SO-SO₂; and

with the proviso that if X is oxygen atom, then Q and Q' are not oxygen atom or sulphur atom; and

30 with the further proviso that if X is SO₂, then Q and Q' are not oxygen atom or sulphur atom;

W is phenyl, pyridyl, pyrimidyl, benzoxazole, benzthiazole, indole, benzo[1,3]dioxole, or naphthyl, wherein W is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,

provided that if W is a six membered aryl or heteroaryl group, Q' and U are not in an ortho position with respect to each other;

R¹ is 1. halogen,

2. -NO₂,

5 3. -CN,

4. -NH₂,

10 5. (C₁-C₆)-alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

6. -OH,

15 7. -SO₂-NH₂,

8. (C₁-C₆)-alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

9. (C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

15 10 (C₁-C₆)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

11. hydroxycarbonyl-(C₁-C₆)-alkylureido-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

12. (C₁-C₆)-alkyloxycarbonyl-(C₁-C₆)-alkylureido-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

20 13. (C₁-C₆)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

14. bis[(C₁-C₆)-alkyl]amino, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

25 15. -C(O)-NH₂,

16. -C(O)-OH,

17. -C(O)-(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

30 18. -C(O)-NH-(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

19. -C(O)-NH-[(C₁-C₆)-alkyl]₂, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

20. -C(NH)-NH₂,

21. ureido,

22. $-(C_1-C_6)$ -alkylthio, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , or

23. $R^{11}R^{12}N-$, or

5 two R^1 residues bonded to adjacent ring carbon atoms together with the carbon atoms to which they are bonded form an aromatic ring condensed to W, where the ring formed by the two R^1 residues is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,

10 R^{11} and R^{12} together with the nitrogen atom to which they are bonded form a saturated or unsaturated 5- to 6-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R^{11} and R^{12} can contain one or two identical or different ring heteroatoms chosen from oxygen, sulphur and nitrogen, and in which

15 one or two of the ring carbon atoms can be substituted by oxo to form $-C(O)-$ residue(s),

R^{13} is halogen, $-CN$, $-(C_1-C_6)$ -alkyl, $-(C_1-C_6)$ -alkyloxy, $-CF_3$, $-C(O)-NH_2$ or $-NH_2$,

R^{10} is hydrogen atom or $-(C_1-C_4)$ -alkyl,

U and G are independently of one another identical or different and are a direct bond,

$-(CH_2)_m$, $-(CH_2)_m-O-(CH_2)_n$, $-(CH_2)_m-C(O)-NR^{10}-$ $-(CH_2)_n$,

20 $-(CH_2)_m-NR^{10}-C(O)-NR^{10}-$ $-(CH_2)_n$, $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n$, $-(CH_2)_m-C(O)-(CH_2)_n$,

$-(CH_2)-S-(CH_2)_n$, $-(CH_2)_m-SO_2-NR^{10}-$ $-(CH_2)_n$, $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n$, or

$-(CH_2)_m-NR^{10}-SO_2-NR^{10}-$ $-(CH_2)_n$,

n and m are independently of one another identical or different and are the integers zero, 1, 2 or 3, wherein the alkylene residues are unsubstituted or mono-, di- or

25 trisubstituted independently of one another by $-(C_1-C_4)$ -alkyl; $-C(O)-OH$,

$-C(O)-O-(C_1-C_4)$ -alkyl, $-C(O)-NR^4R^5$, $-SO_2$, $-NR^4R^5$ or $-(C_1-C_8)$ -alkylsulfonyl,

R^4 and R^5 are independently of one another identical or different and are hydrogen

atom, $-(C_1-C_6)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or

trisubstituted independently of one another by R^{13} , $-(C_6-C_{14})$ -aryl-(C_1-C_4)-alkyl-,

wherein alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R^{13} , $-(C_6-C_{14})$ -aryl-, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , $-(C_6-C_{14})$ -heteroaryl,

wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of

one another by R¹³ or -(C₆-C₁₄)-heteroaryl-(C₁-C₄)-alkyl-, wherein alkyl and heteroaryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, or

R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a saturated 5- to 7-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R⁴ and R⁵ can contain one or two identical or different ring heteroatoms chosen from oxygen, sulphur and nitrogen; wherein said heterocyclic ring is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

V is 1. a direct bond,

10 2. -(C₁-C₄)-alkylene, which is branched or unbranched and which is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, =O, -CN, -OH, -NR⁴R⁵, -C(O)-OH, -C(O)-O-(C₁-C₄)-alkyl, -SO₂,

-NR⁴R⁵, -C(O)-NR⁴R⁵ or -(C₁-C₈)-alkylsulfonyl,

15 3. a 5- to 7-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

20 4. a 6- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or

5. a heteroaryl, wherein said heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R¹⁴ is halogen, -OH, -NR⁴R⁵, =O, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkoxyl, -NO₂, -C(O)-OH, -CN, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵, -(C₁-C₈)-alkylsulfonyl, -C(O)-NR⁴R⁵,

-SO₂-NR⁴R⁵, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH-[(C₁-C₈)-alkyl]₂,

25 -NR¹⁰-C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH₂ or -NR¹⁰-C(O)-NH-[(C₁-C₈)-alkyl]₂,

wherein R⁴, R⁵ and R¹⁰ are as defined above, and

M is 1. a hydrogen atom,

2. -(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

3. -C(O)-NR⁴R⁵,

4. -(C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

- 5. $-(C_6-C_{14})$ -heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,
 - 6. a 5- to 7-membered cyclic group, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} , or
 - 7. a 5- to 7-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} , wherein R^{14} is defined above,
- 10 in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically tolerable salts.

IV) Further preferred are compounds of the formula I, wherein

- 15 R^0 is phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^2 , or pyridyl, wherein pyridyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^2 ,
- R^2 is halogen, -CN, $-C(O)-NH_2$, $-(C_1-C_4)$ -alkyl, or $-(C_1-C_4)$ -alkyloxy, wherein the alkyl- or 20 alkyloxy residue is unsubstituted or mono-, di- or trisubstituted independently of one another by an amino residue or a methoxy residue,
- Q and Q' are independently of one another identical or different and are a direct bond, $-C(O)-$; $-O-$, $-NR^{10}-$, $-C(O)-NR^{10}-$, $-NR^{10}-C(O)-$, $-SO_2-$, $-NR^{10}-SO_2-$, $-SO_2-NR^{10}-$, or $-(C_1-C_4)$ -alkylene,
- 25 X is a direct bond or $-(C_1-C_3)$ -alkylene,
provided that when Q or Q' is $-(C_1-C_3)$ -alkylene then X is $-O-$, $-NR^{10}-$, $-C(O)-$, $-C(O)-NR^{10}-$, $-NR^{10}-C(O)-$, $-SO_2-$, $-NR^{10}-SO_2-$ or $-SO_2-NR^{10}-$;
with the proviso that if X is a direct bond, the fragment $-Q-X-Q'$ is not O-O or SO_2-SO_2 ;
- and with the proviso that if X is oxygen atom, then Q and Q' are not oxygen atom or 30 sulphur atom; and
with the further proviso that if X is SO_2 , then Q and Q' are not oxygen atom or sulphur atom;
- W is phenyl, pyridyl or pyrimidyl, wherein W is unsubstituted or mono-, di- or trisubstituted independently of one another by R^1 ,

provided that Q' and U are not in an ortho position with respect to each other;

- R¹ is
1. halogen,
 2. -NO₂,
 3. -CN,
 4. -NH₂,
 5. (C₁-C₄)-alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 6. -OH,
 7. -SO₂-NH₂,
 10. (C₁-C₄)-alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 9. (C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 10. (C₁-C₄)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 15. hydroxycarbonyl-(C₁-C₄)-alkylureido-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 12. (C₁-C₄)-alkyloxycarbonyl-(C₁-C₄)-alkylureido-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 20. 13. (C₁-C₄)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 14. bis[(C₁-C₄)-alkyl]amino, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 25. 15. -C(O)-NH₂,
 16. -C(O)-OH,
 17. -C(O)-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 18. -C(O)-NH-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 30. 19. -C(O)-NH-[(C₁-C₄)-alkyl]₂, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 20. -C(NH)-NH₂,
 21. ureido,

22. $-(C_1-C_4)$ -alkylthio, wherein alkylthio is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , or
 23. $R^{11}R^{12}N-$, or

two R^1 residues bonded to adjacent ring carbon atoms together with the carbon atoms to which they are bonded form an aromatic ring condensed to W, where the ring formed by the two R^1 residues is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,

R^{11} and R^{12} together with the nitrogen atom to which they are bonded form a saturated or unsaturated 5- to 6-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R^{11} and R^{12} can contain one or two identical or different ring heteroatoms chosen from oxygen, sulphur and nitrogen,

R^{13} is halogen, $-CN$, $-(C_1-C_4)$ -alkyl, $-(C_1-C_4)$ -alkyloxy, $-CF_3$, $-C(O)-NH_2$ or $-NH_2$,
 R^{10} is hydrogen atom or $-(C_1-C_4)$ -alkyl,

U and G are independently of one another identical or different and are a direct bond,

$-(CH_2)_m$, $-(CH_2)_m-C(O)-NR^{10}-(CH_2)_n$, $-(CH_2)_m-NR^{10}-C(O)-NR^{10}-(CH_2)_n$,
 $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n$, $-(CH_2)_m-C(O)-(CH_2)_n$, $-(CH_2)_m-SO_2-NR^{10}-(CH_2)_n$, or
 $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n$,

n and m are independently of one another identical or different and are the integers zero, 1, 2 or 3, wherein the alkylene residues are unsubstituted or mono-, di- or trisubstituted independently of one another by $-(C_1-C_4)$ -alkyl; $-C(O)-OH$,
 $-C(O)-O-(C_1-C_4)$ -alkyl or $-C(O)-NR^4R^5$,

R^4 and R^5 are independently of one another identical or different and are hydrogen atom, $-(C_1-C_6)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , $-(C_6-C_{14})$ -aryl- (C_1-C_4) -alkyl-,
 25 wherein alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R^{13} , $-(C_6-C_{14})$ -aryl-, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , $-(C_6-C_{14})$ -heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} or $-(C_6-C_{14})$ -heteroaryl- (C_1-C_4) -alkyl-, wherein alkyl and heteroaryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R^{13} , or

R^4 and R^5 together with the nitrogen atom to which they are bonded form a saturated 5- to 7-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R^4 and R^5 can contain one or two identical or different ring heteroatoms

chosen from oxygen, sulphur and nitrogen; wherein said heterocyclic ring is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

- V is
1. a direct bond,
 2. -(C₁-C₄)-alkylene, which is branched or unbranched and which is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, =O, -CN, -OH, -NR⁴R⁵, -C(O)-OH, -C(O)-O-(C₁-C₄)-alkyl, -SO₂-NR⁴R⁵, -C(O)-NR⁴R⁵ or -(C₁-C₄)-alkylsulfonyl,
 3. a 5- to 7-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
 4. a 6- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or
 5. a 6- to 14-membered heteroaryl, wherein said heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R¹⁴ is halogen, -OH, -NR⁴R⁵, =O, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkoxyl, -NO₂, -C(O)-OH, -CN, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵, -(C₁-C₈)-alkylsulfonyl, -C(O)-NR⁴R⁵, -SO₂-NR⁴R⁵, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH-[(C₁-C₈)-alkyl]₂, -NR¹⁰-C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH₂ or -NR¹⁰-C(O)-NH-[(C₁-C₈)-alkyl]₂,

wherein R⁴, R⁵ and R¹⁰ are as defined above, and

- M is
1. a hydrogen atom,
 2. -(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
 3. -C(O)-NR⁴R⁵,
 4. -(C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
 5. -(C₆-C₁₄)-heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
 6. a 5- to 7-membered cyclic group, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or
 7. a 5- to 7-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic group is

unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, wherein R¹⁴ is defined above,
in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically tolerable salts.

5

V) Further especially preferred are compounds of the formula I, wherein

R⁰ is phenyl, wherein phenyl is unsubstituted or mono- or disubstituted independently of one another by R², or

10 pyridyl, wherein pyridyl is unsubstituted or mono-, disubstituted independently of one another by R²,

R² is halogen, -CN, -C(O)-NH₂, -(C₁-C₃)-alkyl, or -(C₁-C₃)-alkyloxy, wherein the alkyl- or alkyloxy residue is unsubstituted or mono-, di- or trisubstituted independently of one another by an amino residue or a methoxy residue,

15 Q and Q' are independently of one another identical or different and are a direct bond, -C(O); -O-, -NR¹⁰-, -C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -SO₂-, -NR¹⁰-SO₂-, -SO₂-NR¹⁰-, or -(C₁-C₄)-alkylene,

X is a direct bond or -(C₁-C₃)-alkylene,

provided that when Q or Q' is -(C₁-C₃)-alkylene then X is -O-, -NR¹⁰-, -C(O)-, -C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -SO₂-, -NR¹⁰-SO₂- or -SO₂-NR¹⁰-;

20 with the proviso that if X is a direct bond, the fragment -Q-X-Q'- is not O-O or SO₂-SO₂; and with the proviso that if X is oxygen atom, then Q and Q' are not oxygen atom or sulphur atom; and

25 with the further proviso that if X is SO₂, then Q and Q' are not oxygen atom or sulphur atom;

W is phenyl, pyridyl or pyrimidyl, wherein W is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,

provided that Q' and U are not in an ortho position with respect to each other;

R¹ is 1. halogen,

30 2. -NO₂,

3. -CN,

4. -NH₂,

5. (C₁-C₄)-alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

6. -OH,
7. -SO₂-NH₂,
8. (C₁-C₄)-alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
- 5 9. (C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
10. (C₁-C₄)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
11. (C₁-C₄)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
- 10 12. bis[(C₁-C₄)-alkyl]amino, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
13. -C(O)-NH₂,
14. -C(O)-OH,
- 15 15. -C(O)-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
16. -C(O)-NH-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
17. -C(O)-NH-[(C₁-C₄)-alkyl]₂, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
- 20 18. -C(NH)-NH₂,
19. ureido,
20. -(C₁-C₄)-alkylthio, wherein alkylthio is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, or
- 25 21. R¹¹R¹²N-, or

two R¹ residues bonded to adjacent ring carbon atoms together with the carbon atoms to which they are bonded form an aromatic ring condensed to W, where the ring formed by the two R¹ residues is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

30 R¹¹ and R¹² together with the nitrogen atom to which they are bonded form a saturated or unsaturated 5- to 6-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R¹¹ and R¹² can contain one or two identical or different ring heteroatoms chosen from oxygen or nitrogen,

R¹³ is halogen, -CN, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkyloxy, -CF₃, -C(O)-NH₂ or -NH₂,

R^{10} is hydrogen atom or $-(C_1-C_4)$ -alkyl,

U is a direct bond, $-(CH_2)_m$, $-(CH_2)_m-C(O)-NR^{10}-(CH_2)_n$, $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n$,
 $-(CH_2)_m-C(O)-(CH_2)_n$, $-(CH_2)_m-SO_2-NR^{10}-(CH_2)_n$, or $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n$,

n and m are independently of one another identical or different and are the integers
5 zero, 1, 2 or 3, wherein the alkylene residues are unsubstituted or mono-, di- or
trisubstituted independently of one another by $-(C_1-C_4)$ -alkyl; $-C(O)-OH$,
 $-C(O)-O-(C_1-C_4)$ -alkyl or $-C(O)-NR^4R^5$,

R^4 and R^5 are independently of one another identical or different and are hydrogen
atom, $-(C_1-C_6)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or
10 trisubstituted independently of one another by R^{13} , $-(C_6-C_{14})$ -aryl- (C_1-C_4) -alkyl-,
wherein alkyl and aryl independently from one another are unsubstituted or mono-,
di- or trisubstituted by R^{13} , $-(C_6-C_{14})$ -aryl-, wherein aryl is unsubstituted or mono-,
di- or trisubstituted independently of one another by R^{13} , $-(C_6-C_{14})$ -heteroaryl,
wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of
15 one another by R^{13} or $-(C_6-C_{14})$ -heteroaryl- (C_1-C_4) -alkyl-, wherein alkyl and
heteroaryl independently from one another are unsubstituted or mono-, di- or
trisubstituted by R^{13} , or

R^4 and R^5 together with the nitrogen atom to which they are bonded form a saturated 5-
to 7-membered monocyclic heterocyclic ring which in addition to the nitrogen atom
20 carrying R^4 and R^5 can contain one or two identical or different ring heteroatoms
chosen from oxygen, sulphur and nitrogen; wherein said heterocyclic ring is
unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,

G is a direct bond, $-(CH_2)_m$, $-(CH_2)_m-O-(CH_2)_n$, $-(CH_2)_m-C(O)-NR^{10}-(CH_2)_n$,
 $-(CH_2)_m-NR^{10}-C(O)-NR^{10}-(CH_2)_n$, $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n$, $-(CH_2)_m-C(O)-(CH_2)_n$,
25 $-(CH_2)_2-S-(CH_2)_n$, $-(CH_2)_m-SO_2-NR^{10}-(CH_2)_n$, $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n$,
 $-(CH_2)_m-NR^{10}-SO_2-NR^{10}-(CH_2)_n$ or $-(CH_2)_m-SO_2-(CH_2)_n$,

wherein n, m, and R^{10} are as defined above

V is 1. a direct bond,

2. $-(C_1-C_4)$ -alkylene, which is branched or unbranched and which is

30 unsubstituted or mono-, di- or trisubstituted independently of one another
by halogen, $=O$, $-CN$, $-NR^4R^5$, $-C(O)-OH$, $-C(O)-O-(C_1-C_4)$ -alkyl,
 $-SO_2-NR^4R^5$, $-C(O)-NR^4R^5$ or $-(C_1-C_4)$ -alkylsulfonyl,

- 3. a 5- to 7-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
- 5 4. a 6- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or
- 5 5. a 6- to 14-membered heteroaryl, wherein said heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R¹⁴ is halogen, -OH, -NR⁴R⁵, =O, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkoxyl, -NO₂, -C(O)-OH, -CN,

10 -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵, -(C₁-C₈)-alkylsulfonyl, -C(O)-NR⁴R⁵,

-SO₂-NR⁴R⁵, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH-[(C₁-C₈)-alkyl]₂,

-NR¹⁰-C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH₂ or -NR¹⁰-C(O)-NH-[(C₁-C₈)-alkyl]₂,

wherein R⁴, R⁵ and R¹⁰ are as defined above, and

M is 1. a hydrogen atom,

15 2. -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

3. -C(O)-NR⁴R⁵,

4. -(C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

20 5. -(C₆-C₁₄)-heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

6. a 5- to 7-membered cyclic group, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or

25 7. a 5- to 7-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, wherein R¹⁴ is defined above,

in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically

30 tolerable salts.

VI) Further especially preferred are compounds of the formula I, wherein

R⁰ is phenyl, wherein phenyl is unsubstituted or mono- or disubstituted independently of one another by R², or

pyridyl, wherein pyridyl is unsubstituted or mono-, disubstituted independently of one another by R²,

R² is halogen, -CN, -C(O)-NH₂, -(C₁-C₃)-alkyl, or -(C₁-C₃)-alkyloxy, wherein the alkyl- or alkyloxy residue is unsubstituted or mono-, di- or trisubstituted independently of one another by an amino residue or a methoxy residue,

5 Q and Q' are independently of one another identical or different and are a direct bond, -C(O)-; -O-, -NR¹⁰-, -C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -SO₂-, -NR¹⁰-SO₂-, -SO₂-NR¹⁰-, or -(C₁-C₄)-alkylene,

X is a direct bond or -(C₁-C₃)-alkylene,

10 provided that when Q or Q' is -(C₁-C₃)-alkylene then X is -O-, -NR¹⁰-, -C(O)-, -C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -SO₂-, -NR¹⁰-SO₂- or -SO₂-NR¹⁰-;

with the proviso that if X is a direct bond, the fragment -Q-X-Q'- is not O-O or SO₂-SO₂; and with the proviso that if X is oxygen atom, then Q and Q' are not oxygen atom or sulphur atom; and

15 with the further proviso that if X is SO₂, then Q and Q' are not oxygen atom or sulphur atom;

W is phenyl or pyridyl, wherein W is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,

provided that Q' and U are not in an ortho position with respect to each other;

20 R¹ is 1. halogen,
2. -NO₂,
3. -CN,
4. -NH₂,
5. (C₁-C₄)-alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

25 6. -OH,
7. -SO₂-NH₂,
8. (C₁-C₄)-alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
30 9. (C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
10. (C₁-C₄)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

- 11. (C_1-C_4)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
- 12. bis[(C_1-C_4) -alkyl]amino, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
- 5 13. $-C(O)-NH_2$,
- 14. $-C(O)-OH$,
- 15. $-C(O)-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
- 10 16. $-C(O)-NH-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
- 17. $-C(O)-NH-[(C_1-C_4) -alkyl]₂$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
- 18. $-C(NH)-NH_2$,
- 19. ureido,
- 15 20. $-(C_1-C_4)$ -alkylthio, wherein alkylthio is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , or
- 21. $R^{11}R^{12}N-$, or

two R^1 residues bonded to adjacent ring carbon atoms together with the carbon atoms to which they are bonded form an aromatic ring condensed to W, where the ring formed by the two R^1 residues is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,

R^{11} and R^{12} together with the nitrogen atom to which they are bonded form a saturated or unsaturated 5- to 6-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R^{11} and R^{12} can contain one or two identical or different ring heteroatoms chosen from oxygen or nitrogen,

R^{13} is halogen, $-CN$, $-(C_1-C_4)$ -alkyl, $-(C_1-C_4)$ -alkyloxy, $-CF_3$, $-C(O)-NH_2$ or $-NH_2$,

R^{10} is hydrogen atom or $-(C_1-C_4)$ -alkyl,

U is a direct bond, $-(CH_2)_m$, $-(CH_2)_m-C(O)-NR^{10}-$ $(CH_2)_n$, $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n$, $-(CH_2)_m-C(O)-(CH_2)_n$, $-(CH_2)_m-SO_2-NR^{10}-$ $(CH_2)_n$, or $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n$,

30 n and m are are independently of one another identical or different and are the integers zero, 1, 2 or 3, wherein the alkylene residues are unsubstituted or mono-, di- or trisubstituted independently of one another by $-(C_1-C_4)$ -alkyl; $-C(O)-OH$, $-C(O)-O-(C_1-C_4)$ -alkyl or $-C(O)-NR^4R^5$,

R⁴ and R⁵ are independently of one another identical or different and are hydrogen atom, -(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -(C₆-C₁₄)-aryl-(C₁-C₄)-alkyl-, wherein alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, -(C₆-C₁₄)-aryl-, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -(C₆-C₁₄)-heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³ or -(C₆-C₁₄)-heteroaryl-(C₁-C₄)-alkyl-, wherein alkyl and heteroaryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, or

R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a saturated 5- to 7-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R⁴ and R⁵ can contain one or two identical or different ring heteroatoms chosen from oxygen, sulphur and nitrogen; wherein said heterocyclic ring is

unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

G is a direct bond, -(CH₂)_m, -(CH₂)_m-O-(CH₂)_n, -(CH₂)_m-C(O)-NR¹⁰-(CH₂)_n, -(CH₂)_m-NR¹⁰-C(O)-NR¹⁰-(CH₂)_n, -(CH₂)_m-NR¹⁰-C(O)-(CH₂)_n, -(CH₂)_m-C(O)-(CH₂)_n, -(CH₂)-S-(CH₂)_n, -(CH₂)_m-SO₂-NR¹⁰-(CH₂)_n, -(CH₂)_m-NR¹⁰-SO₂-(CH₂)_n, -(CH₂)_m-NR¹⁰-SO₂-NR¹⁰-(CH₂)_n or -(CH₂)_m-SO₂-(CH₂)_n,

wherein n, m, and R¹⁰ are as defined above

V is 1. a direct bond,
2. -(C₁-C₄)-alkylene, which is branched or unbranched and which is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, =O, -CN, -NR⁴R⁵, -C(O)-OH, -C(O)-O-(C₁-C₄)-alkyl,

25 -SO₂-NR⁴R⁵, -C(O)-NR⁴R⁵ or -(C₁-C₄)-alkylsulfonyl,

3. a 5- to 7-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

4. a 6- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or

5. a 6- to 14-membered heteroaryl, wherein said heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R^{14} is halogen, -OH, -NR⁴R⁵, =O, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkoxyl, -NO₂, -C(O)-OH, -CN, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵, -(C₁-C₈)-alkylsulfonyl, -C(O)-NR⁴R⁵, -SO₂-NR⁴R⁵, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH-[(C₁-C₈)-alkyl]₂, -NR¹⁰-C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH₂ or -NR¹⁰-C(O)-NH-[(C₁-C₈)-alkyl]₂,

wherein R⁴, R⁵ and R¹⁰ are as defined above, and

- M is
1. a hydrogen atom,
 2. -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
 3. -C(O)-NR⁴R⁵,
 4. -(C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
 5. -(C₆-C₁₄)-heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
 6. a 5- to 7-membered cyclic group, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or
 7. a 5- to 7-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, wherein R¹⁴ is defined above,

in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically tolerable salts.

VII) Further especially preferred are compounds of the formula I, wherein

- R^0 is -(C₆-C₁₄)-aryl, wherein aryl is selected out of the group phenyl, naphthyl, biphenyl, fluorenyl and anthracenyl and is unsubstituted or mono- or disubstituted independently of one another by R², or -(C₆-C₁₄)-heteroaryl, wherein heteroarylaryl is selected out of the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, indole, isoindole, benzofuran, benzothiophene, 1,3-benzodioxole, indazole, chromane,

benzimidazole, benzoxazole, benzothiazole, quinoline, isoquinoline, isochromane, cinnoline, quinazoline, quinoxaline, phthalazine, pteridine pyridyl, pyridopyridines, pyridoimidazoles, pyridopyrimidines and purine and is unsubstituted or mono- or disubstituted independently of one another by R²,

5 R² is halogen, -CN, -C(O)-NH₂, -(C₁-C₃)-alkyl, or -(C₁-C₃)-alkyloxy, wherein the alkyl- or alkyloxy residue is unsubstituted or mono-, di- or trisubstituted independently of one another by an amino residue or a methoxy residue,

Q is a direct bond

Q' is -O-,

10 X is -(C₁-C₃)-alkylene,

W is -(C₆-C₁₄)-aryl, wherein aryl is selected out of the group phenyl, naphthyl, biphenylyl, fluorenyl and anthracenyl, or

-(C₆-C₁₄)-heteroaryl, wherein heteroarylaryl is selected out of the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, 15 isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, indole, isoindole, benzofuran, benzothiophene, 1,3-benzodioxole, indazole, chromane, benzimidazole, benzoxazole, benzothiazole, quinoline, isoquinoline, isochromane, cinnoline, quinazoline, quinoxaline, phthalazine, pteridine pyridyl, pyridopyridines, pyridoimidazoles, pyridopyrimidines and purine, wherein W is unsubstituted or 20 mono-, di- or trisubstituted independently of one another by R¹,

provided that Q' and U are in a 1,2- or 1,3- substitution relationship with respect to each

25 other; and further provided if Q' and U are in a 1,3- substitution relationship, the 2 position is unsubstituted,

R¹ is 1. halogen,

2. -NO₂,

3. -CN,

30 4. -NH₂,

5. (C₁-C₄)-alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

6. -OH,

7. -SO₂-NH₂,

- 8. (C_1-C_4) -alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
- 9. $-(C_6-C_{14})$ -aryl, wherein aryl is selected out of the group phenyl, naphthyl, biphenylyl, fluorenyl and anthracenyl and is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
- 5 10. (C_1-C_4) -alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
- 11. (C_1-C_4) -alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
- 10 12. bis[(C_1-C_4) -alkyl]amino, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
- 13. $-C(O)-NH_2$,
- 14. $-C(O)-OH$,
- 15. $-C(O)-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
- 16. $-C(O)-NH-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
- 17. $-C(O)-NH-[(C_1-C_4)$ -alkyl]₂, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
- 20 18. $-C(NH)-NH_2$,
- 19. ureido,
- 20. $-(C_1-C_4)$ -alkylthio, wherein alkylthio is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , or
- 21. $R^{11}R^{12}N-$,

25 R^{11} and R^{12} together with the nitrogen atom to which they are bonded form a residue selected out of the group piperidine, morpholine, piperazine, thiomorpholine, pyrrolidine, pyrrolidinone and ketopiperazine

R^{13} is halogen, $-CN$, $-(C_1-C_4)$ -alkyl, $-(C_1-C_4)$ -alkyloxy, $-CF_3$, $-C(O)-NH_2$ or $-NH_2$,

R^{10} is hydrogen atom or $-(C_1-C_4)$ -alkyl,

30 U is $-(CH_2)_m-C(O)-NR^{10}- (CH_2)_n$, wherein n and m are independently of one another identical or different and are the integers zero, 1 or 2,

R^4 and R^5 are independently of one another identical or different and are hydrogen atom, $-(C_1-C_6)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , $-(C_6-C_{14})$ -aryl- (C_1-C_4) -alkyl-,

wherein aryl is as defined for W and alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, -(C₆-C₁₄)-aryl-, wherein aryl is as defined for W and is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -(C₆-C₁₄)-heteroaryl, wherein heteroaryl is as defined for W and is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³ or -(C₆-C₁₄)-heteroaryl-(C₁-C₄)-alkyl-, wherein heteroaryl is as defined for W and alkyl and heteroaryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, or

R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a residue selected out of the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine and 1,4-diazepine; wherein said residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

G is a direct bond, -(CH₂)_m, -(CH₂)_m-O-(CH₂)_n-, -(CH₂)_m-C(O)-NR¹⁰-(CH₂)_n, -(CH₂)_m-NR¹⁰-C(O)-NR¹⁰-(CH₂)_n, -(CH₂)_m-NR¹⁰-C(O)-(CH₂)_n, -(CH₂)_m-C(O)-(CH₂)_n, -(CH₂)_m-SO₂-NR¹⁰-(CH₂)_n, -(CH₂)_m-NR¹⁰-SO₂-(CH₂)_n, -(CH₂)_m-SO₂-(CH₂)_n or -(CH₂)_m-NR¹⁰-SO₂-NR¹⁰-(CH₂)_n,

wherein n, m, and R¹⁰ are as defined above

V is 1. a 5- to 7-membered cyclic group selected out of the group pyrrolidine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, piperidine, 1,3-dioxolane, 2-imidazoline, imidazolidine, 4,5-dihydro-1,3-oxazol, 1,3-oxazolidine, 4,5-dihydro-1,3-thiazole, 1,3-thiazolidine, perhydro-1,4-dioxane, piperazine, perhydro-1,4-oxazine (= morpholine), perhydro-1,4-thiazine (= thiomorpholine), perhydroazepine, indoline, isoindoline, 1,2,3,4-tetrahydroquinoline and 1,2,3,4-tetrahydroisoquinoline, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

2. -(C₆-C₁₄)-aryl, wherein aryl is selected out of the group phenyl, naphthyl, biphenyl, fluorenyl and anthracenyl and is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or

3. $-(C_6-C_{14})$ -heteroaryl, wherein heteroarylaryl is selected out of the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, indole, isoindole, benzofuran, benzothiophene, 1,3-benzodioxole, indazole, chromane, benzimidazole, benzoxazole, benzothiazole, quinoline, isoquinoline, isochromane, cinnoline, quinazoline, quinoxaline, phthalazine, pteridine pyridyl, pyridopyridines, pyridoimidazoles, pyridopyrimidines and purine, wherein said heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,

R^{14} is halogen, -OH, -NR⁴R⁵, =O, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkoxyl, -NO₂, -C(O)-OH, -CN, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵, -(C₁-C₈)-alkylsulfonyl, -C(O)-NH₂, -SO₂-NR⁴R⁵, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH-[(C₁-C₈)-alkyl]₂, -NR¹⁰-C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH₂ or -NR¹⁰-C(O)-NH-[(C₁-C₈)-alkyl]₂, wherein R⁴, R⁵ and R¹⁰ are as defined above, and

M is 1. a hydrogen atom,

- 20 2. $-(C_1-C_4)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,
 3. -C(O)-NR⁴R⁵,
 4. a 5- to 7-membered cyclic group selected out of the group pyrrolidine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, piperidine, 1,3-dioxolane, 2-imidazoline, imidazolidine,

25 4,5-dihydro-1,3-oxazol, 1,3-oxazolidine, 4,5-dihydro-1,3-thiazole, 1,3-thiazolidine, perhydro-1,4-dioxane, piperazine, perhydro-1,4-oxazine, perhydro-1,4-thiazine, perhydroazepine, indoline, isoindoline, 1,2,3,4-tetrahydroquinoline and 1,2,3,4-tetrahydroisoquinoline, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,

- 30 5. $-(C_6-C_{14})$ -aryl, wherein aryl is selected out of the group phenyl, naphthyl, biphenylyl, fluorenyl and anthracenyl and is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} , or

6. -(C₆-C₁₄)-heteroaryl, wherein heteroarylaryl is selected out of the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, indole, isoindole, benzofuran, benzothiophene, 1,3-benzodioxole, indazole, chromane, benzimidazole, benzoxazole, benzothiazole, quinoline, isoquinoline, isochromane, cinnoline, quinazoline, quinoxaline, phthalazine, pteridine pyridyl, pyridopyridines, pyridoimidazoles, pyridopyrimidines and purine, wherein said heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
- 5 in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically tolerable salts.
- 10
- 15

VIII) More especially preferred are compounds of the formula I, wherein

R⁰ is phenyl, wherein phenyl is unsubstituted or mono- or disubstituted independently of one another by R², or

20 pyridyl, wherein pyridyl is unsubstituted or mono-, disubstituted independently of one another by R²,

R² is halogen or -CN,

Q is a direct bond

Q' is -O-,

25 X is ethylene,

W is phenyl or pyridyl, wherein W is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,

provided that Q' and U are in a 1,2- or 1,3- substitution relationship with respect to each other and the 2 position is unsubstituted,

30 R¹ is halogen, -NO₂, -CN, -NH₂, (C₁-C₄)-alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -OH, -SO₂-NH₂, (C₁-C₄)-alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, (C₆-C₁₄)-aryl, wherein aryl is selected out of the group phenyl, naphthyl, biphenyl, fluorenyl and anthracenyl

and is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, (C₁-C₄)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, (C₁-C₄)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

5 bis[(C₁-C₄)-alkyl]amino, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -C(O)-NH₂, -C(O)-OH, -C(O)-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -C(O)-NH-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

10 -C(O)-NH-[(C₁-C₄)-alkyl]₂, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -C(NH)-NH₂, ureido, -(C₁-C₄)-alkylthio, wherein alkylthio is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, or R¹¹R¹²N-,

15 R¹¹ and R¹² together with the nitrogen atom to which they are bonded form a residue selected out of the group piperidine, morpholine, piperazine, thiomorpholine, pyrrolidine, pyrrolidinone and ketopiperazine

R¹³ is halogen, -CN, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkyloxy, -CF₃, -C(O)-NH₂ or -NH₂,

20 R¹⁰ is hydrogen atom or methyl,

U is -(CH₂)_m-C(O)-NR¹⁰-(CH₂)_n, wherein n is zero, 1 or 2, m is zero or 1,

R⁴ and R⁵ are independently of one another identical or different and are hydrogen atom, -(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -(C₆-C₁₄)-phenyl-(C₁-C₄)-alkyl-, wherein alkyl and phenyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, -(C₆-C₁₄)-phenyl-, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -(C₆-C₁₄)-heteroaryl, wherein heteroaryl is selected from the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 25 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine and 1,4-diazepine and is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³ or -(C₆-C₁₄)-heteroaryl-(C₁-C₄)-alkyl-, wherein alkyl and heteroaryl are as defined

30

above and independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, or

R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a residue selected out of the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine and 1,4-diazepine; wherein said residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

G is a direct bond, -(CH₂)_m, -(CH₂)_m-C(O)-NR¹⁰-(CH₂)_n, -(CH₂)_m-C(O)-(CH₂)_n, -(CH₂)_m-NR¹⁰-C(O)-NR¹⁰-(CH₂)_n, -(CH₂)_m-NR¹⁰-C(O)-(CH₂)_n, -(CH₂)_m-SO₂-NR¹⁰-(CH₂)_n or -(CH₂)_m-NR¹⁰-SO₂-(CH₂)_n, wherein n, m, and R¹⁰ are as defined above . . .

V is 1. a 5- to 7-membered cyclic group selected out of the group pyrrolidine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, piperidine, 1,3-dioxolane, 2-imidazoline, imidazolidine, 4,5-dihydro-1,3-oxazol, 1,3-oxazolidine, 4,5-dihydro-1,3-thiazole, 1,3-thiazolidine, perhydro-1,4-dioxane, piperazine, perhydro-1,4-oxazine (= morpholine), perhydro-1,4-thiazine (= thiomorpholine), perhydroazepine, indoline, isoindoline, 1,2,3,4-tetrahydroquinoline and 1,2,3,4-tetrahydroisoquinoline, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
2. -(C₆-C₁₄)-aryl, wherein aryl is selected out of the group phenyl, naphthyl, biphenyl, fluorenyl and anthracenyl and is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or
3. -(C₆-C₁₄)-heteroaryl, wherein heteroarylaryl is selected out of the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, indole, isoindole, benzofuran, benzothiophene, 1,3-benzodioxole, indazole, chromane, benzimidazole,

benzoxazole, benzothiazole, quinoline, isoquinoline, isochromane, cinnoline, quinazoline, quinoxaline, phthalazine, pteridine pyridyl, pyridopyridines, pyridoimidazoles, pyridopyrimidines and purine, wherein said heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R¹⁴ is halogen, -OH, -NR⁴R⁵, =O, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkoxyl, -C(O)-OH, -CN, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵, -(C₁-C₈)-alkylsulfonyl, -C(O)-NH₂, -SO₂-NR⁴R⁵, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH-[(C₁-C₈)-alkyl]₂, wherein R⁴ or R⁵ are as defined above, and

- 10 M is 1. a hydrogen atom,
2. -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
3. -C(O)-NR⁴R⁵,
4. a 5- to 7-membered cyclic group selected out of the group pyrrolidine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, piperidine, 1,3-dioxolane, 2-imidazoline, imidazolidine, 4,5-dihydro-1,3-oxazol, 1,3-oxazolidine, 4,5-dihydro-1,3-thiazole, 1,3-thiazolidine, perhydro-1,4-dioxane, piperazine, perhydro-1,4-oxazine, perhydro-1,4-thiazine, perhydroazepine, indoline, isoindoline, 1,2,3,4-tetrahydroquinoline and 1,2,3,4-tetrahydroisoquinoline, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
20 5. -(C₆-C₁₄)-aryl, wherein aryl is selected out of the group phenyl, naphthyl, biphenyl, fluorenyl and anthracenyl and is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or
25 6. -(C₆-C₁₄)-heteroaryl, wherein heteroarylaryl is selected out of the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, indole, isoindole, benzofuran, benzothiophene, 1,3-benzodioxole, indazole, chromane, benzimidazole, benzoxazole, benzothiazole, quinoline, isoquinoline, isochromane,

cinnoline, quinazoline, quinoxaline, phthalazine, pteridine pyridyl, pyridopyridines, pyridoimidazoles, pyridopyrimidines and purine, wherein said heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

- 5 in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically tolerable salts.

IX) A further object of the invention are compounds of the formula I, wherein

R⁰ is phenyl, wherein phenyl is unsubstituted or mono- or disubstituted independently of one another by R², or

10 pyridyl, wherein pyridyl is unsubstituted or mono-, disubstituted independently of one another by R²,

R² is chlorine,

Q is a direct bond

15 Q' is -O-,

X is ethylene,

W is phenyl or pyridyl, wherein W is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,

provided that Q' and U are in a 1,2- or 1,3- substitution relationship with respect to each other and the 2 position is unsubstituted,

20 R¹ is halogen, -NO₂, -CN, -NH₂, (C₁-C₄)-alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -OH, -SO₂-NH₂, (C₁-C₄)-alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or

25 trisubstituted independently of one another by R¹³, phenyl, wherein phenyl is

unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, (C₁-C₄)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted

30 independently of one another by R¹³, (C₁-C₄)-alkylsulfonyl-, wherein alkyl is

unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, bis[(C₁-C₄)-alkyl]amino, wherein alkyl is unsubstituted or mono-, di- or

trisubstituted independently of one another by R¹³, -C(O)-NH₂, -C(O)-OH,

-C(O)-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted

independently of one another by R¹³, -C(O)-NH-(C₁-C₄)-alkyl, wherein alkyl is

unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

$-C(O)-NH-[(C_1-C_4)\text{-alkyl}]_2$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , $-C(NH)-NH_2$, ureido, $-(C_1-C_4)\text{-alkylthio}$, wherein alkylthio is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , or $R^{11}R^{12}N-$,

5 R^{11} and R^{12} together with the nitrogen atom to which they are bonded form a residue selected out of the group pyridine, phenyl, pyrazine, pyrimidine, pyran, triazole, tetrahydropyridine, pyrrolidine, tetrazole, imidazole, imidazolin, fuopyridine, cyclic guanidinium, pyrrolopyridine and oxadiazole,

10 R^{13} is halogen, $-CN$, $-(C_1-C_4)\text{-alkyl}$, $-(C_1-C_4)\text{-alkyloxy}$, $-CF_3$, $-C(O)-NH_2$ or $-NH_2$,

10 R^{10} is hydrogen atom or methyl,

U is $-(CH_2)_m-C(O)-NR^{10}-(CH_2)_n$, wherein n is zero, 1 or 2, m is zero or 1,

15 R^4 and R^5 are independently of one another identical or different and are hydrogen atom, $-(C_1-C_6)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , $-(C_6-C_{14})\text{-phenyl-}(C_1-C_4)\text{-alkyl-}$,

15 wherein alkyl and phenyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R^{13} , $-(C_6-C_{14})\text{-phenyl-}$, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,

20 heteroaryl selected out of the group pyridine, pyrazine, pyrimidine, pyran, triazole, tetrahydropyridine, pyrrolidine, tetrazole, imidazole, imidazolin, fuopyridine, cyclic guanidinium, pyrrolopyridine and oxadiazole, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , or

25 R^4 and R^5 together with the nitrogen atom to which they are bonded form a residue selected out of the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine,

25 pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine and 1,4-diazepine; wherein said residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13}

30 G is a direct bond, $-(CH_2)_m$, $-(CH_2)_m-C(O)-NR^{10}-(CH_2)_n$, $-(CH_2)_m-C(O)-(CH_2)_n$,

$-(CH_2)_m-NR^{10}-C(O)-NR^{10}-(CH_2)_n$, $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n$,

$-(CH_2)_m-SO_2-NR^{10}-(CH_2)_n$ or $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n$,

wherein n, m, and R^{10} are as defined above

V is tetrahydropyridine, piperidine, phenyl, piperazine or wherein said groups are unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R¹⁴ is halogen, -OH, -NR⁴R⁵, =O, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkoxyl, -C(O)-OH, -CN, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵, -(C₁-C₈)-alkylsulfonyl, -C(O)-NH₂, -SO₂-NR⁴R⁵, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH-[(C₁-C₈)-alkyl]₂, wherein R⁴ or R⁵

5 are as defined above, and


M is a hydrogen atom, -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, -C(O)-NR⁴R⁵, or a residue out of the group consisting of pyridine, phenyl, pyrazine, pyrimidine, pyran, triazole, cyclohexyl, tetrahydropyridine, pyrrolidine, tetrazole, imidazole, imidazolin,

10 furopyridine, cyclic guanidinium, pyrrolopyridine or oxadiazole,

in all its stereoisomeric forms and mixtures thereof in any ratio, polymorph forms and mixtures thereof in any ratio and its physiologically tolerable salts.

15

X) A further object of the invention are compounds of the formula II,



wherein A is a carbon atom or a nitrogen atom, wherein the carbon atom can be unsubstituted or substituted by Cl, F or Br,

20 R1, R2 and R3 independent from each other are hydrogen atom, F, Cl, -O-CH₃, -CH₃, -C(O)-N(CH₂-CH₃)₂, -C(O)-NH₂, or -C(O)-NH-CH₂-piperidine-pyridine,

in all its stereoisomeric forms and mixtures thereof in any ratio, polymorph forms and mixtures thereof in any ratio and its physiologically tolerable salts.

25

In general, the meaning of any group, residue, heteroatom, number etc. which can occur more than once in the compounds of the formula I, is independent of the meaning of this 5 group, residue, heteroatom, number etc. in any other occurrence. All groups, residues, heteroatoms, numbers etc. which can occur more than once in the compounds of the formula I can be identical or different.

As used herein, the term alkyl is to be understood in the broadest sense to mean 10 hydrocarbon residues which can be linear, i. e. straight-chain, or branched and which can be acyclic or cyclic residues or comprise any combination of acyclic and cyclic subunits. Further, the term alkyl as used herein expressly includes saturated groups as well as unsaturated groups which latter groups contain one or more, for example one, two or three, double bonds and/or triple bonds, provided that the double bonds are not 15 located within a cyclic alkyl group in such a manner that an aromatic system results. All these statements also apply if an alkyl group occurs as a substituent on another residue, for example in an alkyloxy residue, an alkyloxycarbonyl residue or an arylalkyl residue. Examples of alkyl residues containing 1, 2, 3, 4, 5, 6, 7 or 8 carbon atoms are methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl or octyl, the n-isomers of all these residues, 20 isopropyl, isobutyl, 1-methylbutyl, isopentyl, neopentyl, 2,2-dimethylbutyl, 2-methylpentyl, 3-methylpentyl, isoheptyl, sec-butyl, tBu, tert-pentyl, sec-butyl, tert-butyl or tert-pentyl.

Unsaturated alkyl residues are, for example, alkenyl residues such as vinyl, 1-propenyl, 2-propenyl (= allyl), 2-butenyl, 3-butenyl, 2-methyl-2-butenyl, 3-methyl-2-butenyl, 5-25 hexenyl or 1,3-pentadienyl, or alkynyl residues such as ethynyl, 1-propynyl, 2-propynyl (= propargyl) or 2-butynyl. Alkyl residues can also be unsaturated when they are substituted.

Examples of cyclic alkyl residues are cycloalkyl residues containing 3, 4, 5 or 6 ring 30 carbon atoms like cyclopropyl, cyclobutyl, cyclopentyl or cyclohexyl, which can also be substituted and/or unsaturated. Unsaturated cyclic alkyl groups and unsaturated cycloalkyl groups like, for example, cyclopentenyl or cyclohexenyl can be bonded via any carbon atom.

Of course, a cyclic alkyl group has to contain at least three carbon atoms, and an unsaturated alkyl group has to contain at least two carbon atoms. Thus, a group like (C₁-C₈)-alkyl is to be understood as comprising, among others, saturated acyclic (C₁-C₈)-alkyl, (C₃-C₆)-cycloalkyl, and unsaturated (C₂-C₈)-alkyl like (C₂-C₈)-alkenyl or (C₂-C₈)-alkynyl. Similarly, a group like (C₁-C₄)-alkyl is to be understood as comprising, among others, saturated acyclic (C₁-C₄)-alkyl, and unsaturated (C₂-C₄)-alkyl like (C₂-C₄)-alkenyl or (C₂-C₄)-alkynyl.

Unless stated otherwise, the term alkyl preferably comprises acyclic saturated hydrocarbon residues which have from one to six carbon atoms and which can be linear or branched. A particular group of saturated acyclic alkyl residues is formed by (C₁-C₄)-alkyl residues like methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl and tBu.

Unless stated otherwise, and irrespective of any specific substituents bonded to alkyl groups which are indicated in the definition of the compounds of the formula I, alkyl groups can in general be unsubstituted or substituted by one or more, for example one, two or three, identical or different substituents. Any kind of substituents present in substituted alkyl residues can be present in any desired position provided that the substitution does not lead to an unstable molecule. Examples of substituted alkyl residues are alkyl residues in which one or more, for example 1, 2 or 3, hydrogen atoms are replaced with halogen atoms, in particular fluorine atoms.

The term mono- or bicyclic 5- to 14-membered aryl group refers to for example phenyl, biphenyl or napthyl.

The term mono- or bicyclic 5- to 14-membered heteroaryl refers to (C₅-C₁₄)-aryl in which one or more of the 5 to 10 ring carbon atoms are replaced by heteroatoms such as nitrogen, oxygen or sulphur. Examples are pyridyl; such as 2-pyridyl, 3-pyridyl or 4-pyridyl; pyrrolyl; such as 2-pyrrolyl and 3-pyrrolyl; furyl; such as 2-furyl and 3-furyl; thienyl; such as 2-thienyl and 3-thienyl; imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, isothiazolyl, tetrazolyl, pyridazinyl, pyrazinyl, pyrimidinyl, indolyl, isoindolyl, indazolyl, phthalazinyl, quinolyl, isoquinolyl or quinoxalinyl or phenylpyridyl.

The term R¹¹ and R¹² together with the nitrogen atom to which they are bonded form a saturated or unsaturated 5- to 6-membered monocyclic heterocyclic ring refers to pyrrol, piperidine, pyrrolidine, morpholine, piperazine, pyridine, pyrimidine, imidazole or thiomorpholine.

5

The term aryl refers to a monocyclic or polycyclic hydrocarbon residue in which at least one carbocyclic ring is present that has a conjugated pi electron system. In a (C₆-C₁₄)-aryl residue from 6 to 14 ring carbon atoms are present. Examples of (C₆-C₁₄)-aryl residues are phenyl, naphthyl, biphenylyl, fluorenlyl or anthracenyl. Unless stated

10 otherwise, and irrespective of any specific substituents bonded to aryl groups which are indicated in the definition of the compounds of the formula I, aryl residues, for example phenyl, naphthyl or fluorenlyl, can in general be unsubstituted or substituted by one or more, for example one, two or three, identical or different substituents. Aryl residues can be bonded via any desired position, and in substituted aryl residues the substituents can
15 be located in any desired position.

Unless stated otherwise, and irrespective of any specific substituents bonded to aryl groups which are indicated in the definition of the compounds of the formula I, substituents that can be present in substituted aryl groups are, for example, (C₁-C₈)-alkyl, 20 in particular (C₁-C₄)-alkyl, such as methyl, ethyl or tBu, hydroxyl, (C₁-C₈)-alkyloxy, in particular (C₁-C₄)-alkyloxy, such as methoxy, ethoxy or tert-butoxy, methylenedioxy, ethylenedioxy, F, Cl, Br, I, cyano, nitro, trifluoromethyl, trifluoromethoxy, hydroxymethyl, formyl, acetyl, amino, mono- or di-(C₁-C₄)-alkylamino, ((C₁-C₄)-alkyl)carbonylamino like acetylamino, hydroxycarbonyl, ((C₁-C₄)-alkyloxy)carbonyl, carbamoyl, benzyl optionally 25 substituted in the phenyl group, optionally substituted phenyl, optionally substituted phenoxy or benzyloxy optionally substituted in the phenyl group. A substituted aryl group which is present in a specific position of the compounds of formula I can independently of other aryl groups be substituted by substituents selected from any desired subgroup of the substituents listed before and/or in the specific definition of that group. For example, 30 a substituted aryl group may be substituted by one or more identical or different substituents chosen from (C₁-C₄)-alkyl, hydroxyl, (C₁-C₄)-alkyloxy, F, Cl, Br, I, cyano, nitro, trifluoromethyl, amino, phenyl, benzyl, phenoxy and benzyloxy. In general, preferably not more than two nitro groups are present in the compounds of the formula I.

- In monosubstituted phenyl residues the substituent can be located in the 2-position, the 3-position or the 4-position, with the 3-position and the 4-position being preferred. If a phenyl group carries two substituents, they can be located in 2,3-position, 2,4-position, 2,5-position, 2,6-position, 3,4-position or 3,5-position. In phenyl residues carrying three substituents the substituents can be located in 2,3,4-position, 2,3,5-position, 2,3,6-position, 2,4,5-position, 2,4,6-position, or 3,4,5-position. Naphthyl residues can be 1-naphthyl and 2-naphthyl. In substituted naphthyl residues the substituents can be located in any positions, for example in monosubstituted 1-naphthyl residues in the 2-, 3-, 4-, 5-, 6-, 7-, or 8-position and in monosubstituted 2-naphthyl residues in the 1-, 3-, 4-, 5-, 6-, 7-, or 8-position. Biphenylyl residues can be 2-biphenylyl, 3-biphenylyl and 4-biphenylyl. Fluorenly residues can be 1-, 2-, 3-, 4- or 9-fluorenly. In monosubstituted fluorenly residues bonded via the 9-position the substituent is preferably present in the 1-, 2-, 3- or 4-position.
- A 4-15 membered mono- or polycyclic group, which can contain, zero, one, two, three or four heteroatoms, such as nitrogen, sulphur or oxygen comprises groups containing 4 to 15 ring atoms in the parent monocyclic or bicyclic carbocyclic or heterocyclic ring system. In monocyclic groups the carbocyclic or heterocyclic ring preferably is a 5-membered, 6-membered or 7-membered ring, particularly preferably a 5-membered or 6-membered ring. In bicyclic groups preferably two fused rings are present one of which is a 5-membered ring or 6-membered carbocyclic or heterocyclic ring and the other of which is a 5-membered or 6-membered heterocyclic or carbocyclic ring, i. e. a bicyclic ring preferably contains 8, 9 or 10 ring atoms, particularly preferably 9 or 10 ring atoms. It comprises saturated carbocyclic or heterocyclic ring systems which do not contain any double bonds within the rings, as well as mono-unsaturated and poly-unsaturated carbocyclic or heterocyclic ring systems which contain one or more, for example one, two, three, four or five, double bonds within the rings provided that the resulting system is stable. Unsaturated rings may be non-aromatic or aromatic, i. e. double bonds within the rings in this group may be arranged in such a manner that a conjugated pi electron system results. Aromatic rings in a group may be 5-membered or 6-membered rings, i. e. aromatic groups in a group contain 5 to 10 ring atoms. Aromatic rings in this group thus comprise 5-membered and 6-membered monocyclic carbocycles or heterocycles and bicyclic carbocycles or heterocycles composed of two 5-membered rings, one 5-membered ring and one 6-membered ring, or two 6-membered rings. In bicyclic aromatic

groups one or both rings may contain heteroatoms. Aromatic groups may also be referred to by the customary term aryl or heteroaryl for which all the definitions and explanations above and below correspondingly apply.

Examples for carbocyclic groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, 5 cycloheptyl and cyclooctyl, decahydronaphthaline, twistane (= tricyclo[4.4.0.0^{3,8}]decan), adamantan (= tricyclo[3.3.1.1^{3,7}]decan), noradamantan (= tricyclo[3.3.1.0^{3,7}]nonane), tricyclo[2.2.1.0^{2,6}]heptane, tricyclo[5.3.2.0^{4,9}]dodecane, tricyclo[5.4.0.0^{2,9}]undecane or tricyclo[5.5.1.0^{3,11}]tridecane.

In heterocyclic groups preferably 1, 2, 3 or 4 identical or different ring heteroatoms

10 chosen from nitrogen, oxygen and sulphur are present. Particularly preferably in these groups one or two identical or different heteroatoms chosen from nitrogen, oxygen and sulphur are present. The ring heteroatoms can be present in any desired number and in any position with respect to each other provided that the resulting heterocyclic system is known in the art and is stable and suitable as a subgroup in a drug substance. Examples 15 of parent structures of heterocycles from which the 4-15 membered mono- or polycyclic group can be derived are aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 20 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, indole, isoindole, benzofuran, benzothiophene, 1,3-benzodioxole, indazole, benzimidazole, benzoxazole, benzothiazole, quinoline, isoquinoline, chromane, isochromane, cinnoline, quinazoline, quinoxaline, phthalazine, pyridoimidazoles, pyridopyridines, pyridopyrimidines, purine, pteridine etc. as well as ring systems which result from the 25 listed heterocycles by fusion (or condensation) of a carbocyclic ring, for example benzo-fused, cyclopenta-fused, cyclohexa-fused or cyclohepta-fused derivatives of these heterocycles.

The fact that many of the before-listed names of heterocycles are the chemical names of unsaturated or aromatic ring systems does not imply that the , the 4-15 membered

30 mono- or polycyclic group could only be derived from the respective unsaturated ring system. The names here only serve to describe the ring system with respect to ring size and the number of the heteroatoms and their relative positions. As explained above, the 4-15 membered mono- or polycyclic group can be saturated or partially unsaturated or aromatic, and can thus be derived not only from the before-listed heterocycles

themselves but also from all their partially or completely hydrogenated analogues and also from their more highly unsaturated analogues if applicable. As examples of completely or partially hydrogenated analogues of the before-listed heterocycles from which this group may be derived the following may be mentioned: pyrrolidine, 5 tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, piperidine, 1,3-dioxolane, 2-imidazoline, imidazolidine, 4,5-dihydro-1,3-oxazol, 1,3-oxazolidine, 4,5-dihydro-1,3-thiazole, 1,3-thiazolidine, perhydro-1,4-dioxane, piperazine, perhydro-1,4-oxazine (= morpholine), perhydro-1,4-thiazine (= thiomorpholine), perhydroazepine, indoline, isoindoline, 1,2,3,4-tetrahydroquinoline, 1,2,3,4-tetrahydroisoquinoline, etc.

- 10 The 4-15 membered mono- or polycyclic group may be bonded via any ring carbon atom, and in the case of nitrogen heterocycles via any suitable ring nitrogen atom. Thus, for example, a pyrrolyl residue can be 1-pyrrolyl, 2-pyrrolyl or 3-pyrrolyl, a pyrrolidinyl residue can be pyrrolidin-1-yl (= pyrrolidino), pyrrolidin-2-yl or pyrrolidin-3-yl, a pyridinyl residue can be pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, a piperidinyl residue can be 15 piperidin-1-yl (= piperidino), piperidin-2-yl, piperidin-3-yl or piperidin-4-yl. Furyl can be 2-furyl or 3-furyl, thienyl can be 2-thienyl or 3-thienyl, imidazolyl can be imidazol-1-yl, imidazol-2-yl, imidazol-4-yl or imidazol-5-yl, 1,3-oxazolyl can be 1,3-oxazol-2-yl, 1,3-oxazol-4-yl or 1,3-oxazol-5-yl, 1,3-thiazolyl can be 1,3-thiazol-2-yl, 1,3-thiazol-4-yl or 1,3-thiazol-5-yl, pyrimidinyl can be pyrimidin-2-yl, pyrimidin-4-yl (= 6-pyrimidinyl) or 5-pyrimidinyl, piperazinyl can be piperazin-1-yl (= piperazin-4-yl = piperazino) or piperazin-2-yl. Indolyl can be indol-1-yl, indol-2-yl, indol-3-yl, indol-4-yl, indol-5-yl, indol-6-yl or 20 indol-7-yl. Similarly benzimidazolyl, benzoxazolyl and benzothiazol residues can be bonded via the 2-position and via any of the positions 4, 5, 6, and 7. Quinolinyl can be quinolin-2-yl, quinolin-3-yl, quinolin-4-yl, quinolin-5-yl, quinolin-6-yl, quinolin-7-yl or 25 quinolin-8-yl, isoquinolinyl can be isoquinol-1-yl, isoquinolin-3-yl, isoquinolin-4-yl, isoquinolin-5-yl, isoquinolin-6-yl, isoquinolin-7-yl or isoquinolin-8-yl. In addition to being bonded via any of the positions indicated for quinolinyl and isoquinolinyl, 1,2,3,4-tetrahydroquinolinyl and 1,2,3,4-tetrahydroisoquinolinyl can also be bonded via the nitrogen atoms in 1-position and 2-position, respectively.
- 30 Unless stated otherwise, and irrespective of any specific substituents bonded to the 4-15 membered mono- or polycyclic group or any other heterocyclic groups which are indicated in the definition of the compounds of the formula I, the 4-15 membered mono- or polycyclic group can be unsubstituted or substituted on ring carbon atoms with one or more, for example one, two, three, four or five, identical or different substituents like (C₁-

C_8)-alkyl, in particular (C_1 - C_4)-alkyl, (C_1 - C_8)-alkyloxy, in particular (C_1 - C_4)-alkyloxy, (C_1 - C_4)-alkylthio, halogen, nitro, amino, ((C_1 - C_4)-alkyl)carbonylamino like acetylarnino, trifluoromethyl, trifluoromethoxy, hydroxyl, oxo, hydroxy-(C_1 - C_4)-alkyl such as, for example, hydroxymethyl or 1-hydroxyethyl or 2-hydroxyethyl, methylenedioxy,

- 5 ethylenedioxy, formyl, acetyl, cyano, aminosulfonyl, methylsulfonyl, hydroxycarbonyl, aminocarbonyl, (C_1 - C_4)-alkyloxycarbonyl, optionally substituted phenyl, optionally substituted phenoxy, benzyl optionally substituted in the phenyl group, benzyloxy optionally substituted in the phenyl group, etc. The substituents can be present in any desired position provided that a stable molecule results. Of course an oxo group cannot
10 be present in an aromatic ring. Each suitable ring nitrogen atom in the 4-15 membered mono- or polycyclic group can independently of each other be unsubstituted, i. e. carry a hydrogen atom, or can be substituted, i. e. carry a substituent like (C_1 - C_8)-alkyl, for example (C_1 - C_4)-alkyl such as methyl or ethyl, optionally substituted phenyl, phenyl-(C_1 - C_4)-alkyl, for example benzyl, optionally substituted in the phenyl group, hydroxy-(C_2 - C_4)-
15 alkyl such as, for example 2-hydroxyethyl, acetyl or another acyl group, methylsulfonyl or another sulfonyl group, aminocarbonyl, (C_1 - C_4)-alkyloxycarbonyl, etc. In general, in the compounds of the formula I nitrogen heterocycles can also be present as N-oxides or as quaternary salts. Ring sulphur atoms can be oxidized to the sulfoxide or to the sulfone. Thus, for example a tetrahydrothienyl residue may be present as S,S-dioxotetrahydro-
20 thienyl residue or a thiomorpholinyl residue like thiomorpholin-4-yl may be present as 1-oxo-thiomorpholin-4-yl or 1,1-dioxo-thiomorpholin-4-yl. A substituted 4-15 membered mono- or polycyclic group that can be present in a specific position of the compounds of formula I can independently of other groups be substituted by substituents selected from any desired subgroup of the substituents listed before and/or in the definition of that
25 group.

Examples for a 5 to 7-membered monocyclic heterocyclic ring, containing at least one nitrogen atom and which is optionally substituted by oxo are piperidine, morpholine, piperazine, thiomorpholine, pyrrolidine, pyrrolidinone, and ketopiperazine.

30

A 3-7 membered monocyclic group, which can contain, zero, one, two, three or four heteroatoms, such as nitrogen, sulphur or oxygen comprises groups containing 3 to 7 ring atoms in the parent monocyclic carbocyclic or heterocyclic ring system. The carbocyclic or heterocyclic ring preferably is a 5-membered or a 6-membered ring.

It comprises saturated carbocyclic or heterocyclic ring systems which do not contain any double bonds within the rings, as well as mono-unsaturated and poly-unsaturated carbocyclic or heterocyclic ring systems which contain one or more, for example one, two or three double bonds within the ring, provided that the resulting system is stable.

- 5 Unsaturated rings may be non-aromatic or aromatic, i. e. double bonds within the rings in this group may be arranged in such a manner that a conjugated pi electron system results. Aromatic rings in this group thus comprise 5-membered and 6-membered monocyclic carbocycles or heterocycles. Aromatic groups may also be referred to by the customary term aryl or heteroaryl for which all the definitions and explanations above
10 and below correspondingly apply.

Examples for carbocyclic groups are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and cyclooctyl.

- In heterocyclic groups preferably 1, 2, 3 or 4 identical or different ring heteroatoms chosen from nitrogen, oxygen and sulphur are present. Particularly preferably in these
15 groups one or two identical or different heteroatoms chosen from nitrogen, oxygen and sulphur are present. The ring heteroatoms can be present in any desired number and in any position with respect to each other provided that the resulting heterocyclic system is known in the art and is stable and suitable as a subgroup in a drug substance. Examples of parent structures of heterocycles from which the 3-7 membered monocyclic group can
20 be derived are aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine etc.

- 25 The fact that many of the before-listed names of heterocycles are the chemical names of unsaturated or aromatic ring systems does not imply that the , the 3-7 membered monocyclic group can only be derived from the respective unsaturated ring system. The names here only serve to describe the ring system with respect to ring size and the
30 number of the heteroatoms and their relative positions. As explained above, the 3-7 membered monocyclic group can be saturated or partially unsaturated or aromatic, and can thus be derived not only from the before-listed heterocycles themselves but also from all their partially or completely hydrogenated analogues and also from their more highly unsaturated analogues if applicable. As examples of completely or partially

hydrogenated analogues of the before-listed heterocycles from which this group may be derived the following may be mentioned: pyrrolidine, pyrrolidinyl, tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, piperidine, 1,3-dioxolane, 2-imidazoline, imidazolidine, 4,5-dihydro-1,3-oxazol, 1,3-oxazolidine, 4,5-dihydro-1,3-thiazole, 1,3-thiazolidine, perhydro-1,4-dioxane, piperazine, perhydro-1,4-oxazine (= morpholine), perhydro-1,4-thiazine (= thiomorpholine), perhydroazepine etc.

The 3-7 membered monocyclic group may be bonded via any ring carbon atom, and in the case of nitrogen heterocycles via any suitable ring nitrogen atom. Thus, for example, a pyrrolyl residue can be 1-pyrrolyl, 2-pyrrolyl or 3-pyrrolyl, a pyrrolidinyl residue can be pyrrolidin-1-yl (= pyrrolidino), pyrrolidin-2-yl or pyrrolidin-3-yl, a pyridinyl residue can be pyridin-2-yl, pyridin-3-yl or pyridin-4-yl, a piperidinyl residue can be piperidin-1-yl (= piperidino), piperidin-2-yl, piperidin-3-yl or piperidin-4-yl. Furyl can be 2-furyl or 3-furyl, thienyl can be 2-thienyl or 3-thienyl, imidazolyl can be imidazol-1-yl, imidazol-2-yl, imidazol-4-yl or imidazol-5-yl, 1,3-oxazolyl can be 1,3-oxazol-2-yl, 1,3-oxazol-4-yl or 1,3-oxazol-5-yl, 1,3-thiazolyl can be 1,3-thiazol-2-yl, 1,3-thiazol-4-yl or 1,3-thiazol-5-yl, pyrimidinyl can be pyrimidin-2-yl, pyrimidin-4-yl (= 6-pyrimidinyl) or 5-pyrimidinyl, piperazinyl can be piperazin-1-yl (= piperazin-4-yl = piperazino) or piperazin-2-yl. Unless stated otherwise, and irrespective of any specific substituents bonded to the 3-7 membered monocyclic group or any other heterocyclic groups which are indicated in the definition of the compounds of the formula I, can be unsubstituted or substituted on ring carbon atoms with one or more, for example one, two, three, four or five, identical or different substituents like (C₁-C₈)-alkyl, in particular (C₁-C₄)-alkyl, (C₁-C₈)-alkyloxy, in particular (C₁-C₄)-alkyloxy, (C₁-C₄)-alkylthio, halogen, nitro, amino, ((C₁-C₄)-alkyl)carbonylamino like acetylarnino, trifluoromethyl, trifluoromethoxy, hydroxyl, oxo, hydroxy-(C₁-C₄)-alkyl such as, for example, hydroxymethyl or 1-hydroxyethyl or 2-hydroxyethyl, methylenedioxy, ethylenedioxy, formyl, acetyl, cyano, aminosulfonyl, methylsulfonyl, hydroxycarbonyl, aminocarbonyl, (C₁-C₄)-alkyloxycarbonyl, optionally substituted phenyl, optionally substituted phenoxy, benzyl optionally substituted in the phenyl group, benzyloxy optionally substituted in the phenyl group, etc. The substituents can be present in any desired position provided that a stable molecule results. Of course an oxo group cannot be present in an aromatic ring. Each suitable ring nitrogen atom in the 3-7 membered monocyclic group can independently of each other be unsubstituted, i. e. carry a hydrogen atom, or can be substituted, i. e. carry a substituent like (C₁-C₈)-alkyl,

- for example (C_1 - C_4)-alkyl such as methyl or ethyl, optionally substituted phenyl, phenyl-(C_1 - C_4)-alkyl, for example benzyl, optionally substituted in the phenyl group, hydroxy-(C_2 - C_4)-alkyl such as, for example 2-hydroxyethyl, acetyl or another acyl group, methylsulfonyl or another sulfonyl group, aminocarbonyl, (C_1 - C_4)-alkyloxycarbonyl, etc. In 5 general, in the compounds of the formula I nitrogen heterocycles can also be present as N-oxides or as quaternary salts. Ring sulphur atoms can be oxidized to the sulfoxide or to the sulfone. Thus, for example a tetrahydrothienyl residue may be present as S,S-dioxotetrahydrothienyl residue or a thiomorpholinyl residue like thiomorpholin-4-yl may be present as 1-oxo-thiomorpholin-4-yl or 1,1-dioxo-thiomorpholin-4-yl. A substituted 3-7 10 membered monocyclic group that can be present in a specific position of the compounds of formula I can independently of other groups be substituted by substituents selected from any desired subgroup of the substituents listed before and/or in the definition of that group.
- 15 Halogen is fluorine, chlorine, bromine or iodine, preferably fluorine, chlorine or bromine, particularly preferably chlorine or bromine.

Optically active carbon atoms present in the compounds of the formula I can independently of each other have R configuration or S configuration. The compounds of 20 the formula I can be present in the form of pure enantiomers or pure diastereomers or in the form of mixtures of enantiomers and/or diastereomers, for example in the form of racemates. The present invention relates to pure enantiomers and mixtures of enantiomers as well as to pure diastereomers and mixtures of diastereomers. The invention comprises mixtures of two or of more than two stereoisomers of the formula I, 25 and it comprises all ratios of the stereoisomers in the mixtures. In case the compounds of the formula I can be present as E isomers or Z isomers (or cis isomers or trans isomers) the invention relates both to pure E isomers and pure Z isomers and to E/Z mixtures in all ratios. The invention also comprises all tautomeric forms of the compounds of the formula I.

30

Diastereomers, including E/Z isomers, can be separated into the individual isomers, for example, by chromatography. Racemates can be separated into the two enantiomers by customary methods, for example by chromatography on chiral phases or by resolution, for example by crystallisation of diastereomeric salts obtained with optically active acids

or bases. Stereochemically uniform compounds of the formula I can also be obtained by employing stereochemically uniform starting materials or by using stereoselective reactions.

- 5 The choice of incorporating into a compound of the formula I a building block with R configuration or S configuration, or in the case of an amino acid unit present in a compound of the formula I of incorporating a building block designated as D-amino acid or L-amino acid, can depend, for example, on the desired characteristics of the compound of the formula I. For example, the incorporation of a D-amino acid building
- 10 block can confer increased stability in vitro or in vivo. The incorporation of a D-amino acid building block also can achieve a desired increase or decrease in the pharmacological activity of the compound. In some cases it can be desirable to allow the compound to remain active for only a short period of time. In such cases, the incorporation of an L-amino acid building block in the compound can allow endogenous
- 15 peptidases in an individual to digest the compound in vivo, thereby limiting the individual's exposure to the active compound. A similar effect may also be observed in the compounds of the invention by changing the configuration in another building block from S configuration to R configuration or vice versa. By taking into consideration the medical needs one skilled in the art can determine the desirable characteristics, for
- 20 example a favourable stereochemistry, of the required compound of the invention.

Physiologically tolerable salts of the compounds of formula I are non-toxic salts that are physiologically acceptable, in particular pharmaceutically utilisable salts. Such salts of compounds of the formula I containing acidic groups, for example a carboxyl group COOH, are for example alkali metal salts or alkaline earth metal salts such as sodium salts, potassium salts, magnesium salts and calcium salts, and also salts with physiologically tolerable quaternary ammonium ions such as tetramethylammonium or tetraethylammonium, and acid addition salts with ammonia and physiologically tolerable organic amines, such as methylamine, dimethylamine, trimethylamine, ethylamine, triethylamine, ethanolamine or tris-(2-hydroxyethyl)amine. Basic groups contained in the compounds of the formula I, for example amino groups or guanidino groups, form acid addition salts, for example with inorganic acids such as hydrochloric acid, hydrobromic acid, sulphuric acid, nitric acid or phosphoric acid, or with organic carboxylic acids and sulfonic acids such as formic acid, acetic acid, oxalic acid, citric acid, lactic acid, malic

acid, succinic acid, malonic acid, benzoic acid, maleic acid, fumaric acid, tartaric acid, methanesulfonic acid or p-toluenesulfonic acid. Compounds of the formula I which simultaneously contain a basic group and an acidic group, for example a guanidino group and a carboxyl group, can also be present as zwitterions (betaines) which are 5 likewise included in the present invention.


Salts of compounds of the formula I can be obtained by customary methods known to those skilled in the art, for example by combining a compound of the formula I with an inorganic or organic acid or base in a solvent or dispersant, or from other salts by cation 10 exchange or anion exchange. The present invention also includes all salts of the compounds of the formula I which, because of low physiologically tolerability, are not directly suitable for use in pharmaceuticals but are suitable, for example, as intermediates for carrying out further chemical modifications of the compounds of the formula I or as starting materials for the preparation of physiologically tolerable salts. 15 The present invention furthermore includes all solvates of compounds of the formula I, for example hydrates or adducts with alcohols.

The invention also includes derivatives and modifications of the compounds of the formula I, for example prodrugs, protected forms and other physiologically tolerable 20 derivatives, as well as active metabolites of the compounds of the formula I. The invention relates in particular to prodrugs and protected forms of the compounds of the formula I which can be converted into compounds of the formula I under physiological conditions. Suitable prodrugs for the compounds of the formula I, i. e. chemically modified derivatives of the compounds of the formula I having properties which are 25 improved in a desired manner, for example with respect to solubility, bioavailability or duration of action, are known to those skilled in the art. More detailed information relating to prodrugs is found in standard literature like, for example, Design of Prodrugs, H. Bundgaard (ed.), Elsevier, 1985, , Fleisher et al., Advanced Drug Delivery Reviews 19 (1996) 115-130; or H. Bundgaard, Drugs of the Future 16 (1991) 443 which are all 30 incorporated herein by reference. Suitable prodrugs for the compounds of the formula I are especially acyl prodrugs and carbamate prodrugs of acylatable nitrogen-containing groups such as amino groups and the guanidino group and also ester prodrugs and amide prodrugs of carboxylic acid groups which may be present in compounds of the formula I. In the acyl prodrugs and carbamate prodrugs one or more, for example one or


two, hydrogen atoms on nitrogen atoms in such groups are replaced with an acyl group or a carbamate, preferably a (C₁-C₆)-alkyloxycarbonyl group. Suitable acyl groups and carbamate groups for acyl prodrugs and carbamate prodrugs are, for example, the groups R^{P1}-CO- and R^{P2}O-CO-, in which R^{P1} is hydrogen, (C₁-C₁₈)-alkyl, (C₃-C₈)-cycloalkyl, (C₃-C₈)-cycloalkyl-(C₁-C₄)-alkyl-, (C₆-C₁₄)-aryl, Het-, (C₆-C₁₄)-aryl-(C₁-C₄)-alkyl- or Het-(C₁-C₄)-alkyl- and in which R^{P2} has the meanings indicated for R^{P1} with the exception of hydrogen.

X) The present invention also relates to processes of preparation by which the compounds of the formula I are obtainable and which comprise carrying out one or more of the synthesis steps described below. The compounds of the formula I can generally be prepared using procedures described below, together with synthetic methods known to those skilled in the art of organic synthesis (see e.g. J. March, Advanced Organic Chemistry, Fourth Edition, John Wiley & Sons, 1992), or variations thereon as appreciated by those skilled in the art, for example in the course of a convergent synthesis, by linkage of two or more fragments which can be derived retrosynthetically from the formula I and the synthesis of those fragments is known to those skilled in the art. In the course of the preparation of the compounds of the formula I it can generally be advantageous or necessary to introduce functional groups which could lead to undesired reactions or side reactions in the respective synthesis step, in the form of precursor groups which are later converted into the desired functional groups, or to temporarily block functional groups by a protective group strategy suited to the synthesis problem. Such strategies are well known to those skilled in the art (see, for example, Greene and Wuts, Protective Groups in Organic Synthesis, Wiley, 1991 or P. Kocienski, Protecting Groups, Thieme 1994). As examples of precursor groups nitro groups and cyano groups may be mentioned which can later be converted by reduction, for example by catalytic hydrogenation, into amino groups and aminomethyl groups, respectively. Protective groups can also have the meaning of a solid phase, and cleavage from the solid phase stands for the removal of the protective group. The use of such techniques is known to those skilled in the art (Burgess K (Ed.) Solid Phase Organic Synthesis, New York: Wiley, 2000). For example, a phenolic hydroxyl group can be attached to a trityl-polystyrene resin, which serves as a protecting group, and the molecule is cleaved from this resin by treatment with TFA at a later stage of the synthesis.

For example, for the preparation of one of the compounds of the formula I, in which W is phenyl, and in which U has the meaning of $-(\text{CH}_2)_n\text{C}(\text{O})\text{NR}^{10}(\text{CH}_2)_1-$, a building block of the formula XI,



- 5 in which R^0 , Q, Q', X, are as defined above for the compounds of the formula I but functional groups of the formula XI can optionally also be present in the form of precursor groups or can be protected by protective groups known to those skilled in the art, e.g. an amino group can be protected with a tert.-butyloxycarbonyl group or a benzyloxycarbonyl group. R^1 , R^1'' , R^1''' , R^1'''' , are defined as hydrogen or as R^1 which has the same
10 meaning as in formula I but can optionally also be present in the form of precursor groups or can be protected by protective groups known to those skilled in the art, e.g. a hydroxyl group may be attached to a polystyrene resin, and Y is a nucleophilically substitutable leaving group or a hydroxyl group, which may also be attached to a polystyrene resin, is reacted with a fragment of the formula XII



in which R^{10} , V, G, and M are as defined above for the compounds of the formula I but functional groups of the formula XII can optionally also be present in the form of precursor groups or can be protected by protective groups.

- 20 The group COY in the formula XI is preferably the carboxylic acid group COOH or an activated carboxylic acid derivative. Y can thus be, for example, hydroxyl, halogen, in particular chlorine or bromine, alkoxy, in particular methoxy or ethoxy, aryloxy, for example phenoxy or pentafluorophenoxy, phenylthio, methylthio, 2-pyridylthio or a residue of a nitrogen heterocycle bonded via a nitrogen atom, in particular a residue of
25 an azole, such as, for example, 1-imidazolyl. Y can furthermore be, for example, $((\text{C}_1-\text{C}_4)\text{-alkyl})-\text{O}-\text{CO}-\text{O}-$ or tolylsulfonyloxy and the activated acid derivative can thus be a mixed anhydride.

- If Y is hydroxyl, then the carboxylic acid is expediently first activated, for example by one of the various methods used for peptide couplings which are well known to those skilled in the art. Examples of suitable activation agents are O-((cyano(ethoxycarbonyl)methylene)amino)-1,1,3,3-tetramethyluronium tetrafluoroborate (TOTU) ; (König et al.,
5 Proc. 21st Europ. Peptide Symp. 1990 (Eds. Giralt, Andreu), Escom, Leiden 1991, p. 143), O-(benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HBTU), O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate (HATU) (L. A. Carpino, J. Am. Chem. Soc. 115 (1993) 4397), diethylphosphoryl cyanide (DEPC); bis-(2-oxo-3-oxazolidinyl)-phosphoryl chloride (BOP-Cl) or carbodiimides like
10 dicyclohexylcarbodiimide or diisopropylcarbodiimide. The activation of the carboxylic acid function may also favourably be carried, for example, by conversion of the carboxylic acid group into the pentafluorophenyl ester using dicyclohexylcarbodiimide and pentafluorophenol. Another favourable method is the activation of the carboxylic acid group as a carbonylimidazolide with N,N-carbonyldiimidazole (CDI). A number of suitable
15 methods for the preparation of activated carboxylic acid derivatives are also indicated with details of source literature in J. March, Advanced Organic Chemistry, Fourth Edition, John Wiley & Sons, 1992. The activation and the subsequent reaction with the compound of the formula III are usually carried in the presence of an inert solvent or diluent, for example DCM, chloroform, THF, diethyl ether, n-heptane, n-hexane, n-
20 pentane, cyclohexane, diisopropyl ether, methyl tBu ether, acetonitrile, DMF, DMSO, dioxane, toluene, benzene, ethyl acetate or a mixture of these solvents, if appropriate with addition of a base such as, for example, potassium tert-butoxide or tributylamine or triethylamine or diisopropylethylamine.

25 The resulting product is a compound of the formula I in which functional groups can also be present in the form of precursor groups or can be protected by protective groups. If still any protective groups or precursor groups are present they are then removed by known methods (see Greene and Wuts, Protective Groups in Organic Synthesis, Wiley, 1991 or P. Kocienski, Protecting Groups, Thieme 1994), or converted in the desired final
30 groups, respectively. E.g., if a carboxylic acid group protected as tBu ester and the free carboxylic acid is to be prepared as the final compound the protective group can be removed by reaction with trifluoroacetic acid or hydrochloric acid and the tert.-butyloxycarbonyl protecting groups can be removed by treatment with trifluoroacetic acid or hydrochloric acid. If desired, with the obtained compounds further reactions can then

be carried out by standard processes, for example acylation reactions or esterification reactions, or the compounds can be converted into physiologically tolerable salts or prodrugs by standard processes known to those skilled in the art.

Especially the groups present in the compounds with the formula XI can be modified by a

5 variety of reactions and thus the desired residues R^{1'}, R^{1''}, R^{1'''} and R^{1''''} be obtained. For example, nitro groups can be reduced to amino group with various reducing agents, such as sulphides, dithionites, and complex hydrides or by catalytic hydrogenation. A

reduction of a nitro group may also be carried out at a later stage of the synthesis of a compound of the formula I, and a reduction of a nitro group to an amino group may also

10 occur simultaneously with a reaction performed on another functional group, for example when reacting a group like a cyano group with hydrogen sulphide or when hydrogenating a group. Ester groups present in the benzene nucleus can be hydrolysed to the corresponding carboxylic acids, which after activation can then be reacted with amines or alcohols under standard conditions. Ether groups present at the benzene nucleus, for

15 example benzyloxy groups or other easily cleavable ether groups, can be cleaved to give hydroxyl groups which then can be reacted with a variety of agents, for example etherification agents or activating agents allowing replacement of the hydroxyl group by other groups. Sulphur-containing groups can be reacted accordingly. In order to

introduce the residues attached to compounds of the formula XI, amino groups can then
20 be modified according to standard procedures for alkylation, for example by reaction with (substituted) alkyl halogenides or by reductive amination of carbonyl compounds, according to standard procedures for acylation, for example by reaction with activated carboxylic acid derivatives such as acid chlorides, anhydrides, activated esters or others or by reaction with carboxylic acids in the presence of an activating agent, or according

25 to standard procedures for sulfonylation, for example by reaction with sulfonyl chlorides.

Halogens or hydroxyl groups – via the triflate or nonaflate – or primary amines - via its diazonium salt – or after conversion to the corresponding stannane, or boronic acid - present in the structure of formula I can be converted into a variety of other functional groups like for example –CN, -CF₃, ethers, acids, amides, amines, alkyl- or aryl groups

30 mediated by means of transition metals, namely palladium or nickel catalysts or copper salts and reagents referred in the literature cited below (F. Diederich, P. Stang, Metal-catalyzed Cross-coupling Reactions, Wiley-VCH, 1998; or M. Beller, C. Bolm, Transition Metals for Organic Synthesis, Wiley-VCH, 1998; J. Tsuji, Palladium Reagents and Catalysts, Wiley, 1996; J. Hartwig, Angew. Chem. 110 (1998) 2154; B. Yang, S.

Buchwald, J. Organomet. Chem. 576 (1999) 125; S. Wagaw, S. Buchwald J. Org. Chem. 61 (1996) 7240; J. Wolfe, S. Buchwald J. Org. Chem. 65 (2000) 1144; D. Old, J. Wolfe, S. Buchwald J. Am. Chem. Soc. 120 (1998) 9722; J. Hartwig, M. Kawatsura, S. Hauck, K. Shaughnessy L. Alcazar-Roman, J. Org. Chem. 64 (1999) 5575, J. Wolfe, H. Tomori,
5 J. Sadighi, J. Yin, S. Buchwald, J. Org. Chem. 65 (2000) 1158; T. Sakamoto, K. Ohsawa, J. Chem. Soc. Perkin Trans I, (1999) 2323; D. Nichols, S. Frescas, D. Marona-Lewicka, X. Huang, B. Roth, G. Gudelsky, J. Nash, J. Med. Chem. 37 (1994) 4347; P. Lam, C. Clark, S. Saubern, J. Adams, M. Winters, D. Chan, A. Combs, Tetrahedron Lett., 39, (1998) 2941; D. Chan, K. Monaco, R. Wang, M. Winters, Tetrahedron Lett. 39, (1998)
10 2933; D. Su, J. Duan, Q. Chen, Tetrahedron Lett. 32 (1991) 7689; F. Qing, J. Fan, H. Sun, X. Yue, J. Chem. Perkin Trans. 1 (1997) 3053; V. Farina, V. Krishnamurthy, W. Scott, The Stille Reaction, Wiley, 1994)

To attach the groups $R^0-Q-X-Q'$ to W in the formula XI several standard methods are
15 known to those skilled in the art of organic synthesis (see e.g. J. March, Advanced Organic Chemistry, Fourth Edition, John Wiley & Sons, 1992). However, especially the Mitsunobu reaction can be a valuable reaction (O. Mitsunobu, Synthesis 1981, 1) and further modified procedures can be of even greater use (A. Tunoori, D. Dutta, G. Gunda, Tetrahedron Lett. 39 (1998) 8751; J. Pelletier, S. Kincaid, Tetrahedron Lett. 41 (2000)
20 797; D. L.Hughes, R. A.Reamer, J. J.Bergan, E. J. J.Grabowski, J. Am. Chem. Soc. 110 (1998) 6487; D. J. Camp, I. D. Jenkins, J. Org. Chem. 54 (1989) 3045; D. Crich, H. Dyker, R. J. Harris, J. Org. Chem. 54 (1989) 257)

In order to modify during the course of the synthesis or prepare the groups $R^0-Q-X-Q'$ or Y attached to the benzene nucleus by application of parallel synthesis methodology,
25 beside a variety of well-known reactions, palladium catalysis can be extremely useful. Such reactions like the Suzuki coupling, the Stille reaction, the Heck reaction, the Sonogashira coupling or the Buchwald-Hartwig amination are well known by those skilled in the art. (F. Diederich, P. Stang, Metal-catalyzed Cross-coupling Reactions, Wiley-VCH, 1998; or M. Beller, C. Bolm, Transition Metals for Organic Synthesis, Wiley-VCH, 1998; J. Tsuji, Palladium Reagents and Catalysts, Wiley, 1996; J. Hartwig, Angew. Chem. 110 (1998) 2154; B. Yang, S. Buchwald, J. Organomet. Chem. 576 (1999) 125; J. Wolfe, S. Buchwald J. Org. Chem. 65 (2000) 1144; D. Old, J. Wolfe, S. Buchwald J. Am. Chem. Soc. 120 (1998) 9722; J. Hartwig, M. Kawatsura, S. Hauck, K. Shaughnessy L. Alcazar-Roman, J. Org. Chem. 64 (1999) 5575, J. Wolfe, H. Tomori, J. Sadighi, J. Yin, S.

Buchwald, J. Org. Chem. 65 (2000) 1185; P. Lam, C. Clark, S. Saubern, J. Adams, M. Winters, D. Chan, A. Combs, Tetrahedron Lett. 39 (1998) 2941; D. Chan, K. Monaco, R. Wang, M. Winters, Tetrahedron Lett. 39 (1998) 2933; J. Wolfe, H. Tomori, J. Sadicht, J. Yin, S. Buchwald, J. Org. Chem. 65 (2000) 1158; V. Farina, V. Krishnamurthy, W. Scott,

5 The Stille Reaction, Wiley, 1994).

If the residue Y in a compound of the formula I contains a primary or secondary nitrogen atom and is a residue in which functional groups within the residue Y are present in protected form or in the form of a precursor group, which have not already been introduced during a preceding step, these residues can, for example, be introduced at

10 the nitrogen position by conventional literature procedures well known to one skilled in the art for N-alkylation, reductive amination, N-arylation, N-acylation or N-sulfonylation of nitrogen atoms. The starting compound that is to be employed in such a reaction carries a hydrogen atom at the nitrogen position. N-Alkylation of a nitrogen atom can, for example, be performed under standard conditions, preferably in the presence of a base,

15 using an alkylating compound containing a leaving group for example halogen like chlorine, bromine or iodine, or a sulfonyloxy group like tosyloxy, mesyloxy or trifluormethylsulfonyloxy. Leaving group may, for example, also be a hydroxyl group which, in order to achieve the alkylation reaction, is activated by a conventional activating agent. For the preparation of compounds of the formula I in which G is a direct linkage

20 and an aromatic group is directly bonded to the nitrogen atom in Y, conventional standard arylation procedures can be used. For example aryl fluorides like alkyl fluorobenzoates or 4-fluorophenyl methyl sulfones can be employed as arylating agents.

Moreover arylation of nitrogen with heterocycles in compounds of the formula I is easily achieved by well known standard substitution reactions of the corresponding heteroaryl


25 chlorides or triflates. Alternatively a wide variety of substituted aryl chlorides, aryl bromides, aryl iodides or aryl triflates can serve as arylating agents in a copper salt and/or palladium mediated reaction according to R. Sarges, H. Howard, K. Koe, A.

Weissmann, J. Med. Chem. 32 (1989) 437; P. Unangst, D. Connor, R. Stabler, R. Weikert, J. Heterocycl. Chem. 24 (1987) 811; G. Tokmakov, I. Grandberg, Tetrahedron,

30 51 (1995) 2091; D. Old, M. Harris, S. Buchwald, Org. Lett. 2 (2000) 1403, G. Mann, J. Hartwig, M. Driver, C. Fernandez-Rivas, J. Am. Chem. Soc. 120 (1998) 827; J. Hartwig, M. Kawatsura, S. Hauk, K. Shaughnessy, L. J. Org. Chem. 64 (1999) 5575. Moreover such arylations can also be accomplished by reaction of a wide range of substituted aryl boronic acids as demonstrated for example by W. Mederski, M. Lefort, M. Germann, D.

Kux, Tetrahedron 55 (1999) 12757; P. Lam, C. Clark, S. Saubern, J. Adams, M. Winters, D. Chan, A. Combs, Tetrahedron Lett. 39 (1998) 2941; D. Chan, K. Monaco, R. Wang, M. Winters, Tetrahedron Lett. 39 (1998) 2933.

- 5 Other compounds of the formula I can be prepared in a similar fashion as described above by coupling of a compound of the formula XIII with a compound of the formula XII.



in which R^0 , Q, Q', X, W and Y are as defined above for the compounds of the formula I but functional groups can optionally also be present in the form of precursor groups or

- 10 can be protected by protective groups known to those skilled in the art, e.g. an amino group can be protected with a tert.-butyloxycarbonyl group or a benzyloxycarbonyl group or a hydroxyl group may be attached to a polystyrene resin.

The before-mentioned reactions for the conversion of functional groups are furthermore

- 15 in general extensively described in textbooks of organic chemistry like M. Smith, J. March, March's Advanced Organic Chemistry, Wiley-VCH, 2001 and in treatises like Houben-Weyl, "Methoden der Organischen Chemie" (Methods of Organic Chemistry), Georg Thieme Verlag, Stuttgart, Germany, or "Organic Reactions", John Wiley & Sons, New York, or R. C. Larock, " Comprehensive Organic Transformations", Wiley-VCH, 2nd ed (1999), B. Trost, I. Fleming (eds.) Comprehensive Organic Synthesis, Pergamon, 1991 in which details on the reactions and primary source literature can be found. In 20 indeed the compounds of the formula XI, XII and XIII are prepared by methods well known to those skilled in the art by application of various standard procedures. Due to the fact that in the present case the functional groups are attached to an highly functionalised 25 system it may in certain cases become necessary to specifically adapt reaction conditions or to choose specific reagents from a variety of reagents that can in principle be employed into a conversion reaction, or otherwise to take specific measures for achieving a desired conversion, for example to use protection group techniques. However, finding out suitable reaction variants and reaction conditions in such cases 30 does not cause any problems for one skilled in the art.

Preferred methods include, but are not limited to those described in the examples.

The compounds of the present invention are serine protease inhibitors, which inhibit the activity of the blood coagulation enzymes factor Xa and/or factor VIIa. In particular, they are highly active inhibitors of factor Xa. They are specific serine protease inhibitors inasmuch as they do not substantially inhibit the activity of other proteases whose

- 5 inhibition is not desired. The activity of the compounds of the formula I can be determined, for example, in the assays described below or in other assays known to those skilled in the art. With respect to factor Xa inhibition, a preferred embodiment of the invention comprises compounds which have a $K_i \leq 1$ for factor Xa inhibition as determined in the assay described below, with or without concomitant factor VIIa
- 10 inhibition, and which preferably do not substantially inhibit the activity of other proteases involved in coagulation and fibrinolysis whose inhibition is not desired (using the same concentration of the inhibitor). The compounds of the invention inhibit factor Xa catalytic activity either directly, within the prothrombinase complex or as a soluble subunit, or indirectly, by inhibiting the assembly of factor Xa into the prothrombinase complex.

- 15 XI) The present invention also relates to the compounds of the formula I and/or their physiologically tolerable salts and/or their prodrugs for use as pharmaceuticals (or medicaments), to the use of the compounds of the formula I and/or their physiologically tolerable salts and/or their prodrugs for the production of pharmaceuticals for inhibition of
- 20 factor Xa and/or factor VIIa or for influencing blood coagulation, inflammatory response or fibrinolysis or for the therapy or prophylaxis of the diseases mentioned above or below, for example for the production of pharmaceuticals for the therapy and prophylaxis of cardiovascular disorders, thromboembolic diseases or restenoses. The invention also relates to the use of the compounds of the formula I and/or their physiologically tolerable
- 25 salts and/or their prodrugs for the inhibition of factor Xa and/or factor VIIa or for influencing blood coagulation or fibrinolysis or for the therapy or prophylaxis of the diseases mentioned above or below, for example for use in the therapy and prophylaxis of cardiovascular disorders, thromboembolic diseases or restenoses, and to methods of treatment aiming at such purposes including methods for said therapies and prophylaxis.
- 30 The present invention also relates to pharmaceutical preparations (or pharmaceutical compositions) which contain an effective amount of at least one compound of the formula I and/or its physiologically tolerable salts and/or its prodrugs in addition to a customary pharmaceutically acceptable carrier, i. e. one or more pharmaceutically acceptable carrier substances or excipients and/or auxiliary substances or additives.

XII) Preferred are the treatment of disease states such as abnormal thrombus formation, acute myocardial infarction, unstable angina, thromboembolism, acute vessel closure associated with thrombolytic therapy or percutaneous transluminal coronary angioplasty, transient ischemic attacks, stroke, pathologic thrombus formation occurring in the veins 5 of the lower extremities following abdominal, knee and hip surgery, a risk of pulmonary thromboembolism, or disseminated systemic intravascular coagulopathy occurring in vascular systems during septic shock, certain viral infections or cancer.

The compounds of the formula I and their physiologically tolerable salts and their 10 prodrugs can be administered to animals, preferably to mammals, and in particular to humans as pharmaceuticals for therapy or prophylaxis. They can be administered on their own, or in mixtures with one another or in the form of pharmaceutical preparations which permit enteral or parenteral administration.

15 The pharmaceuticals can be administered orally, for example in the form of pills, tablets, lacquered tablets, coated tablets, granules, hard and soft gelatine capsules, solutions, syrups, emulsions, suspensions or aerosol mixtures. Administration, however, can also be carried out rectally, for example in the form of suppositories, or parentally, for example intravenously, intramuscularly or subcutaneously, in the form of injection 20 solutions or infusion solutions, microcapsules, implants or rods, or percutaneously or topically, for example in the form of ointments, solutions or tinctures, or in other ways, for example in the form of aerosols or nasal sprays.

25 The pharmaceutical preparations according to the invention are prepared in a manner known per se and familiar to one skilled in the art, pharmaceutically acceptable inert inorganic and/or organic carriers being used in addition to the compound(s) of the formula I and/or its (their) physiologically tolerable salts and/or its (their) prodrugs. For the production of pills, tablets, coated tablets and hard gelatine capsules it is possible to use, for example, lactose, cornstarch or derivatives thereof, talc, stearic acid or its salts, 30 etc. Carriers for soft gelatine capsules and suppositories are, for example, fats, waxes, semisolid and liquid polyols, natural or hardened oils, etc. Suitable carriers for the production of solutions, for example injection solutions, or of emulsions or syrups are, for example, water, saline, alcohols, glycerol, polyols, sucrose, invert sugar, glucose, vegetable oils, etc. Suitable carriers for microcapsules, implants or rods are, for example,

copolymers of glycolic acid and lactic acid. The pharmaceutical preparations normally contain about 0.5 % to 90 % by weight of the compounds of the formula I and/or their physiologically tolerable salts and/or their prodrugs. The amount of the active ingredient of the formula I and/or its physiologically tolerable salts and/or its prodrugs in the

5 pharmaceutical preparations normally is from about 0.5 mg to about 1000 mg, preferably from about 1 mg to about 500 mg.

In addition to the active ingredients of the formula I and/or their physiologically acceptable salts and/or prodrugs and to carrier substances, the pharmaceutical

10 preparations can contain additives such as, for example, fillers, disintegrants, binders, lubricants, wetting agents, stabilisers, emulsifiers, preservatives, sweeteners, colorants, flavourings, aromatizers, thickeners, diluents, buffer substances, solvents, solubilizers, agents for achieving a depot effect, salts for altering the osmotic pressure, coating agents or antioxidants. They can also contain two or more compounds of the formula I

15 and/or their physiologically tolerable salts and/or their prodrugs. In case a pharmaceutical preparation contains two or more compounds of the formula I the selection of the individual compounds can aim at a specific overall pharmacological profile of the pharmaceutical preparation. For example, a highly potent compound with a shorter duration of action may be combined with a long-acting compound of lower

20 potency. The flexibility permitted with respect to the choice of substituents in the compounds of the formula I allows a great deal of control over the biological and physico-chemical properties of the compounds and thus allows the selection of such desired compounds. Furthermore, in addition to at least one compound of the formula I and/or its physiologically tolerable salts and/or its prodrugs, the pharmaceutical preparations can

25 also contain one or more other therapeutically or prophylactically active ingredients.

As inhibitors of factor Xa and/or factor VIIa the compounds of the formula I and their physiologically tolerable salts and their prodrugs are generally suitable for the therapy and prophylaxis of conditions in which the activity of factor Xa and/or factor VIIa plays a

30 role or has an undesired extent, or which can favourably be influenced by inhibiting factor Xa and/or factor VIIa or decreasing their activities, or for the prevention, alleviation or cure of which an inhibition of factor Xa and/or factor VIIa or a decrease in their activity is desired by the physician. As inhibition of factor Xa and/or factor VIIa influences blood coagulation and fibrinolysis, the compounds of the formula I and their physiologically

tolerable salts and their prodrugs are generally suitable for reducing blood clotting, or for the therapy and prophylaxis of conditions in which the activity of the blood coagulation system plays a role or has an undesired extent, or which can favourably be influenced by reducing blood clotting, or for the prevention, alleviation or cure of which a decreased
5 activity of the blood coagulation system is desired by the physician. A specific subject of the present invention thus are the reduction or inhibition of unwanted blood clotting, in particular in an individual, by administering an effective amount of a compound I or a physiologically tolerable salt or a prodrug thereof, as well as pharmaceutical preparations therefor.

10

Conditions in which a compound of the formula I can be favourably used include, for example, cardiovascular disorders, thromboembolic diseases or complications associated, for example, with infection or surgery. The compounds of the present invention can also be used to reduce an inflammatory response. Examples of specific
15 disorders for the treatment or prophylaxis of which the compounds of the formula I can be used are coronary heart disease, myocardial infarction, angina pectoris, vascular restenosis, for example restenosis following angioplasty like PTCA, adult respiratory distress syndrome, multi-organ failure, stroke and disseminated intravascular clotting disorder. Examples of related complications associated with surgery are thromboses like
20 deep vein and proximal vein thrombosis, which can occur following surgery. In view of their pharmacological activity the compounds of the invention can replace or supplement other anticoagulant agents such as heparin. The use of a compound of the invention can result, for example, in a cost saving as compared to other anticoagulants.

i
25 When using the compounds of the formula I the dose can vary within wide limits and, as is customary and is known to the physician, is to be suited to the individual conditions in each individual case. It depends, for example, on the specific compound employed, on the nature and severity of the disease to be treated, on the mode and the schedule of administration, or on whether an acute or chronic condition is treated or whether
30 prophylaxis is carried out. An appropriate dosage can be established using clinical approaches well known in the medical art. In general, the daily dose for achieving the desired results in an adult weighing about 75 kg is from 0.01 mg/kg to 100 mg/kg, preferably from 0.1 mg/kg to 50 mg/kg, in particular from 0.1 mg/kg to 10 mg/kg, (in each case in mg per kg of body weight). The daily dose can be divided, in particular in the

case of the administration of relatively large amounts, into several, for example 2, 3 or 4, part administrations. As usual, depending on individual behaviour it may be necessary to deviate upwards or downwards from the daily dose indicated.

- 5 A compound of the formula I can also advantageously be used as an anticoagulant outside an individual. For example, an effective amount of a compound of the invention can be contacted with a freshly drawn blood sample to prevent coagulation of the blood sample. Further, a compound of the formula I and its salts can be used for diagnostic purposes, for example in in vitro diagnoses, and as an auxiliary in biochemical
- 10 investigations. For example, a compound of the formula I can be used in an assay to identify the presence of factor Xa and/or factor VIIa or to isolate factor Xa and/or factor VIIa in a substantially purified form. A compound of the invention can be labelled with, for example, a radioisotope, and the labelled compound bound to factor Xa and/or factor VIIa is then detected using a routine method useful for detecting the particular label.
- 15 Thus, a compound of the formula I or a salt thereof can be used as a probe to detect the location or amount of factor Xa and/or factor VIIa activity in vivo, in vitro or ex vivo.

- Furthermore, the compounds of the formula I can be used as synthesis intermediates for the preparation of other compounds, in particular of other pharmaceutical active
- 20 ingredients, which are obtainable from the compounds of the formula I, for example by introduction of substituents or modification of functional groups.

- The general synthetic sequences for preparing the compounds useful in the present invention are outlined in the examples given below. Both an explanation of, and the
- 25 actual procedure for, the various aspects of the present invention are described where appropriate. The following examples are intended to be merely illustrative of the present invention, and not limiting thereof in either scope or spirit. Those with skill in the art will readily understand that known variations of the conditions and processes described in the examples can be used to synthesise the compounds of the present invention.

30

It is understood that changes that do not substantially affect the activity of the various embodiments of this invention are included within the invention disclosed herein. Thus, the following examples are intended to illustrate but not limit the present invention.

Examples

Abbreviations used:


tert-Butyl	tBu
2,2'-bis(diphenylphosphino-1,1'-binaphthyl)	Binap
5 Bis-(oxo-3-oxazolidinyl)-phosphoryl chloride	BOP-Cl
dibenzylidenacetone	dba
Dichloromethane	DCM
Diethyl azodicarboxylate	DEAD
4-Dimethyaminopyridine	DMAP
10 N,N-Dimethylformamide	DMF
Dimethylsulfoxide	DMSO
O-(7-Azabenzotriazol-1-yl)-N,N,N',N'-tetramethyluronium-hexafluorophosphate	HATU
N-Ethylmorpholine	NEM
15 Methanol	MeOH
Tetrahydrofuran	THF
Trifluoroacetic acid	TFA
O-((Ethoxycarbonyl)cyanomethyleneamino)-N,N,N',N'-tetramethyluronium tetrafluoroborate	TOTU

20

When in the final step of the synthesis of a compound an acid such as trifluoroacetic acid or acetic acid was used, for example when trifluoroacetic acid was employed to remove a tBu group or when a compound was purified by chromatography using an eluent which contained such an acid, in some cases, depending on the work-up procedure, for

25 example the details of a freeze-drying process, the compound was obtained partially or completely in the form of a salt of the acid used, for example in the form of the acetic acid salt or trifluoroacetic acid salt or hydrochloric acid salt.

Example 1: {3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-phenyl}-(4-pyridin-4-ylmethyl-piperazin-1-yl)-methanone




0.100 g (0.29 mmol) of 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoic acid was dissolved in 2 ml of DMF and treated with 0.146 ml (1.16 mmol) of N-NEM and 51 mg (0.29 mmol) of 1-Pyridin-4-ylmethyl-piperazine and 0.098 g (0.3 mmol) of TOTU. The solution was stirred for 1 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in DCM and the solution was washed three times with saturated aqueous sodium bicarbonate. The organic phase was dried with sodium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with n-heptane/ethyl acetate (1/1), ethyl acetate, and ethyl acetate/MeOH (10/1).

5 Yield 102 mg.

MS (ES⁺): m/e = 500 (M⁺).

Example 2: {3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-phenyl}-(4-pyridin-2-ylmethyl-piperazin-1-yl)-methanone




15 0.100 g (0.29 mmol) of 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoic acid was dissolved in 2 ml of DMF and treated with 0.146 ml (1.16 mmol) of N-NEM and 51 mg (0.29 mmol) of 1-Pyridin-2-ylmethyl-piperazine and 0.098 g (0.3 mmol) of TOTU. The solution was stirred for 1 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in DCM and the solution was washed three times with saturated aqueous sodium bicarbonate. The organic phase was dried with sodium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with n-heptane/ethyl acetate (1/1), ethyl acetate, and ethyl acetate/MeOH (10/1).

20 Yield 93 mg.

MS (ES⁺): m/e = 500 (M⁺).

25

Example 3: {3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-phenyl}-(4-pyridin-4-yl-piperazin-1-yl)- methanone




0.100 g (0.29 mmol) of 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoic acid was dissolved in 2 ml of DMF and treated with 0.146 ml (1.16 mmol) of N-NEM and 47 mg (0.29 mmol) of 1-Pyridin-4-yl-piperazine and 0.098 g (0.3 mmol) of TOTU. The solution
5 was stirred for 1 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in DCM and the solution was washed three times with saturated aqueous sodium bicarbonate. The organic phase was dried with sodium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with n-heptane/ethyl acetate (1/1), ethyl acetate, and ethyl
10 acetate/MeOH (10/1).

Yield 40 mg.

MS (ES⁺): m/e = 486 (M⁺).

Example 4: {3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methyl-phenyl}-(4-pyridin-4-ylmethyl-piperazin-1-yl)-methanone




15 0.094 g (0.29 mmol) of 3-[2-(2,4-dichloro-phenyl)-ethoxy]-4-methyl-benzoic acid was dissolved in 2 ml of DMF and treated with 0.146 ml (1.16 mmol) of N-NEM and 51 mg (0.29 mmol) of 1-Pyridin-4-ylmethyl-piperazine and 0.098 g (0.3 mmol) of TOTU. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure,
20 the residue was taken-up in DCM and the solution was washed three times with saturated aqueous sodium bicarbonate. The organic phase was dried with sodium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with DCM, and DCM/MeOH (20/1).

Yield 82 mg.

MS (ES⁺): m/e = 484 (M⁺).

25

Example 5: {3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4,5-dimethoxy-phenyl}-(4-pyridin-4-ylmethyl-piperazin-1-yl)-methanone



(i) 3-Hydroxy-4,5-dimethoxy-benzoic acid methyl ester

5 5 g (27.2 mmol) of 3-Hydroxy-4,5-dimethoxy-benzoic acid was added at 0°C to 100 ml of a saturated solution of HCl in MeOH. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with ethyl acetate/n-heptane (2/1).

Yield 4.66g.

MS (Cl⁺): m/e = 212.2 (M⁺).

(ii) 3-[2-(2,4-Dichlorophenyl)-ethoxy]-4,5-dimethoxy-benzoic acid

10 2 g (9.42 mmol) of 3-Hydroxy-4,5-dimethoxy-benzoic acid methyl ester was dissolved in 100 ml of anhydrous tetrahydrofuran. To this solution was added 1.98g (10.37mmol) of 2-(2,4-Dichlorophenyl)-ethanol, 9.415 g (equivalent to 28.27 mmol PPh₃) of triphenylphosphine derivatized polystyrene and 4.924g (28.27 mmol) of DEAD. The solution was shaken for 16 h at RT. The polymer was filtered off and washed with ethyl acetate. The solvent was removed under reduced pressure. The residue was taken-up in ethyl acetate and the solution was washed three times with water and twice with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure.

15 The residue was dissolved in 20 ml of dioxan. 1 ml of water was added to the solution followed by 2N aqueous NaOH to give a pH of 13. The reaction solution was heated at 60 °C for 10 hours. The solution was cooled to 0 °C, 5 ml water was added, followed by concentrated hydrochloric acid to give a pH of 1 to 2, whereupon the product precipitated from solution. The product was filtered off and dried under reduced pressure.

20 Yield 3.3g.

MS (ES⁻): m/e = 369 (M-H)⁻.

25

(iii) {3-[2-(2,4-Dichlorophenyl)-ethoxy]-4,5-dimethoxy-phenyl}-(4-pyridin-4-ylmethyl-piperazin- 1-yl)-methanone


26 0.100 g (0.269 mmol) of 3-[2-(2,4-Dichlorophenyl)-ethoxy]-4,5-dimethoxy-benzoic acid was dissolved in 2 ml of DMF and treated with 0.124 g (1.08 mmol) of N-NEM and 0.0477 g (0.27 mmol) of 1-Pyridin-4-ylmethyl-piperazine and 0.088 g (0.269 mmol) of

TOTU. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in ethyl acetate and the solution was washed twice with saturated aqueous sodium bicarbonate and once with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with a gradient of 0-17% MeOH in DCM.

Yield 23.8 mg.

MS (ES⁺): m/e = 530 (M⁺).

Example 6: 3-[2-(2,4-Dichlorophenyl)-ethoxy]-4,5-dimethoxy-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide




0.100 g (0.269 mmol) of 3-[2-(2,4-Dichlorophenyl)-ethoxy]-4,5-dimethoxy-benzoic acid was dissolved in 2 ml of DMF and treated with 0.372 g (3.23 mmol) of N-NEM and 0.144 mg (0.27 mmol) of C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris-trifluoroacetate salt and 0.088 g (0.269 mmol) of TOTU. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in ethyl acetate and the solution was washed twice with saturated aqueous sodium bicarbonate and once with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with a gradient of 0-17% MeOH in DCM.

Yield 19.2 mg.

MS (ES⁺): m/e = 544 (M⁺).

Example 7: {3-[2-(2,4-Dichlorophenyl)-ethoxy]-phenyl}-(4-pyridin-4-ylmethyl-piperazin-1-yl)- methanone



(i) 3-[2-(2,4-Dichlorophenyl)-ethoxy]-benzoic acid methyl ester

2 g (13.1 mmol) of 3-hydroxybenzoic acid methyl ester and 4.75g (18.1 mmol) of triphenylphosphine were dissolved in 48 ml of anhydrous tetrahydrofuran. The solution was cooled to 0 °C and a solution of 3.04 g (17.5 mmol) DEAD in 7 ml of anhydrous tetrahydrofuran was added dropwise over 20 min. The solution was stirred at RT for 45
5 min. and a solution of 2.76g (14.5mmol) of 2-(2,4-Dichlorophenyl)-ethanol in 3ml anhydrous tetrahydrofuran was added. The reaction was stirred for 16 h at RT. The solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with ethyl acetate/n-heptane (4/1).

Yield 2.6 g. MS (Cl⁺): m/e = 325 (M⁺).

10

(ii) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-benzoic acid

1 g (3.07mmol) of 3-[2-(2,4-Dichlorophenyl)-ethoxy]-benzoic acid methyl ester was dissolved in 20 ml of dioxan. 2N aqueous NaOH was added to the solution to give a pH of 13. The reaction solution was heated at 50 °C for 3 h, and stirred at RT for 16h. 5 ml
15 water was added, followed by concentrated hydrochloric acid to give a pH of 1 to 2, whereupon the product precipitated from solution. The suspension was stirred for 30min, then the product was filtered off and dried under reduced pressure.

Yield 0.92g. MS (Cl⁺): m/e = 311 (M⁺).


20

(iii) {3-[2-(2,4-Dichloro-phenyl)-ethoxy]-phenyl}-(4-pyridin-4-ylmethyl-piperazin-1-yl)-methanone

0.100 g (0.321 mmol) of 3-[2-(2,4-Dichlorophenyl)-ethoxy]-benzoic acid was dissolved in 2 ml of DMF and treated with 0.148 g (1.28 mmol) of N-NEM and 0.105 g (0.321 mmol) of TOTU and 0.0569 g (0.32 mmol) of 1-Pyridin-4-ylmethyl-piperazine. The solution was
25 stirred for 16 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in ethyl acetate and the solution was washed twice with saturated aqueous sodium bicarbonate and once with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with a gradient
30 of 0-17% MeOH in DCM.

Yield 84 mg. MS (ES⁺): m/e = 470 (M⁺).

Example 8: 3-[2-(2,4-Dichlorophenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4- ylmethyl)-benzamide




0.100 g (0.321 mmol) of 3-[2-(2,4-Dichlorophenyl)-ethoxy]-benzoic acid was dissolved in 2 ml of DMF and treated with 0.148 g (1.28 mmol) of N-NEM and 0.105 g (0.321 mmol) of TOTU and 0.123 g (0.64 mmol) of C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in ethyl acetate and the solution was washed twice with saturated aqueous sodium bicarbonate and once with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with a gradient of 0 to 17% MeOH in DCM.

Yield 73 mg.

MS (ES⁺): m/e = 484 (M⁺).

Example 9: {3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-ethoxy-phenyl}-(4-pyridin-4-ylmethyl-piperazin-1-yl)-methanone



(i) 4-Ethoxy-3-hydroxy-benzoic acid ethyl ester
 5 g (27.2 mmol) of 3,4-Dihydroxy-benzoic acid ethyl ester was dissolved in 100 ml DMF and 3.75g (27.2 mmol) of potassium carbonate was added. The solution was cooled to 0°C and a solution of 2.96g (27.2 mmol) ethyl bromide in 10 ml DMF was added dropwise. The solution was stirred for 16 h at room temperature (RT). The solvent was removed under reduced pressure. The residue was taken-up in ethyl acetate and the solution was washed three times with water and twice with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with ethyl acetate/n-heptane (1/4).

Yield 1.84g.

MS (Cl⁺): m/e = 211.1 (M+H)⁺.

(ii) 3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-ethoxy-benzoic acid ethyl ester

0.5 g (2.38 mmol) of 4-Ethoxy-3-hydroxy-benzoic acid ethyl ester was dissolved in 10 ml of anhydrous tetrahydrofuran. To this solution was added 0.5 g (2.62mmol) of 2-(2,4-

Dichlorophenyl)-ethanol, 2.38 g (equivalent to 7.13 mmol PPh₃) of triphenylphosphine

5 derivatized polystyrene and 1.24 g (7.13 mmol) of DEAD. The solution was shaken for 16 h at RT. The polymer was filtered off and washed with ethyl acetate. The solvent was removed under reduced pressure. The residue was taken-up in ethyl acetate and the solution was washed three times with water and twice with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent
10 was removed under reduced pressure. The residue was chromatographed on silica gel eluting with ethyl acetate/n-heptane (1/4).

Yield 300 mg.

LC-MS (ES⁺): m/e = 383 (M)⁺

(iii) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-ethoxy-benzoic acid

15 0.300 g (0.78 mmol) of 3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-ethoxy-benzoic acid ethyl ester was dissolved in 10 ml of dioxan. 2N aqueous NaOH was added to the solution to give a pH of 13. The reaction solution was heated at 60°C for 10 h. 5 ml water was added, followed by concentrated hydrochloric acid to give a pH of 1-2, whereupon the product precipitated from solution. The suspension was stirred for 30min, and then the
20 product was filtered off and dried under reduced pressure.

Yield 0.205g.

MS (Cl⁺): m/e = 355 (M⁺).


(iv) {3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-ethoxy-phenyl}-(4-pyridin-4-ylmethyl-piperazin-1-yl)-methanone

25 0.050 g (0.141 mmol) of 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-ethoxy-benzoic acid was dissolved in 2 ml of DMF and treated with 0.065 g (0.564 mmol) of N-NEM and 0.046 g (0.141 mmol) of TOTU and 0.025 g (0.141 mmol) of 1-Pyridin-4-ylmethyl-piperazine. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in ethyl acetate and the solution was washed twice with
30 saturated aqueous sodium bicarbonate and once with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure. The residue was purified by preparative RP-HPLC eluting with a gradient of 0-100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt.

Yield 28.6 mg.

MS (ES⁺): m/e = 514 (M⁺).

Example 10: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-ethoxy-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



5


0.050 g (0.141 mmol) of 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-ethoxy-benzoic acid was dissolved in 2 ml of DMF and treated with 0.163 g (1.41 mmol) of N-NEM and 0.046 g (0.141 mmol) of TOTU and 0.075 g (0.141 mmol) of C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris-trifluoroacetate salt. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in ethyl acetate and the solution was washed twice with saturated aqueous sodium bicarbonate and once with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure. The residue was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt.

10
15

Yield 26.1 mg.

MS (ES⁺): m/e = 528 (M⁺).

Example 11 : 4-(4-{3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoyl}-piperazin-1-ylmethyl)- benzonitrile



20

(i) 4-{3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-benzoyl}-piperazine-1-carboxylic acid tBu ester

3 g (9 mmol) of 3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-benzoic acid was dissolved in 30 ml DMF and treated with 4.6 ml (36 mmol) of N-NEM and 3.2 g (9.9 mmol) of TOTU and 1.67g (9 mmol) of piperazine-1-carboxylic acid tBu ester. The solution was stirred for

25

40 min. at RT. The solvent was removed under reduced pressure, the residue was taken-up in DCM and the solution was washed three times with saturated aqueous sodium bicarbonate. The organic phase was dried with sodium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on 5 silica gel eluting with n-heptane/ethyl acetate (1/1).

Yield 4.2 g. MS (ES⁺): m/e = 509 (M⁺).

(ii) {3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-phenyl}-piperazin-1-yl-methanone, hydrochloride salt

10 4.2 g (8.2 mmol) of 4-{3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-benzoyl}-piperazine-1-carboxylic acid tBu ester was dissolved in 25 ml of MeOH. To this solution was added 100 ml of a saturated solution of HCl in MeOH. The solution was stirred for 30 min at RT. The solvent was removed under reduced pressure. The residue was treated twice with toluene, which was removed under reduced pressure.

15 Yield 3.8 g. MS (ES⁺): m/e = 409 (M⁺).


(iii) 4-(4-{3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-benzoyl}-piperazin-1-ylmethyl)-benzonitrile

0.050 g (0.112 mmol) of {3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-phenyl}-piperazin-1-yl-methanone, hydrochloride salt was dissolved in 3 ml of DMF. 61.9 mg (0.448mmol)

20 of potassium carbonate was added to the solution, followed by 0.022 g (0.11 mmol) of 4-bromomethyl-benzonitrile. The reaction solution was shaken for 16 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in ethyl acetate and the solution was washed twice with water and once with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was 25 removed under reduced pressure. The residue was chromatographed on silica gel eluting with n-heptane/ethyl acetate (1/1), and DCM/MeOH (10/1).

Yield 33mg. MS (ES⁺): m/e = 524 (M⁺).


Example 12: {3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-phenyl}-[4-(4-fluorobenzyl)-30 piperazin-1- yl]-methanone



0.050 g (0.112 mmol) of {3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-phenyl}-piperazin-1-yl-methanone, hydrochloride salt was dissolved in 3 ml of DMF. 61.9 mg (0.448mmol) of potassium carbonate was added to the solution, followed by 0.021 g (0.11 mmol) of 1-Bromomethyl-4-fluoro-benzene. The reaction solution was shaken for 16 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in ethyl acetate and the solution was washed twice with water and once with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with n-heptane/ethyl acetate (1/1), and DCM/MeOH (10/1).

Yield 42.5mg. MS (ES⁺): m/e = 517 (M⁺).

Example 13: 2-(4-{3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-benzoyl}-piperazin-1-yl)-N,N- dimethyl-acetamide




0.050 g (0.112 mmol) of {3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-phenyl}-piperazin-1-yl-methanone, hydrochloride salt was dissolved in 3 ml of DMF. 61.9 mg (0.448mmol) of potassium carbonate was added to the solution, followed by 0.016 g (0.13 mmol) of 2-chloro-N,N-dimethyl-acetamide. The reaction solution was shaken for 32 h at RT. The solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with a gradient of 0-17% MeOH in DCM, followed by additional purification by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt.

Yield 20.5mg. MS (ES⁺): m/e = 494 (M⁺).

25

Example 14: 2-(4-{3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-benzoyl}-piperazin-1-yl)-1-pyrrolidin-1-yl-ethanone




0.102 g (0.3 mmol) of 3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-benzoic acid was dissolved in 3 ml of DMF. 138.2 mg (1.2 mmol) of N-NEM and 0.098 g (0.3 mmol) TOTU were added to the solution, followed by 0.059 g (0.3 mmol) of 2-piperazin-1-yl-1-

5 pyrrolidin-1-yl-ethanone. The reaction solution was stirred for 4 h at RT. The solvent was removed under reduced pressure. The solvent was removed under reduced pressure, the residue was taken-up in ethyl acetate and the solution was washed three times with saturated aqueous sodium bicarbonate. The organic phase was dried with sodium sulphate, filtered and the solvent was removed under reduced pressure. The residue was purified by preparative RP-HPLC eluting with a gradient of 0-100% acetonitrile in water (10 +0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt.

Yield 74 mg.

MS (ES⁺): m/e = 520 (M⁺).

15 Example 15: 3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-N-(3-piperidin-1-yl-propyl)-benzamide



0.075 g (0.22 mmol) of 3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-benzoic acid was dissolved in 3 ml of DMF. 101.3 mg (0.88 mmol) of N-NEM and 0.072 g (0.22 mmol)


20 TOTU were added to the solution, followed by 0.031 g (0.22 mmol) of 3-piperidin-1-yl-propylamine. The reaction solution was stirred for 4 h at RT. The solvent was removed under reduced pressure. The solvent was removed under reduced pressure, the residue was taken-up in ethyl acetate and the solution was washed three times with saturated aqueous sodium bicarbonate. The organic phase was dried with sodium sulphate, filtered and the solvent was removed under reduced pressure. The residue was purified by preparative RP-HPLC eluting with a gradient of 0-100% acetonitrile in water (+0.01%

trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt.

Yield 50 mg.

MS (ES⁺): m/e = 465 (M⁺).

- 5 Example 16: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(2-piperidin-1-yl-ethyl)-benzamide



0.075 g (0.22 mmol) of 3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-benzoic acid was dissolved in 3 ml of DMF. 101.3 mg (0.88 mmol) of N-NEM and 0.072 g (0.22 mmol)


- 10 TOTU were added to the solution, followed by 0.028 g (0.22 mmol) of 2-piperidin-1-yl-ethylamine. The reaction solution was stirred for 4 h at RT. The solvent was removed under reduced pressure. The solvent was removed under reduced pressure, the residue was taken-up in ethyl acetate and the solution was washed three times with saturated aqueous sodium bicarbonate. The organic phase was dried with sodium sulphate, filtered
15 and the solvent was removed under reduced pressure. The residue was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt.

Yield 50 mg.

MS (ES⁺): m/e = 451 (M⁺).

20

- Example 17: {3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methyl-phenyl}-[4-(1-oxy-pyridin-4-ylmethyl)-piperazin-1-yl]-methanone




- 25 0.020 g (0.04 mmol) of {3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methyl-phenyl}-(4-pyridin-4-ylmethyl-piperazin-1-yl)-methanone was dissolved in 1 ml of DCM. To this solution was added 15.2 mg (0.06 mmol) meta-chloroperbenzoic acid. The reaction was stirred at RT

for 16h, and then the solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with a gradient of 0 to 17% MeOH in DCM.

Yield 5 mg.

MS (ES⁺): m/e = 500 (M⁺).


- 5 Example 18: {3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-hydroxymethyl-phenyl}-[4-(1-oxy-pyridin-4-ylmethyl)- piperazin-1-yl]-methanone



This compound was isolated by chromatography from the reaction described for the synthesis of example 17. Yield 2 mg. MS (ES⁺): m/e = 516 (M⁺).

10

- Example 19: {4-Bromo-3-[2-(2,4-dichlorophenyl)-ethoxy]-5-methoxyphenyl}-[4-pyridin-4-ylmethyl- piperazin-1-yl]-methanone



(i) 4-Bromo-3-[2-(2,4-dichlorophenyl)-ethoxy]-5-methoxy-benzoic acid

- 15 0.2 g (0.49 mmol) of 4-Bromo-3-[2-(2,4-dichlorophenyl)-ethoxy]-5-hydroxy-benzoic acid was dissolved in 5 ml DMF and 0.272 mg (1.97 mmol) of potassium carbonate was added. The solution was cooled to 0°C and 0.699 g (4.9 mmol) methyl bromide was added. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with ethyl acetate/n-heptane (1/1). The resulting compound was dissolved in 10 ml dioxan and 1 ml water. 2N aqueous NaOH was added to the solution to give a pH of 13. The reaction solution was heated at 60°C for 4 h. 5 ml water was added, followed by concentrated hydrochloric acid to give a pH of 1-2, whereupon the product precipitated from solution. The suspension was stirred for 30min, then the product was filtered off and dried under reduced pressure.

Yield 120 mg.

MS (ES⁻): m/e = 416.9 (M-H)⁻.


(ii) {4-Bromo-3-[2-(2,4-dichlorophenyl)-ethoxy]-5-methoxyphenyl}-(4-pyridin-4-ylmethyl-piperazin-1-yl)-methanone

5 0.05 g (0.119 mmol) of 4-Bromo-3-[2-(2,4-dichlorophenyl)-ethoxy]-5-methoxy-benzoic acid was dissolved in 2 ml of DMF and treated with 0.055 g (0.476 mmol) of N-NEM and 0.039 g (0.119 mmol) of TOTU and 0.021 g (0.12 mmol) of 1-Pyridin-4-ylmethyl-piperazine. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in acetonitrile and the residue was purified
10 by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt.

Yield 35.5 mg.

MS (ES⁺): m/e = 578 (M+H)⁺.

15 Example 20: 4-Bromo-3-[2-(2,4-dichloro-phenyl)-ethoxy]-5-methoxy-N-(3,4,5,6-tetrahydro-2H- [1,4']bipyridinyl-4-ylmethyl)-benzamide




0.05 g (0.119 mmol) of 4-Bromo-3-[2-(2,4-dichlorophenyl)-ethoxy]-5-methoxy-benzoic acid was dissolved in 2 ml of DMF and treated with 0.055 g (0.476 mmol) of N-NEM and 0.039 g (0.119 mmol) of TOTU and 0.063 g (0.12 mmol) of C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris-trifluoroacetate salt. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in acetonitrile and the residue was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the
20 product was obtained as its trifluoroacetate salt.

Yield 34.3 mg.

MS (ES⁺): m/e = 592 (M+H)⁺.

Example 21: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(2'-sulfamoyl-biphenyl-4-ylmethyl)- benzamide



(i) 4'-Aminomethyl-biphenyl-2-sulfonic acid dimethylaminomethyleneamide

1.5 g of 4'-formyl-biphenyl-2-sulfonic acid dimethylaminomethyleneamide prepared according to H. Jendralla et al. (Liebigs Ann. 1995, 1253-7) in 15 ml MeOH were treated with 208.6 mg NaCNBH₃ and the reaction was stirred for 4 hours at RT. The pH was adjusted to 4.0, the reaction was filtered, the solvent was removed under reduced pressure and the residue was chromatographed on silica gel eluting with a gradient of 10-20% MeOH in DCM.

Yield 912 mg.

MS (ES⁺): m/e = 318 (M+H⁺).

(ii) 4'-Aminomethyl-biphenyl-2-sulfonic acid amide hydrochloride


400 mg of 4'-Aminomethyl-biphenyl-2-sulfonic acid dimethylaminomethyleneamide were treated with 10 ml MeOH and 4 ml conc. HCl and refluxed for 1h. Solvent and HCl were evaporated and the product used without purification.

(iii) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(2'-sulfamoyl-biphenyl-4-ylmethyl)-benzamide

77 mg of 4'-aminomethyl-biphenyl-2-sulfonic acid amide hydrochloride were reacted with 100 mg of 3-[2-(2,4-dichloro-phenyl)-ethoxy]-4-methoxy-benzoic acid, 111 mg HATU and 0.2 ml DIPEA in 3 ml DMF for 1 h at RT. The pH was adjusted to 4.0, the solvent evaporated, the residue was dissolved in DCM and extracted with brine. After evaporation of the solvent; the product was purified by preparative RP-HPLC eluting with a gradient of 0-100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilisation the product was obtained as its trifluoroacetate salt.

Yield: 33 mg. MS (ES⁺): m/e = 585.1; 587.0 (M+H⁺).

Example 22: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-benzamide



(i) 3-Hydroxy-4-methoxy-benzoic acid methyl ester

- 5 10 ml of thionyl chloride was added to 250 ml of MeOH at 0 °C. The solution was stirred for 10 min. and 25 g of 3-hydroxy-4-methoxybenzoic acid was added. The reaction was stirred for 16 h at RT then heated to 50 °C for 3 h. The solvents were removed under reduced pressure. The residue was directly used in the next reaction.

(ii) 3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-benzoic acid methyl ester

- 10 20 g of triphenylphosphine and 10 g of 3-Hydroxy-4-methoxy-benzoic acid methyl ester were dissolved in 200 ml of anhydrous THF. The solution was cooled to 0 °C to 10 °C and a solution of 11.4 ml DEAD in 30 ml anhydrous THF was added dropwise over 20 min. The reaction was warmed to RT and stirred for 45 min. A solution of 11.3 ml 2-(2,4-Dichlorophenyl)-ethanol in 10 ml anhydrous THF was added with cooling. The reaction
15 was stirred at RT for 16 h, and then the solvents were removed under reduced pressure. The residue was treated with n-heptane:ethyl acetate/1:1. The filtrate was dried under reduced pressure. The product was purified by silica gel chromatography, eluting with n-heptane:ethyl acetate/4:1, then n-heptane:ethyl acetate/3:1.

Yield 17g.

- 20 (iii) 3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-benzoic acid

17g of 3-[2-(2,4-Dichlorophenyl)-ethoxy]-4-methoxy-benzoic acid methyl ester were dissolved in 200ml of MeOH:water/3:1. 4.1g of lithium hydroxide monohydrate was added to the solution, and the reaction was stirred at RT for 16 h then at 90°C for 2 h. The solution was cooled to RT, then acidified with half-concentrated hydrochloric acid.

- 25 The solvents were removed under reduced pressure and the residue was washed twice with warm water to remove salts. The so obtained acid was used for the subsequent reaction without further purification.


(iv) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(1H-pyrrolo[3,2-c]pyridin-2-ylmethyl)-benzamide

To a solution of 100 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoic acid in 1 ml DMF 53 mg carbonyldiimidazole were added. After stirring for 2 h at RT 48 mg of C-(1H-Pyrrolo[3,2-c]pyridin-2-yl)-methylamine tris-trifluoroacetate [prepared by adopting a procedure described by F. Ujjainwalla, D. Warner; Tetrahedron Lett. 1998, 39, 5355 and 5 L. Xu, I. Lewis, S. Davidsen, J. Summers, Tetrahedron Lett. 1998, 39, 5159] were added and stirred over night after addition of 5 mg of DMAP. The solvent was removed under reduced pressure and the residue purified by preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) The fractions containing the product were evaporated and lyophilised. The product was obtained as its 10 trifluoroacetate salt.

Yield 48 mg.

MS (ESI+): 470, chloro pattern


Example 23: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-N-furo[3,2-c]pyridin-2-ylmethyl-4-methoxy- benzamide



15


The title compound was prepared analogously to Example 22 with the difference that C-Furo[3,2-c]pyridin-2-yl-methylamine [prepared by adopting a procedure described by F. Ujjainwalla, D. Warner; Tetrahedron Lett. 1998, 39, 5355 and L. Xu, I. Lewis, S. Davidsen, J. Summers, Tetrahedron Lett. 1998, 39, 5159] was used instead of C-(1H-Pyrrolo[3,2-c]pyridin-2-yl)-methylamine. 20 MS (ESI+): 471, chloro pattern

Example 24: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(3-pyridin-4-yl-4,5-dihydro-isoxazol-5- ylmethyl)-benzamide




The title compound was prepared analogously to Example 22 with the difference that C-(3-Pyridin-4-yl-4,5-dihydro-isoxazol-5-yl)-methylamine was used instead of C-(1H-Pyrrolo[3,2-c]pyridin-2-yl)-methylamine. MS (ESI+): 500, chloro pattern

- 5 Example 25: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(2-pyridin-4-yl-ethyl)-benzamide




The title compound was prepared analogously to Example 22 with the difference that 2-Pyridin-4-yl-ethylamine was used instead of C-(1H-Pyrrolo[3,2-c]pyridin-2-yl)-methylamine. MS (ESI+): 445, chloro pattern

Example 26: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(2-pyridin-2-yl-ethyl)-benzamide



15 The title compound was prepared analogously to Example 22 with the difference that 2-Pyridin-2-yl-ethylamine was used instead of C-(1H-Pyrrolo[3,2-c]pyridin-2-yl)-methylamine. MS (ESI+): 445, chloro pattern

20 Example 27: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-piperidin-4-ylmethyl-benzamide




To a solution of 3 g 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoic acid in 20 ml CH₂Cl₂ 4.5 ml N-NEM and subsequently 2.9 g TOTU were added. After stirring for 1 h at RT 2.8 g 4-Aminomethyl-piperidine-1-carboxylic acid tBu ester in 10 ml CH₂Cl₂ were added and the mixture was stirred for 2 h. The reaction mixture was then diluted with 50 ml CH₂Cl₂ and was washed with saturated aqueous NaHCO₃ solution. The organic layer was dried over Na₂SO₄. After removal of the solvent the white residue was recrystallized from ethyl acetate to yield 4.8 g of the BOC-protected derivative. This crystalline white solid was suspended in EtOH/HCl at RT. After 3 h a clear solution was obtained. Removal of the solvent under reduced pressure yielded a white foam.

10 Yield: 3.7g MS (ESI+) 437, chloro pattern

Alternatively the compound could be obtained by activation with carbonylimidazole and subsequent reaction of the activated intermediate with C-Piperidin-4-yl-methylamine.

15 Example 28: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-N-[3-(1-hydroxy-pyridin-4-yl)-4,5-dihydro-isoxazol-5- ylmethyl]-4-methoxy-benzamide




To a solution of 100 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(3-pyridin-4-yl-4,5-dihydro-isoxazol-5- ylmethyl)-benzamide in 5 ml CH₂Cl₂ 70 mg MCPBA were added at RT and stirred over night. The solvent was removed under reduced pressure and the residue purified by preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5 % TFA) The fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 50 mg MS (ESI+): 516, chloro pattern

25

Example 29: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-N-[3-(1-methyl-pyridin-4-i um)-4,5-dihydro-isoxazol-5- ylmethyl]-4-methoxy-benzamidyl iodide




To a solution 30 mg (0.06 mmol) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(3-pyridin-4-yl-4,5-dihydro-isoxazol-5-ylmethyl)-benzamide in 5 ml acetone 0.3 ml Mel were added at RT and stirred for 2 d. The product precipitated from the solution as a yellow solid which was isolated by filtration.

Yield. 25mg

MS (ESI+): 515, chloro pattern

Example 30: N-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethyl]-3-[2-(2,4-dichloro-phenyl)-ethoxy]-4-methoxy-benzamide




10

To a solution of 250 mg hexamethylenetetraamine (1.8 mmol) in 8 ml CHCl₃ 500 mg (1.8 mmol) 3-Bromomethyl-5-(5-chloro-thiophen-2-yl)-isoxazole [Ewing, William R.; Becker, Michael R.; Choi-Sledeski, Yong Mi; Pauls, Heinz W.; He, Wei; Condon, Stephen M.; Davis, Roderick S.; Hanney, Barbara A.; Spada, Alfred P.; Burns, Christopher J.; Jiang, John Z.; Li, Aiwen; Myers, Michael R.; Lau, Wan F.; Poli, Gregory B; PCT Int. Appl. (2001), 460 pp. WO 0107436 A2]. was added and the reaction mixture stirred at 50 °C for 1 h and kept for additional 3 h at RT. The solvent was removed under reduced pressure and the residue was taken up in 5 ml EtOH and 2 ml concentrated HCl. This solution was heated for 5 h at 50 °C and the precipitate collected by filtration. An aliquot (68 mg) of the obtained amine was then subsequently coupled with 100 mg (0.29 mmol) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoic acid preactivated by addition of 95 mg TOTU and 150 mg N-NEM in 2 ml CH₂Cl₂. After stirring over night at RT the solvent was removed under reduced pressure and taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions

containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt. Yield 10 mg
 MS (ESI+): 537, chloro pattern


Example 31: N-(4-Aminomethyl-cyclohexylmethyl)-3-[2-(2,4-dichloro-phenyl)-ethoxy]-4-methoxy- benzamide
 5



To a solution of 100 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoic acid in 2 ml CH₂Cl₂ 150 µl N-NEM and subsequently 96 mg TOTU were added. After stirring for 1 h at room temperature (RT) 83mg C-(4-Aminomethyl-cyclohexyl)-methylamine in 1 ml
 10 CH₂Cl₂ were added and the mixture was stirred for additional 2 h followed by removal of the solvent under reduced pressure. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5 % TFA)
 15 the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 32 mg MS (ESI+): 465, chloro pattern

Example 32: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(1-pyridin-4-ylmethyl-
 20 piperidin-4- ylmethyl)-benzamide



A suspension of 120 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-piperidin-4-ylmethyl-benzamide, 50 mg 4-Picolychloride hydrochloride and 110 mg Cs₂CO₃ in 2 ml DMF was stirred at RT over night. The reaction mixture was diluted with 2 ml water, 25 filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase

column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield 22 mg

MS (ESI+): 528, chloro pattern


5

Analogously to example 32 the following compounds were prepared by a similar procedure

Example	Structure	MS (ESI+)
33		527, chloro pattern
34		544, chloro pattern
35		578, chloro pattern
36		552, chloro pattern


37		527, chloro pattern
38		595, chloro pattern

Example 39: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(1-methyl-1H-benzoimidazol-5-yl)- benzamide



- 5 This compound was prepared analogously to example 31 employing 1-Methyl-1H-benzoimidazol-5-ylamine as amine component. MS (ESI+): 470, chloro pattern

Example 40: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-[4-(pyrimidin-2-ylsulfamoyl)-phenyl]- benzamide




10

To a solution of 100 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoic acid in 2 ml CH₂Cl₂ 150 µl TEA and subsequently 77 mg TFFH were added. After stirring for 1 h at RT 87 mg 4-Amino-N-pyrimidin-2-yl-benzenesulfonamide in 1 ml CH₂Cl₂ were added and the mixture was stirred over night followed by removal of the solvent under reduced

pressure. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

5 Yield 11 mg MS (ESI+): 573, chloro pattern

Example 41: N-[1-(5-Chloro-thiophene-2-sulfonyl)-piperidin-4-ylmethyl]-3-[2-(2,4-dichloro-phenyl)-ethoxy]-4-methoxy-benzamide



10

To a solution of 50 mg (0.14 mmol) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-piperidin-4-ylmethyl-benzamide and 200 µl TEA in 3 ml DMF/CH₂Cl₂ 1:2, 73 mg 5-Chloro-thiophene-2-sulfonyl chloride were added at RT. The reaction mixture was stirred over night followed by concentration under reduced pressure. The residue was taken up in 1 ml (0.5M) NaOH solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

15


Yield: 15mg MS (ESI+): 617, chloro pattern

Analogously to example 42 the following compounds were prepared by a similar procedure:

Example	Structure	MS (ESI+)
43		583, chloro pattern

44		624, chloro pattern
45		602, chloro pattern
46		581, chloro pattern
47		602, chloro pattern

Example 48: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-N-[1-(4-dimethylamino-benzoyl)-piperidin-4-ylmethyl]- 4-methoxy-benzamide




- 5 To a solution of 50 mg (0.14 mmol) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-piperidin-4-ylmethyl-benzamide and 200 µl TEA in 3 ml DMF/CH₂Cl₂ 1:2, 61mg 4-Dimethylamino-benzoyl chloride hydrochloride were added at RT. The reaction mixture was stirred over night followed by concentration under reduced pressure. The residue was taken up in 1 ml (0.5M) NaOH solution and filtered through a chem elut® cartridge

by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

- 5 Yield: 10mg MS (ESI+): 584, chloro pattern


Example 49: N-[1-(2-Chloro-pyridine-4-carbonyl)-piperidin-4-ylmethyl]-3-[2-(2,4-dichlorophenyl)-ethoxy]-4-methoxy-benzamide



- 10 The title compound was prepared analogously to example 48 employing 2-Chloroisonicotinoyl chloride hydrochloride as acylation component.


MS (ESI+): 576, chloro pattern

- 15 Example 50: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-[1-(pyridine-3-carbonyl)-piperidin-4-ylmethyl]-benzamide




The title compound was prepared analogously to example 48 employing Nicotinoyl chloride hydrochloride as acylation component. MS (ESI+): 542, chloro pattern

- 20 Example 51: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-N-[1-(2,2-dimethyl-propionyl)-piperidin-4-ylmethyl]- 4-methoxy-benzamide



This compound was prepared analogously to example 48 employing pivalic anhydride as acylation component. MS (ESI+): 521, chloro pattern


Example 52: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-N-[1-(6-hydroxy-pyridine-3-carbonyl)-5-piperidin-4- ylmethyl]-4-methoxy-benzamide



To a solution of 100 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-piperidin-4-ylmethyl-benzamide in 2 ml CH₂Cl₂ 150µl N-NEM and subsequently 150 mg TOTU were added. After stirring for 1 h at RT 70 mg 6-Hydroxy-nicotinic acid in 1 ml CH₂Cl₂ were added and the mixture was stirred for additional 2 h followed by removal of the solvent under reduced pressure. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5 % TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.


Yield: 45mg MS (ESI+): 558, chloro pattern

Example 53: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-[1-(2-methoxy-pyridine-3-carbonyl)- piperidin-4-ylmethyl]-benzamide



The title compound was prepared analogously to example 52 employing 2-Methoxy-nicotinic acid as acylation component MS (ESI+): 572, chloro pattern

25 Example 54: N-(1-Cyclopentyl-piperidin-4-ylmethyl)-3-[2-(2,4-dichloro-phenyl)-ethoxy]-4-methoxy- benzamide



To a solution of 100 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-piperidin-4-ylmethyl-benzamide and 35 mg cyclopentanone in 2 ml acetonitrile 27 mg Na(CN)BH₃ were introduced. After stirring at RT overnight the reaction mixture was heated to 80°C for 4 h. After removal of the solvent under reduced pressure and purification by preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 47 mg

MS (ESI+): 505, chloro pattern


10

Analogously to example 54 the following compounds were prepared by a similar procedure:

Example	Structure	MS (ESI+)
55		479, chloro pattern
56		519, chloro pattern
57		533, chloro pattern

58		577, chloro pattern
59		520, chloro pattern
60		521, chloro pattern

Example 61: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(2'-methyl-3,4,5,6-tetrahydro-2H- [1,4']bipyridinyl-4-ylmethyl)-benzamide




- 5 A solution of 100 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-piperidin-4-ylmethyl-benzamide and 60 mg 4-Chloro-2-picoline in 6 ml n-BuOH/NEt₃ 5:1 was refluxed overnight. After subsequent removal of the solvent under reduced pressure and purification by preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5 % TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.
- 10 Yield: 67 mg MS (ESI+): 528, chloro pattern

Analogously to example 61 the following compounds were prepared by a similar procedure:

Example	Structure	MS (ESI+)
62		515, chloro pattern
63		544, chloro pattern
64		561, chloro pattern
65		575, chloro pattern
66		530, chloro pattern

Example 67: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide




A mixture of 110 mg (0.25 mmol) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-piperidin-4-ylmethyl-benzamide, 49 mg (0.49 mmol) 4-Bromopyridine hydrochloride, 57 mg sodium-t-butoxide in 5 ml THF were purged with argon for 10 min. Then 15 mg of (+)-R-Binap and 15 mg Pd(OAc)₂ were added under argon and the mixture refluxed
 5 overnight. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. Subsequent removal of the solvent under reduced pressure and purification by preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its
 10 trifluoroacetate salt.

Yield: 35 mg

MS (ESI+): 514, chloro pattern


Example 68: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(3,4,5,6-tetrahydro-2H-[1,2']bipyridinyl-4-ylmethyl)-benzamide



15

This compound was prepared analogously to example 67 employing 2-Bromopyridine hydrochloride coupling component. MS (ESI+): 514, chloro pattern

Example 69: N-[1-(4-Chloro-phenyl)-piperidin-4-ylmethyl]-3-[2-(2,4-dichloro-phenyl)-ethoxy]-4-methoxy-benzamide



A mixture of 100 mg (0.2 mmol) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-piperidin-4-ylmethyl-benzamide, 66 mg (0.34 mmol) 4-Bromochlorobenzene, 33 mg sodium-t-butoxide in 5 ml THF were purged with argon for 10min. Then 37 mg of dppf
 25 and 5 mg Pd(OAc)₂ were added under argon and the mixture refluxed overnight. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. Subsequent removal of the solvent under

reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 47 mg

MS (ESI+): 547, chloro pattern


5

Analogously to example 69 the following compounds were prepared by a similar procedure:

Example	Structure	MS (ESI+)
70		538, chloro pattern
71		591, chloro pattern
72		585, chloro pattern
73		544, chloro pattern

Example 74: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(1-pyrimidin-5-yl-piperidin-

10 4-ylmethyl)- benzamide




A mixture of 100 mg (0.2 mmol) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-piperidin-4-ylmethyl-benzamide, 50 mg (0.32 mmol) 4-Bromopyrimidine, 70 mg sodium-t-butoxide in 5 ml dioxane were purged with argon for 10 min. Then 37 mg of 2-(Dicyclohexylphosphino)biphenyl and 20 mg Pd₂(dba)₃ were added under argon and the mixture refluxed overnight. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. Subsequent removal of the solvent under reduced pressure and purification by preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5 % TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 21 mg

MS (ESI+): 515, chloro pattern

Example 75: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(6'-methoxy-3,4,5,6-tetrahydro-2H- [1,3']bipyridinyl-4-ylmethyl)-benzamide




A mixture of 100 mg (0.2 mmol) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-piperidin-4-ylmethyl-benzamide, 55 mg (0.32 mmol) 5-Brom-2-methoxypyridine, 70 mg sodium-t-butoxide in 5 ml dioxane were purged with argon for 10min. Then 37 mg of 2-(Dicyclohexylphosphino)biphenyl and 20 mg Pd₂(dba)₃ were added under argon and the mixture refluxed overnight. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. Subsequent removal of the solvent under reduced pressure and purification by preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5 % TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 52 mg

MS (ESI+): 544, chloro pattern

Example 76: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(1-phenyl-piperidin-4-ylmethyl)- benzamide




A mixture of 100 mg (0.2 mmol) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-piperidin-4-ylmethyl-benzamide, 50 mg (0.32 mmol) Bromobenzene, 70 mg sodium-t-butoxide in 5 ml dioxane were purged with argon for 10 min. Then 37 mg of 2-(Dicyclohexylphosphino)biphenyl and 20 mg Pd₂(dba)₃ were added under argon and the mixture refluxed overnight. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. Subsequent removal of the solvent under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised.


Yield: 14 mg

MS (ESI+): 513, chloro pattern

Example 77: 4-Bromo-3-[2-(2,4-dichloro-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl- 4-ylmethyl)-benzamide




(i) (3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-carbamic acid tBu ester



A suspension of 5 g (23.3 mmol) piperidin-4-ylmethyl-carbamic acid tBu ester 3.85 g (25.7 mmol) 4-chloropyridin hydrochloride in 15 ml n-BuOH/H₂O/NEt₃ 1:1:1 was refluxed for 3 days. After removal of the solvent under reduced pressure the residue was purified by chromatography on silica with CH₂Cl₂/MeOH 100:1 -> 50:1 -> 10:1 – 5:1 to yield a white solid.

(ii) C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris trifluoroacetate



To a solution of 4.58 g (3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-carbamic acid tBu ester in 12 ml CH₂Cl₂ 12 ml TFA were added at RT. After stirring for 30 min the
5 solution was diluted with 20 ml of toluene and evaporated under reduced pressure. The residue was codestilled twice with toluene and then used in the subsequent reactions without further purification.

(iii) 4-Bromo-3-hydroxy-benzoic acid methyl ester

1.5 ml of thionyl chloride was added to 40 ml of MeOH at 0 °C. The solution was stirred
10 for 10 min and 5 g of 4-Bromo-3-hydroxy-benzoic acid was added. The reaction was stirred for 16 h at RT then heated to 50 °C for 3 h. The solvents were removed under reduced pressure. The residue was used directly in the next step. Yield 5.92g

(iv) 4-Bromo-3-[2-(2,4-dichloro-phenyl)-ethoxy]-benzoic acid methyl ester

1.6 g of triphenylphosphine and 1 g of 4-Bromo-3-hydroxy-benzoic acid methyl ester
15 were dissolved in 15 ml of anhydrous THF. The solution was cooled to 0°C to 10°C and a solution of 0.88 ml DEAD in 5 ml anhydrous THF was added dropwise over 20 min. The reaction was warmed to RT and stirred for 45 min. A solution of 0.69 ml 2-(2,4-Dichlorophenyl)-ethanol in 2 ml anhydrous THF was added with cooling. The reaction was stirred at RT for 3 h, then the solvents were removed under reduced pressure. The
20 residue was treated with n-heptane:ethyl acetate/1:1. The filtrate was dried under reduced pressure. The product was purified by silica gel chromatography, eluting with n-heptane:ethyl acetate/4:1 to n-heptane:ethyl acetate/1:1. Yield 2g.

(v) 4-Bromo-3-[2-(2,4-dichloro-phenyl)-ethoxy]-benzoic acid

2 g of 4-Bromo-3-[2-(2,4-dichloro-phenyl)-ethoxy]-benzoic acid methyl ester was dissolved in 10 ml of MeOH:water/3:1. 230 mg of lithium hydroxide monohydrate were added to the solution, and the reaction was stirred at RT for 16 h then at 50°C for 2 h. The solution was cooled to RT, then acidified with half-concentrated hydrochloric acid. The suspension was concentrated under reduced pressure and then extracted with ethyl acetate. The organic layer was dried over Na₂SO₄ and the solvent was removed under reduced pressure to yield a white solid. Yield 2.2g







(vi) 4-Bromo-3-[2-(2,4-dichloro-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide

To a solution of 200 mg 4-Bromo-3-[2-(2,4-dichloro-phenyl)-ethoxy]-benzoic acid in 4 ml CH₂Cl₂ 259 µl N-NEM and subsequently 168 mg TOTU were added. After stirring for 1 h at RT 272 mg C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris trifluoroacetate in 1 ml CH₂Cl₂ were added and the mixture was stirred for additional 2 h followed by removal of the solvent under reduced pressure. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 178 mg MS (ESI+): 563, chloro pattern


Analogously to example 77 the following compounds were prepared by a similar procedure:

Example	Structure	MS (ESI+)
78		498, chloro pattern
79		499, chloro pattern
80		502, chloro pattern

81		518, chloro pattern
82		518, chloro pattern
83		514, chloro pattern
84		529, chloro pattern
85		485, chloro pattern
86		579, chloro pattern

87	<p>The structure shows a benzene ring substituted with two chlorine atoms at the 2 and 4 positions. A methylene group is attached to the ring, followed by an ethoxy group (-OCH₂CH₃). This is linked via an amide group (-CONH-) to a piperidinyl ring. The piperidinyl ring is further substituted with a 4-(pyridin-2-yl)methyl group.</p>	485, chloro pattern
----	---	---------------------

Example 88: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-4-trifluoromethyl-benzamide



5 (i) 3-Hydroxy-4-iodo-benzoic acid

To a solution of 26 g 3-Hydroxybenzoic acid and 43 g Na₂CO₃ in 45 mg H₂O at 100°C was added dropwise a solution of 48 g KI and 48 g iodine in 135 ml H₂O. After heating for additional 3 h the mixture was cooled to RT and acidified with concentrated HCl. The title compound precipitated as a white solid and was collected by filtration.

10 Yield 20 g

(ii) 3-Hydroxy-4-iodo-benzoic acid methyl ester

5 ml of thionyl chloride was added to 120 ml of MeOH at 0 °C. The solution was stirred for 10 min and 20 g of 4-Iodo-3-hydroxy-benzoic acid was added. The reaction was stirred for 16 h at RT then heated to 50 °C for 3 h. The solvents were removed under reduced pressure. The residue was used directly in the next step. Yield 21 g

15 (iii) 4-Iodo-3-[2-(2,4-dichlorophenyl)-ethoxy]-benzoic acid methyl ester

6.6 g of triphenylphosphine and 5 g of 4-Iodo-3-hydroxy-benzoic acid methyl ester were dissolved in 65 ml of anhydrous THF. The solution was cooled to 0 °C to 10 °C and a solution of 3.7 ml DEAD in 7.5 ml anhydrous THF was added dropwise over 20 min. The reaction was warmed to RT and stirred for 45 min. A solution of 2.8 ml 2-(2,4-Dichlorophenyl)-ethanol in 3 ml anhydrous THF was added with cooling. The reaction was stirred at RT for 3 h, then the solvents were removed under reduced pressure. The residue was treated with n-heptane:ethyl acetate/1:1. The filtrate was dried under

reduced pressure. The product was purified by silica gel chromatography, eluting with n-heptane:ethyl acetate/4:1 to n-heptane:ethyl acetate/1:1.

Yield 8 g.

(iv) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-trifluoromethyl-benzoic acid methyl ester

- 5 To suspension of 800 mg 4-Iodo-3-[2-(2,4-dichloro-phenyl)-ethoxy]-benzoic acid methyl ester, 520 mg Cul and 160 mg KF in 5 ml DMF 0.57 ml chloro-difluoro-acetic acid methyl ester were added dropwise at 120 °C and then stirred over night. After addition of 5 ml saturated aqueous NH₄Cl the suspension was filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by
10 preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 720 mg

MS (ESI+): 451, chloro pattern

(v) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-trifluoromethyl-benzoic acid

- 15 500 mg of 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-trifluoromethyl-benzoic acid methyl ester was dissolved in 10 ml of MeOH:water/3:1. 230 mg of lithium hydroxide monohydrate were added to the solution, and the reaction was stirred at RT for 16 h then at 50 °C for 2 h. The solution was cooled to RT, then acidified with half-concentrated hydrochloric acid. The solution was concentrated under reduced pressure and then extracted with ethyl
20 acetate. The organic layer was dried over Na₂SO₄ and the solvent was removed under reduced pressure to yield a white solid.

Yield: 480 mg

(vi) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-4-trifluoromethyl-benzamide


- 25 To a solution of 200 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-trifluoromethyl-benzoic acid in 4 ml CH₂Cl₂ 1 ml N-NEM were added followed by 237 mg TOTU. After stirring for 1 h at RT 282 mg C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris trifluoroacetate in 1 ml CH₂Cl₂ was added and the mixture was stirred for additional 2 h followed by removal of the solvent under reduced pressure. The residue was taken up in
30 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

100

Yield: 180 mg

MS (ESI+): 552, chloro pattern

Example 89: 4-Cyano-3-[2-(2,4-dichloro-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl- 4-ylmethyl)-benzamide



5

(i) 4-Cyano-3-[2-(2,4-dichloro-phenyl)-ethoxy]-benzoic acid methyl ester

A suspension of 800 mg 4-Iodo-3-[2-(2,4-dichloro-phenyl)-ethoxy]-benzoic acid methyl ester, 180 mg CuCN, 312 mg Et₄N CN in 8 ml dioxane were purged with argon for 10 min. Then 91 mg Pd₂(dba)₃ and 111 mg dppf were added and the mixture refluxed overnight. After addition of 5 ml saturated aqueous NH₄Cl the suspension was filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5 % TFA) the fractions containing the product were evaporated and lyophilised.

15

Yield: 500 mg MS (ESI+): 350, chloro pattern

(ii) 4-Cyano-3-[2-(2,4-dichloro-phenyl)-ethoxy]-benzoic acid

500mg of 4-Cyano-3-[2-(2,4-dichloro-phenyl)-ethoxy]-benzoic acid methyl ester was dissolved in 50ml of MeOH:water/3:1. 1 g of lithium hydroxide monohydrate was added to the solution, and the reaction was stirred at RT for 16 h and 2 h at 50°C. The solution was cooled to RT, then acidified with half-concentrated hydrochloric acid. The suspension was concentrated under reduced pressure and then extracted with ethyl acetate. The organic layer was dried over Na₂SO₄ and the solvent was removed under reduced pressure to yield a white solid.

20

Yield: 480 mg

25

(iii) 4-Cyano-3-[2-(2,4-dichloro-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl- 4-ylmethyl)-benzamide

30


To a solution of 200 mg 4-Cyano-3-[2-(2,4-dichloro-phenyl)-ethoxy]-benzoic acid in 4ml CH₂Cl₂ 1 ml N-NEM were added followed by 237 mg TOTU. After stirring for 1 h at RT 282 mg C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris trifluoroacetate in 1 ml CH₂Cl₂ were added and the mixture was stirred for additional 2 h followed by

removal of the solvent under reduced pressure. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 124 mg

MS (ESI+): 509, chloro pattern

Example 90: 3-[3-(2,4-Dichloro-phenyl)-ureido]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



To a solution of 200 mg 3-Isocyanato-benzoic acid methyl ester in 2 ml ethyl acetate is added dropwise a solution of 162 mg 2,4-dichloroaniline in 1 ml ethyl acetate. After 5 h at RT the solvent was removed under reduced pressure and the residue dissolved in 5 ml MeOH/THF/H₂O 2:2:1. 100 mg lithium hydroxide monohydrate was added and the mixture stirred over night at RT. After removal of the solvent the residue was acidified by addition of 5 ml half concentrated HCl. The precipitating acid was filtered off and dried.


(ii) 3-[3-(2,4-Dichloro-phenyl)-ureido]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide

To a solution of 100 mg 3-[3-(2,4-Dichloro-phenyl)-ureido]-benzoic acid in 5 ml ethyl acetate 0.5 ml NEt₃ and 102 mg BOP-Cl were added. After 10 min 100 mg C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris trifluoroacetate in 1 ml CH₂Cl₂ were added and the mixture stirred for 2 h at RT followed by removal of the solvent under reduced pressure. The residue was taken-up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 73mg

MS (ESI+): 498, chloro pattern


Example 91: 3-[3-(5-Chloro-pyridin-2-yl)-ureido]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



5

This compound was prepared analogously to example 90 employing 5-Chloro-pyridin-2-ylamine as amine component. MS (ESI+): 465, chloro pattern

- 10 Example 92: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methylsulfanyl-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



(i) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methylsulfanyl-benzoic acid

To a solution of 300 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-fluoro-benzoic acid methyl ester in 0.5 ml DMSO 70 mg NaSMe were added and stirred over night. After addition of 0.3 ml H₂O and 20 mg lithium hydroxide monohydrate the solution was stirred for 5 h and then acidified with diluted HCl. The mixture was extracted with ethyl acetate, the organic layer dried over Na₂SO₄. Removal of the solvent yielded the acid as a yellow solid.


(ii) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methylsulfanyl-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide

To a solution of 120 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methylsulfanyl-benzoic acid in 5 ml ethyl acetate 0.5 ml NEt₃ and 102 mg BOP-Cl were added. After 10 min 100 mg C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris trifluoroacetate in 1 ml CH₂Cl₂ were added and the mixture stirred for 10 h at RT followed by removal of the solvent under reduced pressure. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After

concentration under reduced pressure and purification by preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5 % TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

- 5 Yield: 57mg MS (ESI+): 530, chloro pattern

Example 93: 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethoxy]-4-methoxy-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



- 10 (i) 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethoxy]-4-methoxy-benzoic acid

To a solution of 145 mg 3-Hydroxy-4-methoxy-benzoic acid methyl ester in 2 ml DMF 200 mg 3-Bromomethyl-5-(5-chloro-thiophen-2-yl)-isoxazole [prepared as described in example 30] and 325 mg Cs₂CO₃ were added. The mixture was stirred for 3 h at RT and then diluted with 1 ml H₂O and 1 ml EtOH. After addition of 500 mg lithium hydroxide monohydrate the suspension was stirred over night. Subsequent removal of the solvent under reduced pressure and addition of diluted HCl yielded the acid as a white precipitate which was collected by filtration.

(ii) 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethoxy]-4-methoxy-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide

- 20 To a solution of 180 mg 3-[5-(5-Chloro-thiophen-2-yl)-isoxazol-3-ylmethoxy]-4-methoxy-benzoic acid in 5 ml ethyl acetate 0.5 ml NEt₃ and 250 mg BOP-Cl were added. After 30 min 200 mg C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris trifluoroacetate in 1ml CH₂Cl₂ were added and the mixture stirred for 10 h at RT followed by removal of the solvent under reduced pressure. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.


- 30 Yield: 157 mg MS (ESI+): 539, chloro pattern

Analogously to example 93 the following compounds were prepared by a similar procedure:

Example	Structure	MS (ESI+)
94		509, chloro pattern
95		558
96		543, chloro pattern

Example 97: 3-(6-Chloro-benzo[b]thiophene-2-sulfonylamino)-4-methoxy-N-(3,4,5,6-

5 tetrahydro-2H- [1,4']bipyridinyl-4-ylmethyl)-benzamide



(i) 3-(6-Chloro-benzo[b]thiophene-2-sulfonylamino)-4-methoxy-benzoic acid

To a solution of 36 mg 3-Amino-4-methoxy-benzoic acid methyl ester in 1 ml acetonitrile and 0.1 ml NEt₃ 50 mg 6-Chloro-benzo[b]thiophene-2-sulfonyl chloride [prepared by a

procedure described by Ewing, William R.; Becker, Michael R.; Choi-Sledeski, Yong Mi; Pauls, Heinz W.; He, Wei; Condon, Stephen M.; Davis, Roderick S.; Hanney, Barbara A.; Spada, Alfred P.; Burns, Christopher J.; Jiang, John Z.; Li, Aiwen; Myers, Michael R.; Lau, Wan F.; Poli, Gregory B., PCT Int. Appl. (1999), 300 pp. WO99/37304] were added

5 at RT. The mixture was stirred at RT for 5 h, then diluted with 2 ml MeOH/THF/H₂O 2:2:1. After addition of 100 mg lithium hydroxide monohydrate the suspension was stirred over night. Subsequent removal of the solvent and addition of diluted HCl yielded the acid as a white precipitate, which was filtered off.


10 (ii) 3-(6-Chloro-benzo[b]thiophene-2-sulfonylamino)-4-methoxy-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide

To a solution of 80 mg 3-(6-Chloro-benzo[b]thiophene-2-sulfonylamino)-4-methoxybenzoic acid in 5 ml ethyl acetate 0.1 ml NEt₃ and 100 mg BOP-Cl were added. After 30 min 200 mg C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris trifluoroacetate in 1 ml CH₂Cl₂ were added and the mixture stirred for 10 h at RT followed by 15 removal of the solvent under reduced pressure. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was 20 obtained as its trifluoroacetate salt.

Yield: 44mg

MS (ESI+): 571, chloro pattern

Example 98: 3-(2,4-Dichloro-benzylsulfamoyl)-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



25

(i) 3-(2,4-Dichloro-benzylsulfamoyl)-benzoic acid

To a solution of 1.3 g 2,4-Dichloro-benzylamine and 5 mg DMAP in 10 ml pyridine 1 g 3-Chlorosulfonyl-benzoic acid in 10 ml ethyl acetate was added dropwise. After stirring over night the solvent was removed under reduced pressure and the residue was taken


up in 10 ml diluted HCl and extracted with ethyl acetate. The organic layer is dried over Na₂SO₄ and concentrated to yield the acid as a yellow solid.

(ii) 3-(2,4-Dichloro-benzylsulfamoyl)-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide

- 5 To a solution of 100mg 3-(2,4-Dichloro-benzylsulfamoyl)-benzoic acid in 4 ml CH₂Cl₂ 259 µl N-NEM and subsequently 47 mg TOTU were added. After stirring for 1 h at RT 172 mg C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris trifluoro-acetate in 1 ml CH₂Cl₂ were added and the mixture was stirred for additional 2 h followed by removal of the solvent under reduced pressure. The residue was taken up in 3 ml saturated
10 NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.


- 15 Yield: 32 mg MS (ESI+): 533, chloro pattern

Example 99: 3-(5-Chloro-pyridin-2-ylsulfamoyl)-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



- This compound was prepared analogously to example 95 employing 5-Chloro-pyridin-2-ylamine as amine component. MS (ESI+): 486, chloro pattern

Example 100: 3-[2-(2,4-Dichloro-phenyl)-acetylamino]-4-methoxy-N-(3,4,5,6-tetrahydro-2H- [1,4']bipyridinyl-4-ylmethyl)-benzamide



- 25 (i) 3-[2-(2,4-Dichloro-phenyl)-acetylamino]-4-methoxy-benzoic acid methyl ester

To a solution of 1.1 g 3-Amino-4-methoxy-benzoic acid methyl ester and 1g (2,4-Dichloro-phenyl)-acetic acid in 15 ml CH₂Cl₂, 2.7 ml NEt₃ and 1.24 g BOP-Cl and 10 mg DMAP were added. After stirring over night the solvent was removed under reduced pressure and the residue directly purified by chromatography on silica with ethyl acetate/heptane 1:5 -> 1:1 to yield the ester as a yellow oil.

5 (ii) 3-[2-(2,4-Dichloro-phenyl)-acetylamino]-4-methoxy-benzoic acid

To a solution of 400 mg 3-[2-(2,4-Dichloro-phenyl)-acetylamino]-4-methoxy-benzoic acid methyl ester in 5 ml MeOH/H₂O 2:1 56 mg lithium hydroxide monohydrate were added and the mixture was stirred over night. The suspension was diluted with 5 ml concentrated HCl to precipitate the acid. After filtration the filter cake was washed twice with water and then dried to yield the acid as a white powder.

10 (iii) 3-[2-(2,4-Dichloro-phenyl)-acetylamino]-4-methoxy-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide


To a solution of 150 mg 3-[2-(2,4-Dichloro-phenyl)-acetylamino]-4-methoxy-benzoic acid in 4 ml CH₂Cl₂ 259 µl N-NEM and subsequently 70 mg TOTU were added. After stirring for 1 h at RT 268 mg C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris trifluoroacetate in 1 ml CH₂Cl₂ were added and the mixture was stirred for additional 2 h followed by removal of the solvent under reduced pressure. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

20 Yield: 97 mg

MS (ESI+): 527, chloro pattern

25

Example 101: 5-[2-(2,4-Dichloro-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-isophthalamide



(i) 5-[2-(2,4-Dichloro-phenyl)-ethoxy]-isophthalic acid dimethyl ester

- 1.75 g of triphenylphosphine and 1 g of 5-Hydroxy-isophthalic acid dimethyl ester were dissolved in 17ml of anhydrous THF. The solution was cooled to 0-10°C and a solution of 1 ml DEAD in 1 ml anhydrous THF was added dropwise over 20 min. The reaction was warmed to RT and stirred for 45 min. A solution of 11.3 ml 2-(2,4-Dichlorophenyl)-ethanol in 1 ml anhydrous THF was added with cooling. The reaction was stirred at RT for 16 h, then the solvents were removed under reduced pressure. The residue was treated with n-heptane:ethyl acetate/1:1. The filtrate was dried under reduced pressure and the product was purified by silica gel chromatography, eluting with n-heptane:ethyl acetate/4:1 to n-heptane:ethyl acetate/3:1.
- 5 (ii) 5-[2-(2,4-Dichloro-phenyl)-ethoxy]-isophthalic acid
500 mg 5-[2-(2,4-Dichloro-phenyl)-ethoxy]-isophthalic acid dimethyl ester were dissolved in 50 ml of MeOH:water/3:1. Then 1 g of lithium hydroxide monohydrate was added the solution, and the reaction was stirred at RT for 16 h and 2 h at 50°C. The solution was cooled to RT and then acidified with half-concentrated hydrochloric acid. The suspension
10 was concentrated under reduced pressure and then extracted with ethylacetate. The organic layer was dried over Na₂SO₄ and the solvent was removed under reduced pressure to yield a white solid.
- 15 (iii) 5-[2-(2,4-Dichloro-phenyl)-ethoxy]-isophthalamic acid
To a solution of 100 mg 5-[2-(2,4-Dichloro-phenyl)-ethoxy]-isophthalic acid in 3 ml THF
20 46 mg N,N-carbonyldiimidazole was added at RT. After 1 h 0.5 ml concentrated aqueous NH₃ solution were added and the reaction mixture was stirred for further 4 h. Concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised to yield a white solid. The
25 product was obtained as its trifluoroacetate salt.
- (iv) 5-[2-(2,4-Dichloro-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-isophthalamide
To a solution of 40 mg 5-[2-(2,4-Dichloro-phenyl)-ethoxy]-isophthalamic acid in 2 ml CH₂Cl₂ 59 µl N-NEM and subsequently 37mg TOTU were added. After stirring for 1 h at
30 RT 43 mg C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris trifluoroacetate in 1 ml CH₂Cl₂ were added and the mixture was stirred for additional 2 h followed by removal of the solvent under reduced pressure. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative


HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 12mg

MS (ESI+): 527, chloro pattern

5

Example 102: 5-[2-(2,4-Dichloro-phenyl)-ethoxy]-1-oxy-N-(3,4,5,6-tetrahydro-2H-[1,4"]bipyridinyl-4- ylmethyl)-nicotinamide



(i) 5-Hydroxy-1-oxy-nicotinic acid methyl ester

10 To a solution of 600 mg 5-Hydroxy-nicotinic acid methyl ester in 8 ml CH₂Cl₂ 880 mg MCPBA were added at 0°C. After stirring at RT over night the solvent was removed under reduced pressure. The residue was extracted with ethylacetate/heptane 1:1 . The product was isolated after filtration as a white solid and used without further purification in the subsequent reaction.

15 Yield: 600 mg.

(ii) 5-[2-(2,4-Dichloro-phenyl)-ethoxy]-1-oxy-nicotinic acid methyl ester

1.4 g of diphenyl-2-pyridylphosphine and 600mg 5-Hydroxy-1-oxy-nicotinic acid methyl ester and 0.5 ml 2-(2,4-dichlorophenyl)-ethanol were dissolved in 16 ml of anhydrous THF. The solution was cooled to 0-10°C and a solution of 1.22 g di- tert- butyl

20 azodicarboxylate in 1 ml anhydrous THF was added dropwise over 20 min. The reaction was warmed to RT and stirred over night. After addition of 14 ml saturated methanolic HCl the reaction mixture was stirred for 1 h and then the solvent was removed under reduced pressure. The residue was dissolved in CH₂Cl₂ and extracted with half-concentrated hydrochloric acid. The organic layer was evaporated and residue subjected

25 to the subsequent reaction without further purification.

Yield: 1.2 g

(iii) 5-[2-(2,4-Dichloro-phenyl)-ethoxy]-1-oxy-nicotinic acid

1.2 g 5-[2-(2,4-Dichloro-phenyl)-ethoxy]-1-oxy-nicotinic acid methyl ester were dissolved in 15 ml of MeOH/water 3:1. Then 200 mg of lithium hydroxide monohydrate was added 30 to the solution, and the reaction was stirred at RT for 16 h. The solution was acidified with

half-concentrated hydrochloric acid under precipitation of the product. After filtration a white solid was obtained.

Yield: 900 mg


(iv) 5-[2-(2,4-Dichloro-phenyl)-ethoxy]-1-oxy-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-nicotinamide

To a solution of 100 mg 5-[2-(2,4-Dichloro-phenyl)-ethoxy]-1-oxy-nicotinic acid in 4 ml CH₂Cl₂ 150 µl N-NEM and subsequently 50 mg TOTU were added. After stirring for 1 h at RT 223 mg C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris trifluoroacetate in 1 ml CH₂Cl₂ were added and the mixture was stirred over night followed by removal of the solvent under reduced pressure. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 55 mg

MS (ESI+): 501, chloro pattern

Example 103: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(4-pyridin-4-yl-phenyl)-benzamide



(i) 3-[2-(2,4-dichloro-phenyl)-ethoxy]-4-methoxy-benzamidoyl-4- phenyl-boronic acid

To a solution of 3.8 g 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoic acid in 20 ml CH₂Cl₂ 5.6 ml N-NEM and subsequently 3.6 g TOTU were added. After stirring for 1 h at RT 4- aminophenyl boronic acid 10 ml CH₂Cl₂ were added and the mixture was over night followed by removal of the solvent under reduced pressure. The residue was taken up in 10 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure the residue was subjected to the subsequent reaction without further purification.






(ii) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(4-pyridin-4-yl-phenyl)-benzamide

A mixture of 100 mg 3-[2-(2,4-dichloro-phenyl)-ethoxy]-4-methoxy-benzamidoyl-4-phenyl-boronic acid, 64 mg 4-Bromopyridine hydrochloride, 0.2 ml aqueous Na₂CO₃ (10M) in 5 ml dme were purged with argon for 10 min. Then 5 mg Pd(PPh₃)₃ were added under argon and the mixture refluxed overnight. The residue was taken up in 3 ml saturated 5 NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. Subsequent removal of the solvent under reduced pressure and purification by preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5 % TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

10 Yield: 8 mg MS (ESI-): 493, chloro pattern


Analogously to example 103 the following compounds were prepared by a similar procedure:

Example	Structure	MS (ESI+)
104		523, chloro pattern
105		535, chloro pattern
106		494, chloro pattern

107		493, chloro pattern
108		494, chloro pattern
109		517, chloro pattern
110		626, chloro pattern
111		508 chloro pattern

112		517, chloro pattern
113		510, chloro pattern
114		528, chloro pattern
115		523, chloro pattern
116		493, chloro pattern

Example 117: 2-[2-(2,4-Dichloro-phenyl)-ethoxy]-N4-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-terephthalamide



(i) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-terephthalamic acid methyl ester

To a solution of 100 mg 4-Cyano-3-[2-(2,4-dichloro-phenyl)-ethoxy]-benzoic acid methyl ester in 2 ml DMSO 93 mg K₂CO₃ and 68 µl H₂O₂ (35%) were added at RT. After stirring 5 the reaction over night the mixture was taken up in 5 ml ethyl acetate and 3 ml water and filtered through a chem elut® cartridge by elution with ethyl acetate. After removal of the solvent the crude product was subjected to the subsequent reaction.

Yield: 103 mg

(ii) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-terephthalamic acid

10 103 mg of 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-terephthalamic acid methyl ester were dissolved in 1.2 ml of MeOH/water 3:1. 14 mg of lithium hydroxide monohydrate were added to the added to the solution, and the reaction was stirred at RT for 16 h and 2 h at 50°C. The solution was cooled to RT, then acidified with half-concentrated hydrochloric 15 acid. The suspension was concentrated under reduced pressure and then extracted with ethyl acetate. The organic layer was dried over Na₂SO₄ and the solvent was removed under reduced pressure to yield a white solid.

Yield: 50 mg


(iii) 2-[2-(2,4-Dichloro-phenyl)-ethoxy]-N4-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)methyl)-terephthalamide:

20 To a solution of 50 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-terephthalamic acid in 2 ml CH₂Cl₂ 100 µl N-NEM and subsequently 27mg TOTU were added. After stirring for 1 h at RT 82 mg C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris trifluoroacetate in 1 ml CH₂Cl₂ were added and the mixture was stirred for additional 2 h followed by removal of the solvent under reduced pressure. The residue was taken up in 3 ml 25 saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

30 Yield: 8 mg


MS (ESI+): 527, chloro pattern

Example 118: 4-Acetylamino-3-[2-(2,4-dichloro-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



- 5 To a solution of 50 mg 4-Amino-3-[2-(2,4-dichloro-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide and 42 µl NEt₃ in 1 ml acetonitrile 30 µl acetic acid anhydride were added at RT. After stirring the reaction over night the mixture was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.
- 10 Yield: 15 mg MS (ESI+): 541, chloro pattern


- 15 Example 119: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-4-ureido-benzamide



- A solution of 50 mg 4-Amino-3-[2-(2,4-dichloro-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide and 13 mg KCNO in 2 ml acetic was stirred reaction over night at RT. The mixture was taken up in 5 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 8 mg MS (ESI+): 541, chloro pattern

Example 120: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methylamino-N-(3,4,5,6-tetrahydro-2H- [1,4']bipyridinyl-4-ylmethyl)-benzamide




- 5 (i) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methylamino-benzoic acid methyl ester
To a solution of 500 mg 4-Amino-3-[2-(2,4-dichloro-phenyl)-ethoxy]-benzoic acid methyl ester in 2.5 ml acetonitrile 0.5 ml MeI were added and stirred over night at RT. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.
- 10 (ii) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methylamino-benzoic acid
To a solution of 100 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methylamino-benzoic acid methyl ester in 3 ml of MeOH:water/3:1, 14 mg of lithium hydroxide monohydrate were added and the reaction was stirred at RT for 16 h. The solution was acidified with half-concentrated hydrochloric acid and the solvent was evaporated. The crude acid was subjected to the subsequent amide coupling without further purification.
- 15 (iii) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methylamino-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide
20 To a solution of 60 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methylamino-benzoic acid in 1 ml CH₂Cl₂ 100 µl N-NEM and subsequently 30 mg TOTU were added. After stirring for 1 h at RT 106 mg C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris trifluoro-acetate in 1 ml CH₂Cl₂ were added and the mixture was stirred over night followed by removal of the solvent under reduced pressure. The residue was taken up in 25 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 12 mg

MS (ESI+): 513, chloro pattern

Example 121: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-formylamino-N-(3,4,5,6-tetrahydro-2H- [1,4']bipyridinyl-4-ylmethyl)-benzamide



5


A solution of 50 mg 4-Amino-3-[2-(2,4-dichloro-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl- 4-ylmethyl)-benzamide in 0.2 ml formic acid were heated to 100°C for 1 h. The mixture was purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) and the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

10

Yield: 25 mg

MS (ESI+): 527, chloro pattern

Example 122: {2-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-[(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4- ylmethyl)-carbamoyl]-phenyl}-carbamic acid methyl ester



15

To a solution of 50 mg 4-Amino-3-[2-(2,4-dichloro-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl- 4-ylmethyl)-benzamide, 20 µl NEt₃ in 1 ml CH₂Cl₂ 10 µl chloroformic acid methyl ester were added at RT. After stirring over night the mixture was concentrated and purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) and the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.


20

Yield: 25 mg

MS (ESI+): 557, chloro pattern

Example 123: N-[1-(4-Chloro-phenyl)-piperidin-4-yl]-3-[2-(2,4-dichloro-phenyl)-ethoxy]-4-methoxy- benzamide

25



(i) 4-{3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoylamino}-piperidine-1-carboxylic acid tert-butyl ester

To a solution of 1 g 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoic acid in 15 ml

5 CH₂Cl₂ 1.5 ml N-NEM and subsequently 962 mg TOTU were added. After stirring for 1 h at RT 881 mg Boc-(4-amino)piperidine in 5 ml CH₂Cl₂ were added and the mixture was stirred for additional 2 h followed by addition of 20 ml saturated NaHCO₃ solution. The organic layer was separated and dried over Na₂SO₄ and the solvent evaporated. The residue was recrystallized from ethyl acetate/heptane to afford a white powder.

10 Yield: 1.4 g

(ii) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-piperidin-4-yl-benzamide

1.4 g 4-{3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoylamino}-piperidine-1-carboxylic acid tert-butyl ester was suspended in 20 ml HCl in ethanol at RT. After 2 h a clear solution was obtained. Addition of 50 ml toluene followed by evaporation of the solvent and repeatedly coevaporation of the residue with toluene yielded the product as a white foam.

15 Yield: 1 g

(iii) N-[1-(4-Chloro-phenyl)piperidin-4-yl]-3-[2-(2,4-dichlorophenyl)ethoxy]-4-methoxybenzamide

20 A mixture of 100 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-piperidin-4-yl-benzamide hydrochloride (0.2 mmol), 62 mg (0.33 mmol) 4-Bromochlorobenzene, 73 mg sodium-t-butoxide in 5 ml dioxane were purged with argon for 10 min. Then 37 mg of 2-(Dicyclohexylphosphino)biphenyl and 20 mg Pd₂(dba)₃ were added under argon and the mixture refluxed overnight. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. Subsequent removal of the solvent under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.


Yield: 3 mg

MS (ESI+): 533, chloro pattern

Analogously to example 123 the following compounds were prepared by a similar procedure::

Example	Structure	MS (ESI+)
124		530, chloro pattern
125		516, chloro pattern
126		501, chloro pattern
127		524, chloro pattern

Example 128: N-(1-Cyclohexyl-piperidin-4-yl)-3-[2-(2,4-dichlorophenyl)-ethoxy]-4-methoxy- benzamide



To a solution of 100 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-piperidin-4-yl-benzamide hydrochloride and 43 mg cyclohexanone in 2 ml acetonitrile 27 mg Na(CN)BH₃ were introduced. After stirring at RT overnight the reaction mixture was heated to 80°C for 4 h. After removal of the solvent under reduced pressure and purification by preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 26 mg MS (ESI+): 505, chloro pattern


10

Analogously to example 128 the following compounds were prepared by a similar procedure:

Example	Structure	MS (ESI+)
129		507, chloro pattern
130		506, chloro pattern

131	<p>The structure shows a benzamide group (benzene ring with a carbonyl group) attached to a 3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl group. This is further substituted with a 2-(5-chloropyridin-2-yl)ethoxy group and a methoxy group.</p>	563, chloro pattern
-----	--	---------------------

Example 132: 3-[2-(5-Chloro-pyridin-2-yl)-ethoxy]-4-methoxy-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



5 (i) 5-Chloro-2-vinyl-pyridine

A solution of 2 g 2,5-dichloropyridine and 4.3 g tributylvinylstannane in 20 ml toluene was purged with argon for 15 min. Then 50 mg Pd(PPh₃)₄ was added under argon and the reaction mixture was refluxed for 3 h. After removal of the solvent under reduced pressure the residue was taken up in ethyl acetate and saturated aqueous KF solution.

10 Filtration through a chem elut® cartridge by elution with ethyl acetate and evaporation of the solvent yielded a slightly brown oil.

Yield: 2 g

(ii) 2-(5-Chloro-pyridin-2-yl)-ethanol

To a solution of 2 g 5-Chloro-2-vinyl-pyridine in 10 ml THF was added dropwise 86 ml of a 9-BBN solution in THF (0.5 M) at RT. After 1 h 2.2 ml of a aqueous NaOH solution (10%) were added cautiously followed by the addition of 25 ml H₂O₂ (35%). This reaction mixture was stirred over night at RT. Then saturated Na₂SO₃ solution and 20 ml ethylacetate was added and the organic layer was separated. After removal of the solvent under reduced pressure and purification by preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 1.5 g

(iii) 3-[2-(5-Chloro-pyridin-2-yl)-ethoxy]-4-methoxy-benzoic acid methyl ester

To a solution of 400 mg 3-Hydroxy-4-methoxy-benzoic acid methyl ester, 346 mg 2-(5-Chloro-pyridin-2-yl)-ethanol, 1800 mg polymerbound triphenyl phosphine (Fluka, 3 mmol triphenylphosphine/g resin) and 1015 µl DEAD were introduced and the mixture was shaken over night at RT. After filtration, evaporation of the solvent the residue was purified by preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) and the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 530 mg

(iv) 3-[2-(5-Chloro-pyridin-2-yl)-ethoxy]-4-methoxy-benzoic acid

85 mg 3-[2-(5-Chloro-pyridin-2-yl)-ethoxy]-4-methoxy-benzoic acid methyl ester was dissolved in 1.2 ml of MeOH:water/3:1. 30 mg of lithium hydroxide monohydrate were added to the solution, and the reaction was stirred at RT for 16 h. The reaction mixture was acidified with half-concentrated hydrochloric acid. The suspension was concentrated under reduced pressure, coevaporated twice with toluene (2x10 ml) and then directly subjected to the subsequent amide coupling.

Yield. 50 mg


3-[2-(5-Chloro-pyridin-2-yl)-ethoxy]-4-methoxy-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide

To a solution of 50 mg 3-[2-(5-Chloro-pyridin-2-yl)-ethoxy]-4-methoxy-benzoic acid in 5 ml ethyl acetate 0.1 ml NEt₃ and 100 mg BOP-Cl were added. After 30 min 200 mg C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris trifluoro-acetate in 1 ml CH₂Cl₂ were added and the mixture stirred for 10 h at RT followed by removal of the solvent under reduced pressure. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C₁₈ reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 16 mg


MS (ESI+): 480, chloro pattern

Example 133: 4-Chloro-3-[2-(5-chloro-pyridin-2-yl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



This compound was prepared analogously to example 132 employing 4-Chloro-3-hydroxy-benzoic acid ethyl ester coupling component. MS (ESI+): 485, chloro pattern


- 5 Example 134: 3-[2-(5-Chloro-pyridin-2-yl)-ethoxy]-4-fluoro-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



This compound was prepared analogously to example 132 employing 4-Fluoro-3-hydroxy-benzoic acid ethyl ester coupling component. MS (ESI+): 569, chloro pattern

10

- Example 135: N-[1-(3-Acetylamino-phenyl)-piperidin-4-ylmethyl]-3-[2-(2,4-dichlorophenyl)-ethoxy]-4-methoxy-benzamide



To a solution of 50 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-piperidin-4-ylmethyl-benzamide hydrochloride, 38 mg 3-acetamidoboronic acid in 1 ml CH₂Cl₂, 100 mg molsieve 3Å, 38.5 mg Cu(OAc)₂ and 25 µl pyridine were added. The suspension was stirred for 3 d, then 3 ml saturated NaHCO₃ solution were added and the mixture filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column,

elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 2 mg


MS (ESI+); chloro pattern

- 5 Analogously to example 135 the following compounds were prepared by a similar procedure:

Example	Structure	MS (ESI+)
136		571, chloro pattern
137		543, chloro pattern
138		556, chloro pattern

- 10 Example 139: 3-[1-(4-Chlorophenyl)-cyclobutylmethoxy]-4-methoxy-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide

\



(i) [1-(4-Chloro-phenyl)-cyclobutyl]-methanol

To a solution of 1 g 1-(4-Chloro-phenyl)-cyclobutanecarboxylic acid in 15 ml THF were added dropwise at 0°C 9.5 ml BH₃*THF in THF (1M). Then the reaction mixture was 5 heated at reflux for 2 h and then cooled again to 0°C followed by cautious addition of 30 ml methanol. After evaporation of the solvents the residue was codestilled twice with toluene. The crude product was subjected to the subsequent reaction without further purification.

(ii) 3-[1-(4-Chloro-phenyl)-cyclobutylmethoxy]-4-methoxy-benzoic acid

10 To a solution of 300 mg 3-Hydroxy-4-methoxy-benzoic acid methyl ester, 388 mg [1-(4-Chloro-phenyl)-cyclobutyl]-methanol 1645 mg polymerbound triphenyl phosphine (Fluka, 3 mmol triphenyl phosphine/g resin) and 762 µl DEAD were introduced and the mixture was shaken over night at RT. After filtration, evaporation of the solvent the residue was taken up in 5 ml MeOH/H₂O 3:1 and 20 mg LiOH monohydrate was added. After heating 15 the mixture at 60°C for 2 h the mixture was acidified with half concentrated HCl and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure the crude product was subjected to the following amide coupling without further purification.

(iii) 3-[1-(4-Chloro-phenyl)-cyclobutylmethoxy]-4-methoxy-N-(3,4,5,6-tetrahydro-2H-

20 [1,4']bipyridinyl-4-ylmethyl)-benzamide





To a solution of 50 mg acid in 5 ml ethyl acetate 0.1 ml NEt₃ and 100 mg BOP-Cl were added. After 30 min 111 mg C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris trifluoro-acetate in 1 ml CH₂Cl₂ were added and the mixture stirred for 10 h at RT followed by removal of the solvent under reduced pressure. The residue was taken up in 25 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 10 mg

MS (ESI+): 520, chloro pattern


Analogously to example 139 the following compounds were prepared by a similar procedure:

5

Example	Structure	MS (ESI+)
140		506, chloro pattern
141		505, chloro pattern
142		502, chloro pattern
143		460, chloro pattern

144		480, chloro pattern
145		480, chloro pattern

Example 146: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-[1-(2-oxo-2-pyrrolidin-1-yl-ethyl)- piperidin-4-ylmethyl]-benzamide



5

(i) [4-(3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoylamino)-methyl]-piperidin-1-yl]- acetic acid

To 1 g 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-piperidin-4-ylmethyl-benzamide hydrochloride and 400 mg NaOH in 50 ml EtOH/H₂O 1:1 0.35 g bromo acetic acid were added at RT. After stirring over night the reaction mixture was acidified with half concentrated HCl. After evaporation of the solvent the residue was coevaporated with toluene. The waxy brown solid was subjected to the subsequent reaction without further purification.






Yield: 1.1 g

15 (ii) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-[1-(2-oxo-2-pyrrolidin-1-yl-ethyl)- piperidin-4-ylmethyl]-benzamide

To a solution of 60 mg [4-(3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoylamino}-methyl)-piperidin-1-yl]- acetic acid, 100 µl NEt₃ in 2 ml THF 30 mg CDI was added and the reaction mixture stirred for 2 h at RT. Then 18 mg pyrrolidine were added and the reaction was stirred for further 16 h . After removal of the solvent the residue was directly purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA). The fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.


- 5 Yield: 12 mg MS (ESI+): 547, chloro pattern
- 10 Analogously to example 146 the following compounds were prepared by a similar procedure:

Example	Structure	MS (ESI+)
147		564, chloro pattern
148		564, chloro pattern
149		576, chloro pattern

150		562, chloro pattern
151		576, chloro pattern
152		577, chloro pattern
153		560, chloro pattern
154		587, chloro pattern

155		522, chloro pattern
156		576, chloro pattern
157		536, chloro pattern

Example 158: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-[1-(2-oxo-2-pyrrolidin-1-yl-ethyl)- piperidin-4-yl]-benzamide



5

(i) (4-{3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoylamino}-piperidin-1-yl)-acetic acid

To 360 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-piperidin-4-yl-benzamide hydrochloride and 162 mg NaOH in 20 ml EtOH/H₂O 1:1 142 mg bromo acetic acid was

added at RT. After stirring over night the reaction mixture was acidified with half concentrated HCl. After evaporation of the solvent the residue was coevaporated with toluene. The waxy brown solid was subjected to the subsequent reaction without further purification.

5 Yield: 330 mg

(iii) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-[1-(2-oxo-2-pyrrolidin-1-yl-ethyl)-piperidin-4-yl]-benzamide

To a solution of 60 mg (4-{3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoylamino}-piperidin-1-yl)-acetic acid, 100 µl NEt₃ in 2 ml DMF 30 mg CDI was added and the reaction mixture stirred for 2 h at RT. Then 18 mg pyrrolidine were added and the reaction was stirred for further 16 h . After removal of the solvent the residue was directly purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA). The fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.


15 Yield: 22 mg MS (ESI+): 534, chloro pattern

Analogously to example 158 the following compounds were prepared by a similar procedure:

Example	Structure	MS (ESI+)
159		522, chloro pattern
160		563, chloro pattern

161		537, chloro pattern
162		550, chloro pattern

Example 163: 2-[3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoylamino]-3-furo[3,2-c]pyridin-2-yl- propionic acid methyl ester



5 (i) 3-Iodo-pyridin-4-ol

A solution of 20 g 4-hydroxypyridine and 13 g Na₂SO₄ in 50 ml water was heated to 100°C. To this mixture a solution of 27 g I₂, 28 g KI was added dropwise. After 3 h the mixture was washed with ethylacetate. Concentration of the aqueous layer led to precipitation of the product, which was isolated by filtration:

10 Yield: 12.5 g

(ii) 2-[3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoylamino]-pent-4-yneic acid methyl ester

To a solution of 1 g 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoic acid in 15 ml CH₂Cl₂ 1.5 ml N-NEM and subsequently 1.1 g TOTU were added. After stirring for 1 h at

15 RT 500 mg 2-Amino-pent-4-yneic acid methyl ester hydrochloride in 5 ml CH₂Cl₂ were added and the mixture was stirred over night followed by addition of 20 ml saturated

NaHCO₃ solution. The organic layer was separated and dried over Na₂SO₄ and the solvent evaporated. The residue was purified by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) and the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 1.4 g


(iii) 2-{3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoylamino}-3-furo[3,2-c]pyridin-2-yl- propionic acid methyl ester

A solution of 100 mg 2-{3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoylamino}-pent-4-yneic acid methyl ester, 74 mg 3-Iodo-pyridin-4-ol, 123 µl NEt₃, 1 mg CuI in 3 ml DMF was purged with argon for 15 min. Then 8 mg Pd(PPh₃)₂Cl₂, were added under argon and the mixture was heated to 100°C for 2 h. After cooling to 50°C 66 µl DBU was added, followed by stirring for 2 h at this temperature. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. Subsequent removal of the solvent under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 6mg

20

Example 164: 2-{3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoylamino}-3-(1H-pyrrolo[3,2- c]pyridin-2-yl)-propionic acid methyl ester



(i) (3-Iodo-pyridin-4-yl)-carbamic acid tert-butyl ester

25 To a solution of 20 g 4-aminopyridine in 50 ml acetic acid 46 g ICl were added at RT. The reaction mixture was heated to 100°C for 4 h and then quenched with 100 ml water. The pH was adjusted to 9 by addition of Na₂CO₃ solution followed by addition of Na₂SO₃. Extraction of the aqueous solution was done with ethylacetate. The organic layer was dried over Na₂SO₄ and the solvent removed under reduced pressure. The residue was

dissolved in 70 ml CH₂Cl₂ and 15 ml NEt₃. Then 20 g Boc₂O were added at RT and the reaction mixture was stirred over night. After removal of the solvent the residue was chromatographed on silica gel with heptane/ethylacetate to yield a brown solid.


Yield: 20 g

- 5 (ii) 2-(2-{3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoylamino}-2-methoxycarbonyl-ethyl)- pyrrolo[3,2-c]pyridine-1-carboxylic acid tert-butyl ester
A solution of 100 mg 2-{3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoylamino}-pent-4-yneic acid methyl ester, 106 mg (3-Iodo-pyridin-4-yl)-carbamic acid tert-butyl ester, 123 µl NEt₃, 1 mg CuI in 3 ml DMF was purged with argon for 15 min. Then 8 mg Pd(PPh₃)₂Cl₂ were added under argon and the mixture was heated to 100°C for 2 h.
10 After cooling to 50°C 66 µl DBU was added, followed by stirring for 2 h at this temperature. The residue was taken up in 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. Subsequent removal of the solvent under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.
- 15 Yield: 9 mg

- 20 (iii) 2-{3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoylamino}-3-(1H-pyrrolo[3,2-c]pyridin-2-yl)-propionic acid methyl ester

To a solution of 9 mg 2-(2-{3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoylamino}-2-methoxycarbonyl-ethyl)- pyrrolo[3,2-c]pyridine-1-carboxylic acid tert-butyl ester in 1 ml CH₂Cl₂ 0.5 ml TFA was added dropwise at 0°C. After 1 h 5 ml toluene were added and the solvent removed under reduced pressure to yield a brown foam. The product was obtained as its trifluoroacetate salt. Yield: 5 mg

Example 165: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-N-(2'-hydroxy-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-4-methoxy-benzamide



(i) (2'-Hydroxy-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-carbamic acid tert- butyl ester

To a solution of 500 mg 2,4 dihydroxypyridine in DMF 216 mg NaH (60% in mineral oil) were added at RT. After 30 min N-phenyltrifluoromethanesulfonamide was added and
5 the mixture stirred for 1 h. Then 960 mg (boc-aminomethyl)piperidine were added and the reaction mixture stirred over night. After water and extraction with ethylacetate the organic layer was dried over Na₂SO₄. Subsequent removal of the solvent under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were
10 evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 1.2 g

(ii) 4-Aminomethyl-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-2'-ol

To a solution of 500 mg (2'-Hydroxy-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)- carbamic acid tert- butyl ester in 5 ml CH₂Cl₂ 3 ml TFA was added dropwise at 0°C.
15 After 16 h 20 ml toluene were added and the solvent removed under reduced pressure to yield a brown foam.

Yield: 503 mg


(iii) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-N-(2'-hydroxy-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-4-methoxy-benzamide

20 To a solution of 200 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoic acid in 5 ml CH₂Cl₂ 300 µl N-NEM and subsequently 192 mg TOTU were added. After stirring for 1 h at RT 243 mg 4-Aminomethyl-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-2'-ol tris trifluoroacetate in 1 ml CH₂Cl₂ were added and the mixture was stirred for over night followed by removal of the solvent under reduced pressure. The residue was taken up in 5 ml
25 saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.


30 Yield: 85 mg

MS (ESI+): 530, chloro pattern

Example 166 : 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(1-pyrimidin-4-yl-piperidin-4-ylmethyl)- benzamide



(i) [1-(2-Chloro-pyrimidin-4-yl)-piperidin-4-ylmethyl]-carbamic acid tert-butyl ester




Piperidin-4-ylmethyl-carbamic acid tert-butyl ester (2 g, 9.33 mmol), 2,4-dichloro-pyrimidine (1.67 g, 11.2 mmol) and ethyl-diisopropyl-amine (2.41g, 18.66 mmol) were heated under reflux in 100 ml of ethanol for 4 hours. The reaction mixture was evaporated, dissolved in ethyl acetate and extracted with aqueous solution (pH4). The organic layer was dried with MgSO₄ and evaporated to yield a mixture of the main isomer [1-(2-chloro-pyrimidin-4-yl)-piperidin-4-ylmethyl]-carbamic acid tert-butyl ester and traces of [1-(4-chloro-pyrimidin-2-yl)-piperidin-4-ylmethyl]-carbamic acid tert-butyl ester.

Yield: 2.67 g (87%)

MS: 327.1/329.1 (M+H)⁺.

(ii) (1-Pyrimidin-4-yl-piperidin-4-ylmethyl)-carbamic acid tert-butyl ester




[1-(2-chloro-pyrimidin-4-yl)-piperidin-4-ylmethyl]-carbamic acid tert-butyl (400 mg) was dissolved in 100 ml of methanol. After addition of 50 mg of palladium on charcoal (10%) hydrogen was introduced in a shaking apparatus for 3 hours. After filtration of the catalyst the solution was evaporated.

Yield: 350 mg

MS: 293.2 (M+H)⁺.


(iii) C-(1-Pyrimidin-4-yl-piperidin-4-yl)-methylamine




(1-Pyrimidin-4-yl-piperidin-4-ylmethyl)-carbamic acid tert-butyl ester (400 mg) and 50 % aqueous trifluoro-acetic acid (5 ml) were stirred 24 hours at room temperature. The mixture was evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

- 5 Yield: 519 mg, MS: 193.2 (M+H)⁺.
 (iv) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-N-(1-pyrimidin-4-yl-piperidin-4-ylmethyl)-benzamide
 To a solution of 70 mg 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoic acid in 3 ml CH₂Cl₂ 200 µl N-NEM and subsequently 120 mg TOTU were added. After stirring for 1 h
 10 at RT 120 mg C-(1-Pyrimidin-4-yl-piperidin-4-yl)-methylamine tris trifluoro-acetate in 1 ml CH₂Cl₂ were added and the mixture was stirred for over night followed by removal of the solvent under reduced pressure. The residue was taken up in 5 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18
 15 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.
 Yield. 8 mg MS (ESI+): 515, chloro pattern

- 20 Example 167: 4-Chloro-3-[2-(6-chloro-pyridin-3-yl)-ethoxy]-N-(2'-methyl-3,4,5,6-tetrahydro-2H- [1,4']bipyridinyl-4-ylmethyl)-benzamide




- (i) (2'-Methyl-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-carbamic acid tert-butyl ester



A suspension of 1 g piperidin-4-ylmethyl-carbamic acid tBu ester 0.65 g 4-chloropicoline in 5 ml n-BuOH/H₂O/NEt₃ 1:1:1 was refluxed for 3 days. After removal of the solvent under reduced pressure the residue was purified by chromatography on silica with CH₂Cl₂/MeOH 100:1 -> 50:1 -> 10:1 – 5:1 to yield a white solid.

- 5 (ii) C-(2'-Methyl-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris trifluoroacetate




To a solution of 1.24 (2'-Methyl-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-carbamic acid tert- butyl ester in 5 ml CH₂Cl₂ 2 ml TFA were added at RT. After stirring 10 for 30 min the solution was diluted with 20 ml of toluene and evaporated under reduced pressure. The residue was codestilled twice with toluene and then used in the subsequent reactions without further purification

- (iii) 4-Chloro-3-[2-(6-chloro-pyridin-3-yl)-ethoxy]-N-(2'-methyl-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide
- 15 To a solution of 100 mg 3-[2-(5-Chloro-pyridin-2-yl)-ethoxy]-4-methoxy-benzoic acid in 5 ml ethyl acetate 0.1 ml NEt₃ and 150 mg BOP-Cl were added. After 30 min 124 mg C-(2'-Methyl-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris trifluoroacetate tris trifluoro-acetate in 1 ml CH₂Cl₂ were added and the mixture stirred for 10 h at RT followed by removal of the solvent under reduced pressure. The residue was taken up in 20 3 ml saturated NaHCO₃ solution and filtered through a chem elut® cartridge by elution with ethyl acetate. After concentration under reduced pressure and purification by preparative HPLC (C18 reverse phase column, elution with a H₂O/MeCN gradient with 0.5% TFA) the fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.
- 25 Yield: 18 mg MS (ESI+): 484, chloro pattern


Analogously to example 167 the following compounds were prepared by a similar procedure:

Example	Structure	MS (ESI+)
168		562, chloro pattern
169		484, chloro pattern
170		499, chloro pattern
171		494, chloro pattern

Example 172: N-[1-(2-Chloro-pyrimidin-4-yl)-piperidin-4-ylmethyl]-3-[2-(2,4-dichlorophenyl)-ethoxy]- 4-methyl-benzamide



(i) C-[1-(2-Chloro-pyrimidin-4-yl)-piperidin-4-yl]-methylamine



[1-(2-Chloro-pyrimidin-4-yl)-piperidin-4-ylmethyl]-carbamic acid tert-butyl ester (200 mg)

5 was stirred with 50 % aqueous trifluoro-acetic acid (5 ml) 24 hours at room temperature. The mixture was evaporated and lyophilized. The product was obtained as its trifluoroacetate salt.

Yield: 300 mg MS: 227.2/229.2 ($M+H$)⁺.


(ii) N-[1-(2-Chloro-pyrimidin-4-yl)-piperidin-4-ylmethyl]-3-[2-(2,4-dichloro-phenyl)-ethoxy]-10 4-methyl-benzamide

3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methyl-benzoic acid (50 mg, 0.15 mmol) and triethyl-amine (46.7 mg, 0.46 mmol) were dissolved in 5 ml of dichloro-methane. After cooling to -15°C ethyl chloroformate (18.4 mg, 0.17 mmol) in 5 ml of dichloro-methane was added and stirred at room temperature for 24 hours. The mixture was evaporated and the solid was washed with sodium bicarbonate solution and water and was dried.

15 Yield: 37 mg (37%) MS: 533.1/535.1 ($M+H$)⁺.

Example 173: N-[1-(5-Amino-[1,2,4]oxadiazol-3-yl)-piperidin-4-ylmethyl]-3-[2-(2,4-dichloro-phenyl)-ethoxy]-4-methyl-benzamide

20 (i) (1-Cyano-piperidin-4-ylmethyl)-carbamic acid tert-butyl ester




Piperidin-4-ylmethyl-carbamic acid tert-butyl ester (4 g, 18.66 mmol) was suspended in 120 ml of acetonitrile. Dried potassium carbonate (2.837 g, 20.53 mmol) was added. A solution of bromoacetonitrile in (3.72 ml, 5mmolar solution, 18.66 mmol) was added (argon atmosphere) and the mixture was stirred for 3 hours. After addition of aqueous

25

FeSO₄ solution and ethyl acetate, the separated solid was filtered and the organic layer separated, dried and evaporated.

Yield: 4.04 g (90%) MS: 240.2 (M+H)⁺.

(ii) [1-(N-Hydroxycarbamimidoyl)-piperidin-4-ylmethyl]-carbamic acid tert-butyl ester




5

(1-Cyano-piperidin-4-ylmethyl)-carbamic acid tert-butyl ester (2 g, 8.36 mmol), hydroxylamine hydrochloride (3.48 g, 50.14 mmol) and triethylamine (5.92 g, 58.5 mmol) were stirred in 30 ml of isopropanol at room temperature for 4 hours. The mixture was evaporated. After addition of water (pH4) and ethyl acetate, the organic layer was

10 separated and evaporated.

Yield: 1.3 g (57%) MS: 273.2 (M+H)⁺.

(iii) [1-(5-Trichloromethyl-[1,2,4]oxadiazol-3-yl)-piperidin-4-ylmethyl]-carbamic acid tert-butyl ester




15 Trichloroacetic acid anhydride (1.24 g, 4 mmol) was added at 0°C to a solution of [1-(N-Hydroxycarbamimidoyl)-piperidin-4-ylmethyl]-carbamic acid tert-butyl ester (1 g, 3.67 mmol) in 80 ml of tetrahydro-furan. The temperature was raised at room temperature and stirred for 3 hours. After addition of triethylamine (0.74 ml, 7.34 mmol) the mixture was heated at 70°C for 2 hours and evaporated. The residue was diluted with water and

20 extracted with ethyl acetate. The organic layer was dried with MgSO₄, evaporated and purified by column chromatography (RP18, acetonitrile/water). The product was obtained as its trifluoroacetate salt.

Yield: 1.07 g (73%) MS: 399.0/401.1 (M+H)⁺.

(iv) C-[1-(5-Trichloromethyl-[1,2,4]oxadiazol-3-yl)-piperidin-4-yl]-methylamine; compound 25 with trifluoro-acetic acid




[1-(5-Trichloromethyl-[1,2,4]oxadiazol-3-yl)-piperidin-4-ylmethyl]-carbamic acid tert- butyl ester (500 mg, 1.25 mmol) and 30 % aqueous trifluoro-acetic acid (5 ml) were stirred for

24 hours at room temperature. The mixture was evaporated and lyophilised. The product contains excess of trifluoro-acetic acid.

Yield: 577 mg MS: 298.9/300.9 ($M+H$)⁺.


(v) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methyl-N-[1-(5-trichloromethyl-[1,2,4]oxadiazol-3-yl)-piperidin-4-ylmethyl]-benzamide



3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methyl-benzoic acid (200 mg, 0.615 mmol) was dissolved in 5 ml DMF. After cooling to -15°C HATU (257.34 mg, 0.676 mmol) and N-ethylmorpholine (283.3 mg, 2.46 mmol) were added. The mixture was stirred at 0°C for 10 15 min. and 30 min. at room temperature. C-[1-(5-trichloromethyl-[1,2,4]oxadiazol-3-yl)-piperidin-4-yl]-methylamine; compound with trifluoro-acetic acid (254.4 mg, 0.615 mmol) was added and the mixture stirred for 1 hour and evaporated under reduced pressure. The residue was dissolved in sodium bicarbonate solution and extracted with ethyl acetate. The organic layer was dried with MgSO₄ and evaporated. The crude material 15 was used without further purification.

Yield: 250 mg.

(vi) N-[1-(5-Amino-[1,2,4]oxadiazol-3-yl)-piperidin-4-ylmethyl]-3-[2-(2,4-dichloro-phenyl)-ethoxy]-4-methyl-benzamide; compound with trifluoro-acetic acid




Crude 3-[2-(2,4-dichloro-phenyl)-ethoxy]-4-methyl-N-[1-(5-trichloromethyl-[1,2,4]oxadiazol-3-yl)-piperidin-4-ylmethyl]-benzamide (250 mg) was dissolved in 60 ml of methanol (containing ammonia, 7 molar) in an autoclave at 50 bar pressure and 50°C

for 24 hours. The mixture was evaporated under reduced pressure and purified on RP18 (5µm) (gradient acetonitrile/water (containing 0.1% trifluoro-acetic acid) 90:10 to 0:100). The fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.


5 Yield: 18 mg MS: 504.3/506.3 (M+H)⁺.

Example 174: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methyl-N-[4-(pyridin-4-yloxy)-3,4,5,6-tetrahydro- 2H-[1,4']bipyridinyl-4-ylmethyl]-benzamide



10


(i) 4-Cyano-4-trimethylsilyloxy-piperidine-1-carboxylic acid tert-butyl ester



4-Oxo-piperidine-1-carboxylic acid tert-butyl ester (6.48 g, 32.52 mmol) was dissolved in 50 ml of tetrahydro-furan. At 0°C trimethylsilyl cyanide (5.08 g, 51.38 mmol) and zink iodide (87 mg, 0.27 mmol) were added. The mixture was stirred 3 hours at 0°C and 3 hours at 60°C. The solid was filtered, the filtrate evaporated and the crude product was used without further purification.

15 Yield: 7.54 g MS: 299.1 (M+H)⁺.

(ii) 4-Aminomethyl-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester




20

4-Cyano-4-trimethylsilyloxy-piperidine-1-carboxylic acid tert-butyl ester (7.5 g) was dissolved in 100 ml of tetrahydro-furan under an argon atmosphere. A solution of lithium

aluminium hydride in tetrahydro-furan (30 ml, 1 molar) was dropwise added at 0°C. After stirring for 15 hours at room temperature, a sodium hydroxide solution (20%) was slowly added under cooling. The solid was filtered after dilution with ethyl acetate and the organic layer evaporated. The crude material contains a mixture of the desired product (MS: 231.2 (M+H)⁺) and the corresponding trimethylsilyl ether (MS: 303.1 (M+H)⁺) and was used without further purification.

Yield: 2.1 g.

(iii) 3-{3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methyl-benzoyl}-1-oxa-3,8-diaza-spiro[4.5]decane- 8-carboxylic acid tert-butyl ester




10

3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methyl-benzoic acid (300 mg, 0.922 mmol) and crude 4-aminomethyl-4-hydroxy-piperidine-1-carboxylic acid tert-butyl ester (212.5 mg, 0.922 mmol) was dissolved in 5 ml DMF. After cooling to -15°C HATU (386 mg, 1 mmol) and N-ethylmorpholine (318.9 mg, 2.77 mmol) were added. The mixture was stirred at 0°C for 2 hours and at room temperature for 15 hours, evaporated and purified on RP18 (5µm) (gradient acetonitrile water 90:10 to 0:100). The fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 155 mg (31%) MS: 549.2 (M+H)⁺.

(iv) {3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methyl-phenyl}-(1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)- methanone



3-{3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methyl-benzoyl}-1-oxa-3,8-diaza-spiro[4.5]decane- 8-carboxylic acid tert-butyl ester (41 mg, 0.075 mmol) were stirred with

80 % aqueous trifluoro-acetic acid (2 ml) for 24 hours at room temperature. The mixture was evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.


Yield: 42 mg (100%)

MS: 449.1/451.1 (M+H)⁺.

- 5 (v) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methyl-N-[4-(pyridin-4-yloxy)-3,4,5,6-tetrahydro-
2H-[1,4']bipyridinyl-4-ylmethyl]-benzamide
{3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methyl-phenyl}-(1-oxa-3,8-diaza-spiro[4.5]dec-3-yl)-
methanone; compound with trifluoro-acetic acid (42 mg, 0.075 mmol), 4-Chloro-pyridine;
hydrochloride (33.5 mg, 0.22 mmol) and triethyl-amine (37.7 mg, 0.37 mmol) were
10 heated in 10 ml of n-butanol under reflux for 7 days. The mixture was evaporated and
purified on RP18 (5μm) (gradient acetonitrile water (containing 0.1% trifluoro-acetic acid)
90:10 to 0:100). The fractions containing the product were evaporated and lyophilised.
The product was obtained as its trifluoroacetate salt.
- Yield: 14 mg (23%) MS: 591.3/593.3 (M+H)⁺.


15

Example 175: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methyl-N-[1-[1-(2-oxo-1,2-dihydro-
pyrimidin-4-yl)- piperidin-4-yl]-ethyl]-benzamide



(i) N-(1-Pyridin-4-yl-ethyl)-formamide

20




- 1-Pyridin-4-yl-ethanone (24.2 g, 199.77 mmol) and 10 ml of formic acid were heated to
180°C and formamide (126 g, 2.797 mol) in 10 ml of formic acid was added within 30
25 min. The mixture was stirred for 90 min., cooled and poured in 100 ml of water. After
addition of conc. sodium hydroxide solution until pH13 the product was extracted with

diethyl-ether. The organic layer was dried with MgSO₄ and evaporated. Purification by distillation (165°C/4 mbar) yields pure product.

Yield: 17.9 g (60%) MS: 151.1 (M+H)⁺.

(ii) N-(1-Piperidin-4-yl-ethyl)-formamide

5




N-(1-Piperidin-4-yl-ethyl)-formamide (1.86 g, 12.38 mmol) was dissolved in 50 ml of acetic acid. After addition of Rh (5% on Al₂O₃, 307 mg) the mixture was hydrogenated with 10

10 bar hydrogen and 100°C for 120 hours. The mixture was evaporated and lyophilised. The crude material was used without purification.

Yield: 2.52 g MS: 157.2 (M+H)⁺.


(iii) N-{1-[1-(2-Chloro-pyrimidin-4-yl)-piperidin-4-yl]-ethyl}-formamide



15 N-(1-Piperidin-4-yl-ethyl)-formamide; compound with acetic acid (350 mg, 1.61 mmol), 2,4-dichloro-pyrimidine (265 mg, 1.78 mmol) and ethyl-diisopropyl-amine (848 mg, 6.56 mmol) in 20 ml of ethanol were heated under reflux for 5 hours. The mixture was evaporated and the residue dissolved in water and extracted with ethyl acetate. The organic layer was dried with MgSO₄ and evaporated.

20 Yield: 246 mg (46%) MS: 269.2 (M+H)⁺.


(vi) 4-[4-(1-Amino-ethyl)-piperidin-1-yl]-1H-pyrimidin-2-one



N-{1-[1-(2-Chloro-pyrimidin-4-yl)-piperidin-4-yl]-ethyl}-formamide (240 mg, 0.89 mmol) in 10 ml of 6 N hydrochloric acid was heated under reflux for 1 hour. The mixture was 25 evaporated and lyophilised.

Yield: 200 mg MS: 223.3 (M+H)⁺.

(v) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methyl-N-{1-[1-(2-oxo-1,2-dihydro-pyrimidin-4-yl)-piperidin-4-yl]-ethyl}-benzamide




3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methyl-benzoic acid (50 mg, 0.15 mmol) and 4-[4-(1-Amino-ethyl)-piperidin-1-yl]-1H-pyrimidin-2-one; hydrochloride (39.8 mg, 0.15 mmol) was dissolved in 3 ml DMF. After cooling to -15°C HATU (64 mg, 0.17 mmol) and N-ethylmorpholine (53.1 mg, 0.46 mmol) were added. The mixture was stirred at 0°C for 2 hours and at room temperature for 5 hours, evaporated and purified on RP18 (5µm) (gradient acetonitrile water 90:10 to 0:100). The fractions containing the product were evaporated and lyophilised. The product was obtained as its trifluoroacetate salt.

Yield: 33 mg (40%)

MS: 529.3/531.3 (M+H)⁺.

10

Example 176: {4-Bromo-3-[2-(2,4-dichloro-phenyl)-ethoxy]-phenyl}-(4-pyridin-4-ylmethyl-piperazin-1-yl)- methanone




0.05 g (0.13 mmol) of 4-Bromo-3-[2-(2,4-dichloro-phenyl)-ethoxy]-benzoic acid was dissolved in 3 ml of DMF and treated with 0.059 g (0.51 mmol) of NEM and 0.042 g (0.13 mmol) of TOTU and 0.023 g (0.13 mmol) of 1-Pyridin-4-ylmethyl-piperazine. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in acetonitrile and the residue was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt.

Yield 44.4 mg.

MS (ES⁺): m/e = 550 (M+H)⁺.

Example 177: {3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4,5-diethoxy-phenyl}-(4-pyridin-4-ylmethyl-piperazin-1-yl)-methanone (S0013313)



(i) 3,4-Diethoxy-5-hydroxy-benzoic acid ethyl ester

5 5 g (25.2 mmol) of 3,4,5-trihydroxy-benzoic acid ethyl ester was dissolved in 20 ml of DMF and treated at 0°C with 13.95 g (100.9 mmol) of potassium carbonate and 6.185 g (56.7 mmol) of ethyl bromide. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in ethyl acetate and the solution was washed three times with water and twice with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel 10 eluting with n-heptane/ethyl acetate (5/1).

Yield 1.2 g. MS (ES⁺): m/e = 255 (M+H⁺).

(ii) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4,5-diethoxy-benzoic acid ethyl ester

15 1.0 g (3.93 mmol) of 3,4-Diethoxy-5-hydroxy-benzoic acid ethyl ester was dissolved in 20 ml of anhydrous tetrahydrofuran. To this solution was added 0.83 g (4.33 mmol) of 2-(2,4-Dichlorophenyl)-ethanol, 3.93 g (equivalent to 11.8 mmol PPh₃) of triphenylphosphine derivatized polystyrene and 2.05 g (11.8 mmol) of DEAD. The solution was shaken for 16 h at RT. The polymer was filtered off and washed with ethyl acetate. The solvent was removed under reduced pressure. The residue was taken-up in ethyl acetate and the solution was washed three times with water and twice with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with ethyl acetate/n-heptane (1/5).

20 Yield 660 mg. LC-MS (ES⁺): m/e = 427 (M)⁺

(iii) 3-[2-(2,4-Dichlorophenyl)-ethoxy]-4,5-diethoxy-benzoic acid

25 0.66 g (1.54 mmol) of 3-[2-(2,4-Dichlorophenyl)-ethoxy]-4,5-diethoxy-benzoic acid ethyl ester was dissolved in 6 ml of dioxan. 5 ml of water and 2N aqueous NaOH was added to the solution to give a pH of 13. The reaction solution was heated at 60°C for 4 h and stirred at room temperature for 16h. The reaction solution was cooled to 0°C and concentrated hydrochloric acid was added to give a pH of 1-2, whereupon the product 30 precipitated from solution. The suspension was stirred for 30 min, then the product was

filtered off and dried under reduced pressure.


Yield 0.571g. MS (ES⁺): m/e = 399 (M⁺).

(iv) {3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4,5-diethoxy-phenyl}-(4-pyridin-4-ylmethyl-piperazin- 1-yl)-methanone

- 5 0.05 g (0.13 mmol) of 3-[2-(2,4-Dichlorophenyl)-ethoxy]-4,5-diethoxy-benzoic acid was dissolved in 2 ml of DMF and treated with 0.059 g (0.51 mmol) of NEM and 0.041 g (0.13 mmol) of TOTU and 0.022 g (0.13 mmol) of 1-Pyridin-4-ylmethyl-piperazine. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in acetonitrile and the residue was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt.


10 Yield 17.8 mg. MS (ES⁺): m/e = 558 (M+H)⁺.

- 15 Example 178: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4,5-diethoxy-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



- 20 0.050 g (0.13 mmol) of 3-[2-(2,4-Dichlorophenyl)-ethoxy]-4,5-diethoxy-benzoic acid was dissolved in 2 ml of DMF and treated with 0.058 g (0.5 mmol) of NEM and 0.041 g (0.13 mmol) of TOTU and 0.067 g (0.13 mmol) of C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris-trifluoroacetate salt. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in ethyl acetate and the solution was washed twice with saturated aqueous sodium bicarbonate and once with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure. The residue was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt. Yield 35.3 mg. MS (ES⁺): m/e = 572 (M⁺).

Example 179: 4-Bromo-3-[2-(2,4-dichloro-phenyl)-ethoxy]-5-ethoxy-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide (S0013436)



(i) 4-Bromo-3-[2-(2,4-dichlorophenyl)-ethoxy]-5-ethoxy-benzoic acid ethyl ester

5 200 mg (0.49 mmol) of 4-Bromo-3-[2-(2,4-dichloro-phenyl)-ethoxy]-5-hydroxy-benzoic acid was dissolved in 5 ml of DMF and treated at 0°C with 272 mg (1.97 mmol) of potassium carbonate and 537 mg (4.93 mmol) of ethyl bromide. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in ethyl acetate and the solution was washed three times with water and twice with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure.

Yield 219 mg. MS (ES⁺): m/e = 463 (M+H⁺).

(ii) 4-Bromo-3-[2-(2,4-dichlorophenyl)-ethoxy]-5-ethoxy-benzoic acid

15 0.21 g (0.47 mmol) of 4-Bromo-3-[2-(2,4-dichlorophenyl)-ethoxy]-5-ethoxy-benzoic acid ethyl ester was dissolved in 6 ml of dioxan. 6 ml of water and 2N aqueous NaOH was added to the solution to give a pH of 13. The reaction solution was heated at 60°C for 4 h and stirred at room temperature for 16h. The reaction solution was cooled to 0°C and concentrated hydrochloric acid was added to give a pH of 1-2, whereupon the product 20 precipitated from solution. The suspension was stirred for 30min, then the product was filtered off and dried under reduced pressure.

Yield 0.175 g. MS (ES⁺): m/e = 434 (M⁺).

(iii) 4-Bromo-3-[2-(2,4-dichlorophenyl)-ethoxy]-5-ethoxy-N-(3,4,5,6-tetrahydro-2H-


25 [1,4']bipyridinyl-4-ylmethyl)-benzamide

0.050 g (0.12 mmol) of 4-Bromo-3-[2-(2,4-dichlorophenyl)-ethoxy]-5-ethoxy-benzoic acid was dissolved in 3 ml of DMF and treated with 0.053 g (0.46 mmol) of NEM and 0.038 g (0.12 mmol) of TOTU and 0.061 g (0.12 mmol) of C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris-trifluoroacetate salt. The solution was stirred for 16

h at RT. The solvent was removed under reduced pressure. The residue was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt. Yield 42 mg. MS (ES⁺): m/e = 608 (M+H⁺).

5


Example 180: {4-Bromo-3-[2-(2,4-dichloro-phenyl)-ethoxy]-5-ethoxy-phenyl}-(4-pyridin-4-ylmethyl- piperazin-1-yl)-methanone (S0013437)



0.050 g (0.12 mmol) of 4-Bromo-3-[2-(2,4-dichlorophenyl)-ethoxy]-5-ethoxy-benzoic acid
10 was dissolved in 3 ml of DMF and treated with 0.053 g (0.46 mmol) of NEM and 0.038 g (0.12 mmol) of TOTU and 0.020 g (0.12 mmol) of 1-Pyridin-4-ylmethyl-piperazine. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in acetonitrile and the residue was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt. Yield 17.8 mg. MS (ES⁺): m/e = 594 (M+H)⁺.

15

Example 181: 4-Chloro-3-[2-(2,4-dichloro-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide (S0013438)



20

(i) 4-Chloro-3-hydroxy-benzoic acid methyl ester

5 g (29 mmol) of 4-Chloro-3-hydroxy-benzoic acid was suspended in 30 ml of saturated methanolic HCl and stirred at room temperature for 16h. 20ml of saturated methanolic HCl was added and stirred at room temperature for a further 16h. The solvent was removed under reduced pressure, and the residue was dried under reduced pressure.

25

Yield 5.3 g. MS (ES⁺): m/e = 187 (M+H)⁺.

(ii) 4-Chloro-3-[2-(2,4-dichloro-phenyl)-ethoxy]-benzoic acid methyl ester

2.0 g (10.72 mmol) of 4-Chloro-3-hydroxy-benzoic acid methyl ester was dissolved in 20

ml of anhydrous tetrahydrofuran. To this solution was added 2.25 g (11.79 mmol) of 2-

5 (2,4-Dichlorophenyl)-ethanol, 10.71 g (equivalent to 32.2 mmol PPh₃) of triphenylphosphine derivatized polystyrene and 5.6 g (32.2 mmol) of DEAD. The solution was shaken for 16 h at RT. The polymer was filtered off and washed with ethyl acetate. The solvent was removed under reduced pressure. The residue was taken-up in ethyl acetate and the solution was washed three times with water and twice with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with ethyl acetate/n-heptane (1/6).

10 Yield 3 g. LC-MS (ES⁺): m/e = 359 (M)⁺

(iii) 4-Chloro-3-[2-(2,4-dichloro-phenyl)-ethoxy]-benzoic acid

15 1.0 g (2.78 mmol) of 4-Chloro-3-[2-(2,4-dichloro-phenyl)-ethoxy]-benzoic acid methyl ester was dissolved in 10 ml of dioxan. 5 ml of water and 2N aqueous NaOH was added to the solution to give a pH of 13. The reaction solution was heated at 60°C for 4 h and stirred at room temperature for 16h. The reaction solution was cooled to 0°C and concentrated hydrochloric acid was added to give a pH of 1-2, whereupon the product


20 precipitated from solution. The suspension was stirred for 30min, then the product was filtered off and dried under reduced pressure.

Yield 0.910g. MS (ES⁺): m/e = 345 (M⁺).

(iv) 4-Chloro-3-[2-(2,4-dichloro-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide

25 0.050 g (0.15 mmol) of 4-Chloro-3-[2-(2,4-dichloro-phenyl)-ethoxy]-benzoic acid was dissolved in 3 ml of DMF and reacted with 0.067 g (0.58 mmol) of NEM and 0.048 g (0.15 mmol) of TOTU and 0.077 g (0.14 mmol) of C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris-trifluoroacetate salt. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure. The residue was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt. Yield 45.7 mg. MS (ES⁺): m/e = 518 (M⁺).


Example 182: {4-Chloro-3-[2-(2,4-dichloro-phenyl)-ethoxy]-phenyl}-(4-pyridin-4-ylmethyl-piperazin-1-yl)-methanone (S0013439)



0.050 g (0.15 mmol) of 4-Chloro-3-[2-(2,4-dichloro-phenyl)-ethoxy]-benzoic acid was
5 dissolved in 3 ml of DMF and treated with 0.067 g (0.58 mmol) of NEM and 0.048 g (0.15 mmol) of TOTU and 0.026 g (0.15 mmol) of 1-Pyridin-4-ylmethyl-piperazine. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure. The residue was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was
10 obtained as its trifluoroacetate salt.

Yield 62.6 mg. MS (ES⁺): m/e = 504 (M⁺).

Example 183: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-isopropoxy-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide (S0013552)



15

(i) 3-Hydroxy-4-isopropoxy-benzoic acid ethyl ester

5 g (27.5 mmol) of 3,4-Dihydroxy-benzoic acid ethyl ester was dissolved in 110 ml of DMF and treated at 0°C with 3.8 g (27.5 mmol) of potassium carbonate and 3.38 g (27.5 mmol) of isopropyl bromide. The solution was stirred for 16 h at RT, then a further 1.014 g (8.3 mmol) of isopropyl bromide was added. The reaction solution was heated at 50°C for 3h. The solvent was removed under reduced pressure, the residue was taken-up in ethyl acetate and the solution was washed three times with water and twice with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure. The residue was

chromatographed on silica gel eluting with n-heptane/ethyl acetate (5/1).

Yield 2.45 g. MS (ES⁺): m/e = 225 (M+H⁺).

(ii) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-isopropoxy-benzoic acid ethyl ester

1.5 g (6.69 mmol) of 3-Hydroxy-4-isopropoxy-benzoic acid ethyl ester was dissolved in 5 20 ml of anhydrous tetrahydrofuran. To this solution was added 1.4 g (7.36 mmol) of 2-(2,4-Dichlorophenyl)-ethanol, 6.7 g (equivalent to 20 mmol PPh₃) of triphenylphosphine derivatized polystyrene and 3.5 g (20 mmol) of DEAD. The solution was shaken for 16 h at RT. The polymer was filtered off and washed with ethyl acetate. The solvent was removed under reduced pressure. The residue was taken-up in ethyl acetate and the 10 solution was washed three times with water and twice with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with ethyl acetate/n-heptane (1/6).

Yield 0.77 g. LC-MS (ES⁺): m/e = 397 (M)⁺

15 (iii) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-isopropoxy-benzoic acid

0.75 g (1.89 mmol) of 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-isopropoxy-benzoic acid ethyl ester was dissolved in 15 ml of dioxan. 5 ml of water and 2N aqueous NaOH was added to the solution to give a pH of 13. The reaction solution was heated at 60°C for 4 h and stirred at room temperature for 16h. The reaction solution was cooled to 0°C and 20 concentrated hydrochloric acid was added to give a pH of 1-2, whereupon the product precipitated from solution. The suspension was stirred for 30min, then the product was filtered off and dried under reduced pressure.

Yield 0.630 g. MS (ES⁺): m/e = 369 (M⁺).


(iv) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-isopropoxy-N-(3,4,5,6-tetrahydro-2H-

25 [1,4"]bipyridinyl-4-ylmethyl)-benzamide

0.050 g (0.14 mmol) of 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-isopropoxy-benzoic acid was dissolved in 3 ml of DMF and treated with 0.062 g (0.54 mmol) of NEM and 0.044 g (0.14 mmol) of TOTU and 0.072 g (0.14 mmol) of C-(3,4,5,6-Tetrahydro-2H-[1,4"]bipyridinyl-4-yl)-methylamine tris-trifluoroacetate salt. The solution was stirred for 16 h at RT. The 30 solvent was removed under reduced pressure. The residue was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt.

Yield 27.9 mg. MS (ES⁺): m/e = 542 (M⁺).

Example 184: {3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-isopropoxy-phenyl}-(4-pyridin-4-ylmethyl-piperazin- 1-yl)-methanone




0.050 g (0.14 mmol) of 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-isopropoxy-benzoic acid was dissolved in 3 ml of DMF and treated with 0.062 g (0.54 mmol) of NEM and 0.044 g (0.14 mmol) of TOTU and 0.024 g (0.14 mmol) of 1-Pyridin-4-ylmethyl-piperazine. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure. The residue was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt.

Yield 44.3 mg.

MS (ES⁺): m/e = 528 (M⁺).

Example 185: 7-[2-(2,4-Dichloro-phenyl)-ethoxy]-benzo[1,3]dioxole-5-carboxylic acid (3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-amide

15



(i) 7-Hydroxy-benzo[1,3]dioxole-5-carboxylic acid ethyl ester

5 g (25.2 mmol) of 3,4,5-Trihydroxy-benzoic acid ethyl ester was dissolved in 50 ml of DMF and treated at 0°C with 13.95 g (101 mmol) of potassium carbonate and 4.39 g (25.2 mmol) of dibromomethane. The reaction solution was heated at 60°C for 3h. The solvent was removed under reduced pressure, the residue was taken-up in ethyl acetate and the solution was washed three times with water and twice with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with n-heptane/ethyl acetate (3/1).

Yield 0.45 g. MS (ES⁺): m/e = 211 (M+H⁺).

(ii) 7-[2-(2,4-Dichloro-phenyl)-ethoxy]-benzo[1,3]dioxole-5-carboxylic acid ethyl ester.
410 mg (1.95 mmol) of 7-Hydroxy-benzo[1,3]dioxole-5-carboxylic acid ethyl ester was dissolved in 20 ml of anhydrous tetrahydrofuran. To this solution was added 410 mg (2.15 mmol) of 2-(2,4-Dichlorophenyl)-ethanol, 1.9 g (equivalent to 5.85 mmol PPh₃) of triphenylphosphine derivatized polystyrene and 1.0 g (5.85 mmol) of DEAD. The solution was shaken for 16 h at RT. The polymer was filtered off and washed with ethyl acetate. The solvent was removed under reduced pressure. The residue was taken-up in ethyl acetate and the solution was washed three times with water and twice with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with ethyl acetate/n-heptane (1/5).

Yield 0.41 g. LC-MS (ES⁺): m/e = 383 (M)⁺

(iii) 7-[2-(2,4-Dichloro-phenyl)-ethoxy]-benzo[1,3]dioxole-5-carboxylic acid .

0.41 g (1.07 mmol) of 7-[2-(2,4-Dichloro-phenyl)-ethoxy]-benzo[1,3]dioxole-5-carboxylic acid ethyl ester was dissolved in 15 ml of dioxan. 5 ml of water and 2N aqueous NaOH was added to the solution to give a pH of 13. The reaction solution was heated at 60°C for 4 h and stirred at room temperature for 16h. The reaction solution was cooled to 0°C and concentrated hydrochloric acid was added to give a pH of 1-2, whereupon the product precipitated from solution. The suspension was stirred for 30min, then the product was filtered off and dried under reduced pressure.


Yield 0.35 g. ^ MS (ES⁺): m/e = 355 (M⁺).

(iv) 7-[2-(2,4-Dichloro-phenyl)-ethoxy]-benzo[1,3]dioxole-5-carboxylic acid (3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-amide

0.050 g (0.14 mmol) of 7-[2-(2,4-Dichloro-phenyl)-ethoxy]-benzo[1,3]dioxole-5-carboxylic acid was dissolved in 3 ml of DMF and treated with 0.065 g (0.56 mmol) of NEM and 0.046 g (0.14 mmol) of TOTU and 0.075 g (0.14 mmol) of C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris-trifluoroacetate salt. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure. The residue was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt.


Yield 47.4 mg. MS (ES⁺): m/e = 528 (M⁺).

Example 186: {7-[2-(2,4-Dichloro-phenyl)-ethoxy]-benzo[1,3]dioxol-5-yl}-(4-pyridin-4-ylmethyl- piperazin-1-yl)-methanone



0.050 g (0.14 mmol) of 7-[2-(2,4-Dichloro-phenyl)-ethoxy]-benzo[1,3]dioxole-5-carboxylic acid was dissolved in 3 ml of DMF and treated with 0.065 g (0.56 mmol) of NEM and 0.046 g (0.14 mmol) of TOTU and 0.025 g (0.14 mmol) of 1-Pyridin-4-ylmethyl-piperazine. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure. The residue was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt. Yield 74.9 mg. MS (ES⁺): m/e = 514 (M⁺).

Example 187: {4-Chloro-3-[2-(2,4-dichloro-phenyl)-ethoxy]-phenyl}-[4-(1-oxy-pyridin-4-ylmethyl)- piperazin-1-yl]-methanone




10 mg (0.01mmol) of {4-Chloro-3-[2-(2,4-dichloro-phenyl)-ethoxy]-phenyl}-(4-pyridin-4-ylmethyl-piperazin-1-yl)-methanone was dissolved in 0.5ml of dichloromethane and 3.5 mg (0.01 mmol) of 3-chloroperbenzoic acid was added. The solution was allowed to stand for 1 h at RT. The solvent was removed under reduced pressure. The residue was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt.

Yield 5.2 mg.

MS (ES⁺): m/e = 520 (M⁺).

Example 188: (4-Cyclohexylmethyl-piperazin-1-yl)-{3-[2-(2,4-dichloro-phenyl)-ethoxy]-4-methoxy-phenyl}- methanone








3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoic acid

- 5 0.050 g (0.15 mmol) of 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-4-methoxy-benzoic acid was dissolved in 3 ml of DMF and treated with 0.067 g (0.59 mmol) of NEM and 0.048 g (0.15 mmol) of TOTU and 0.027 g (0.15 mmol) of 1-cyclohexylmethyl-piperazine. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure. The residue was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt. Yield 66.7 mg. MS (ES⁺): m/e = 505 (M⁺).
- 10


The following examples were prepared analogously to example 188:

Example	Structure	MS (ES ⁺)
189		551
190		555

191		477
192		543
193		531
194		513
195		494

196		534
197		480
198		506

Example 199: 4-Chloro-3-[2-(2,4-dichlorophenyl)-ethoxy]-5-methoxy-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



5

(i) 4-Chloro-3,5-dihydroxy-benzoic acid methyl ester

10 g (42.9 mmol) of 4-Bromo-3,5-dihydroxy-benzoic acid was suspended in 40 ml of NMP and treated with 6.37 g (64.3 mmol) of CuCl. The reaction was heated at 205°C for 2 h. The solution was poured into 1 L of water. The resulting precipitate was filtered off.

10

The product was extracted from the resulting solution with ethyl acetate. The organic phase was washed twice with saturated aqueous sodium chloride. The organic phase was dried with sodium sulphate, filtered and the solvent was removed under reduced pressure. The residue was dissolve in saturated methanolic HCl and stirred at RT for 16 h. The solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with dichloromethane/methanol (10/1).

Yield 3.9 g. MS (ES⁺): m/e = 203 (M+H⁺).

(ii) 4-Chloro-3-hydroxy-5-methoxy-benzoic acid methyl ester

3.9 g (19.3 mmol) of 4-Chloro-3,5-dihydroxy-benzoic acid methyl ester was dissolved in 250 ml of DMF and treated at 0°C with 8.6 g (62 mmol) of potassium carbonate and 2.72 g (19.2 mmol) of iodomethane. The reaction solution was stirred at RT for 16h. The solvent was removed under reduced pressure, the residue was taken-up in ethyl acetate and this solution was washed three times with water and twice with saturated aqueous sodium chloride. The organic phase was dried with sodium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with n-heptane/ethyl acetate (5/1).

Yield 1.2 g. MS (ES⁺): m/e = 217 (M+H⁺).

(iii) 4-Chloro-3-[2-(2,4-dichloro-phenyl)-ethoxy]-5-methoxy-benzoic acid methyl ester

500 mg (2.31 mmol) of 4-Chloro-3-hydroxy-5-methoxy-benzoic acid methyl ester was dissolved in 15 ml of anhydrous tetrahydrofuran. To this solution was added 485 mg (2.54 mmol) of 2-(2,4-Dichlorophenyl)-ethanol, 2.3 g (equivalent to 6.92 mmol PPh₃) of triphenylphosphine derivatized polystyrene and 1.2 g (6.92 mmol) of DEAD. The solution was shaken for 16 h at RT. The polymer was filtered off and washed with ethyl acetate. The solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with ethyl acetate/n-heptane (1/5).

Yield 0.66 g. LC-MS (ES⁺): m/e = 389 (M)⁺

(iii) 4-Chloro-3-[2-(2,4-dichloro-phenyl)-ethoxy]-5-methoxy-benzoic acid

0.51 g (1.31 mmol) of 4-Chloro-3-[2-(2,4-dichloro-phenyl)-ethoxy]-5-methoxy-benzoic acid methyl ester was dissolved in 15 ml of dioxan. 5 ml of water and 2N aqueous NaOH was added to the solution to give a pH of 13. The reaction solution was heated at 60°C for 4 h and stirred at room temperature for 16h. The reaction solution was cooled to 0°C and concentrated hydrochloric acid was added to give a pH of 1-2, whereupon the product precipitated from solution. The suspension was stirred for 30min, then the product was filtered off and dried under reduced pressure.


Yield 0.46 g. MS (ES⁺): m/e = 375 (M⁺).

(iv) 4-Chloro-3-[2-(2,4-dichloro-phenyl)-ethoxy]-5-methoxy-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide

0.050 g (0.13 mmol) of 4-Chloro-3-[2-(2,4-dichloro-phenyl)-ethoxy]-5-methoxy-benzoic acid was dissolved in 3 ml of DMF and treated with 0.061 g (0.53 mmol) of NEM and 0.043 g (0.13 mmol) of TOTU and 0.071 g (0.13 mmol) of C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris-trifluoroacetate salt. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure. The residue was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt.

Yield 24.8 mg. MS (ES⁺): m/e = 550 (M+H⁺).


Example 200: {4-Chloro-3-[2-(2,4-dichloro-phenyl)-ethoxy]-5-methoxy-phenyl}-(4-pyridin-4-ylmethyl- piperazin-1-yl)-methanone



0.050 g (0.13 mmol) of 4-Chloro-3-[2-(2,4-dichloro-phenyl)-ethoxy]-5-methoxy-benzoic acid was dissolved in 3 ml of DMF and treated with 0.061 g (0.53 mmol) of NEM and 0.043 g (0.13 mmol) of TOTU and 0.024 g (0.13 mmol) of 1-Pyridin-4-ylmethyl-piperazine. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure. The residue was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt.

Yield 56.8 mg. MS (ES⁺): m/e = 536 (M+H⁺).

Example 201: 4-Chloro-3-[2-(4-methoxy-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4- ylmethyl)-benzamide (S0100717)



(i) 4-Chloro-3-[2-(4-methoxy-phenyl)-ethoxy]-benzoic acid methyl ester

1.0 g (5.36 mmol) of 4-Chloro-3-hydroxy-benzoic acid methyl ester was dissolved in 40 ml of anhydrous tetrahydrofuran. To this solution was added 0.897 g (5.9 mmol) of 2-(4-Methoxy-phenyl)-ethanol, 5.35 g (equivalent to 16.1 mmol PPh₃) of triphenylphosphine derivatized polystyrene and 2.80 g (16.1 mmol) of DEAD. The solution was shaken for 16 h at RT. The polymer was filtered off and washed with ethyl acetate. The solvent was removed under reduced pressure. The residue was taken-up in ethyl acetate and the solution was washed three times with water and twice with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with ethyl acetate/n-heptane (1/5).

Yield 1.27 g.

LC-MS (ES⁺): m/e = 321 (M)⁺

(ii) 4-Chloro-3-[2-(4-methoxy-phenyl)-ethoxy]-benzoic acid

1.27 g (3.96 mmol) of 4-Chloro-3-[2-(4-methoxy-phenyl)-ethoxy]-benzoic acid methyl ester was dissolved in 15 ml of dioxan. 5 ml of water and 2N aqueous NaOH was added to the solution to give a pH of 13. The reaction solution was heated at 60°C for 2 h and stirred at room temperature for 16h. The reaction solution was cooled to 0°C and concentrated hydrochloric acid was added to give a pH of 1-2, whereupon the product precipitated from solution. The suspension was stirred for 30min, then the product was filtered off and dried under reduced pressure.

Yield 1.10 g.


MS (ES⁺): m/e = 307 (M+H⁺).

(iii) 4-Chloro-3-[2-(4-methoxy-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide

0.050 g (0.16 mmol) of 4-Chloro-3-[2-(4-methoxy-phenyl)-ethoxy]-benzoic acid was dissolved in 3 ml of DMF and treated with 0.188 g (1.63 mmol) of NEM and 0.054 g (0.16 mmol) of TOTU and 0.087 g (0.16 mmol) of C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris-trifluoroacetate salt. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure. The residue was purified by preparative

RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt. Yield 40.1 mg. MS (ES⁺): m/e = 480 (M⁺).

- 5 Example 202: 4-Chloro-3-[2-(4-chloro-phenyl)-ethoxy]-5-methoxy-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide




This compound was prepared analogously to Example 199.

Yield 44.4 mg. MS (ES⁺): m/e = 514 (M⁺).

10

- Example 203: 4-Chloro-3-[2-(4-chloro-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



(i) 4-Chloro-3-[2-(4-chloro-phenyl)-ethoxy]-benzoic acid methyl ester

- 15 1.0 g (5.36 mmol) of 4-Chloro-3-hydroxy-benzoic acid methyl ester was dissolved in 40 ml of anhydrous tetrahydrofuran. To this solution was added 0.923 g (5.9 mmol) of 2-(4-chloro-phenyl)-ethanol, 5.35 g (equivalent to 16.1 mmol PPh₃) of triphenylphosphine derivatized polystyrene and 2.80 g (16.1 mmol) of DEAD. The solution was shaken for 16 h at RT. The polymer was filtered off and washed with ethyl acetate. The solvent was removed under reduced pressure. The residue was taken-up in ethyl acetate and the solution was washed three times with water and twice with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with ethyl acetate/n-heptane (1/5). Yield 1.6 g. LC-MS (ES⁺): m/e = 325 (M)⁺
- 20

(ii) 4-Chloro-3-[2-(4-chloro-phenyl)-ethoxy]-benzoic acid

1.6 g (4.94 mmol) of 4-Chloro-3-[2-(4-chloro-phenyl)-ethoxy]-benzoic acid methyl ester was dissolved in 15 ml of dioxan. 5 ml of water and 2N aqueous NaOH was added to the solution to give a pH of 13. The reaction solution was heated at 60°C for 2 h. The

5 reaction solution was cooled to 0°C and concentrated hydrochloric acid was added to give a pH of 1-2, whereupon the product precipitated from solution. The suspension was stirred for 30min, then the product was filtered off and dried under reduced pressure.

Yield 1.21 g.

MS (ES⁺): m/e = 311 (M⁺).

(iii) 4-Chloro-3-[2-(4-chloro-phenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-

10 ylmethyl)-benzamide

0.050 g (0.16 mmol) of 4-Chloro-3-[2-(4-chloro-phenyl)-ethoxy]-benzoic acid was dissolved in 3 ml of DMF and treated with 0.185 g (1.61 mmol) of NEM and 0.054 g (0.16 mmol) of TOTU and 0.087 g (0.16 mmol) of C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine tris-trifluoroacetate salt. The solution was stirred for 16 h at RT. The

15 solvent was removed under reduced pressure. The residue was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt.






Yield 44 mg.


MS (ES⁺): m/e = 484 (M⁺).

20


The following examples were prepared analogously to example 203:

Example	Structure	MS (ES ⁺)
204		528
205		468

206		464
207		502
208		475
209		484
210		480



Example 212: 3-[2-(4-Chloro-phenyl)-ethoxy]-4-fluoro-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4- ylmethyl)-benzamide



- 5 (i) 4-Fluoro-3-hydroxy-benzoic acid methyl ester
5.16 g (33 mmol) of 4-Fluoro-3-hydroxy-benzoic acid was suspended in 150 ml of
saturated methanolic HCl and stirred at room temperature for 16h. The solvent was
removed under reduced pressure, and the residue was dried under reduced pressure.
Yield 5.5 g. MS (ES⁺): m/e = 171 (M+H)⁺.

10 (ii) 3-[2-(4-Chloro-phenyl)-ethoxy]-4-fluoro-benzoic acid methyl ester
0.5 g (2.94 mmol) of 4-Fluoro-3-hydroxy-benzoic acid methyl ester was dissolved in 30
ml of anhydrous tetrahydrofuran. To this solution was added 0.506 g (3.23 mmol) of 2-(4-
chloro-phenyl)-ethanol, 2.93 g (equivalent to 8.8 mmol PPh₃) of triphenylphosphine
derivatized polystyrene and 1.53 g (8.8 mmol) of DEAD. The solution was shaken for 16
15 h at RT. The polymer was filtered off and washed with tetrahydrofuran. The solvent was removed
under reduced pressure. The residue was taken-up in ethyl acetate/n-heptane
(1/5) and the insoluble residue was removed by filtration. The solvent was removed
under reduced pressure. The residue was chromatographed on silica gel eluting with
ethyl acetate/n-heptane (1/5).
20 Yield 0.75 g. LC-MS (ES⁺): m/e = 309 (M+H)⁺

(iii) 3-[2-(4-Chloro-phenyl)-ethoxy]-4-fluoro-benzoic acid

0.75 g (2.43 mmol) of 3-[2-(4-Chloro-phenyl)-ethoxy]-4-fluoro-benzoic acid methyl ester was dissolved in 25 ml of dioxan. 5 ml of water and 2N aqueous NaOH was added to the solution to give a pH of 13. The reaction solution was heated at 60°C for 2 h. The reaction solution was cooled to 0°C and concentrated hydrochloric acid was added to give a pH of 1-2, whereupon the product precipitated from solution. The suspension was stirred for 30min, then the product was filtered off and dried under reduced pressure.

5 Yield 0.64 g.

MS (ES⁺): m/e = 295 (M+H⁺).

(iv) 3-[2-(4-Chloro-phenyl)-ethoxy]-4-fluoro-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide






10 0.053 g (0.18 mmol) of 3-[2-(4-Chloro-phenyl)-ethoxy]-4-fluoro-benzoic acid was dissolved in 2 ml of DMF and treated with 0.206 g (1.8 mmol) of NEM and 0.059 g (0.18 mmol) of TOTU and 0.075 g (0.18 mmol) of C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine bis-trifluoroacetate salt. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure. The residue was purified by preparative



15 RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt. Yield 42 mg.

MS (ES⁺): m/e = 468 (M⁺).


The following examples were prepared analogously to example 212:

Example	Structure	MS (ES ⁺)
213		512
214		452

215		485
216		459
217		447
218		468
219		464


220		477
221		448

Example 222: 4-Chloro-3-[2-(4-chloro-phenyl)-ethoxy]-5-methoxy-N-(2'-methyl-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



- 5 This compound was prepared analogously to Example 202, using C-(2'-Methyl-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine trifluoroacetate salt.
Yield 62 mg. MS (ES⁺): m/e = 528 (M⁺).

Example 223: 4-Chloro-3-[2-(4-chloro-phenyl)-ethoxy]-N-(2'-methyl-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide




This compound was prepared analogously to Example 203, using C-(2'-Methyl-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine trifluoroacetate salt.

Yield 106 mg.

MS (ES⁺): m/e = 498 (M⁺).

5

Example 224: 4-Bromo-3-[2-(4-chlorophenyl)ethoxy]-5-methoxy-N-(3,4,5,6-tetrahydro-2H- [1,4']bipyridinyl-4-ylmethyl)-benzamide




This compound was prepared analogously to Example 20.

10 Yield 88 mg.

MS (ES⁺): m/e = 558 (M⁺).

Example 225: 4-Bromo-3-[2-(4-chlorophenyl)ethoxy]-5-methoxy-N-(2'-methyl-3,4,5,6-tetrahydro-2H- [1,4']bipyridinyl-4-ylmethyl)-benzamide




15 This compound was prepared analogously to Example 224, using C-(2'-Methyl-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine trifluoroacetate salt.

Yield 86 mg.

MS (ES⁺): m/e = 572 (M⁺).


Example 226: 5-[2-(2,4-Dichlorophenyl)-ethoxy]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4- ylmethyl)-isophthalamic acid



0.2 g (0.56 mmol) of 5-[2-(2,4-Dichlorophenyl)-ethoxy]-isophthalic acid was dissolved in
5 25 ml of DMF and treated with 0.649 g (5.63 mmol) of NEM and 0.277 g (0.84 mmol) of
TOTU and 0.215 g (1.13 mmol) of C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-
methylamine. The solution was stirred for 16 h at RT. The solvent was removed under
reduced pressure. The residue was purified by preparative RP-HPLC eluting with a
gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After
10 lyophilization the product was obtained as its trifluoroacetate salt.

Yield 65 mg. MS (ES⁺): m/e = 528 (M⁺).


Example 227: 5-[2-(2,4-Dichloro-phenyl)-ethoxy]-N,N'-bis-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-isophthalamide



15 0.2 g (0.56 mmol) of 5-[2-(2,4-Dichlorophenyl)-ethoxy]-isophthalic acid was dissolved in
25 ml of DMF and treated with 0.649 g (5.63 mmol) of NEM and 0.277 g (0.84 mmol) of
TOTU and 0.215 g (1.13 mmol) of C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-
methylamine. The solution was stirred for 16 h at RT. The solvent was removed under
reduced pressure. The residue was purified by preparative RP-HPLC eluting with a
gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After
20 lyophilization the product was obtained as its trifluoroacetate salt.

Yield 4 mg. MS (ES⁺): m/e = 701 (M⁺).

Example 228: 4-Chloro-3-[2-(2,4-dichloro-phenyl)-ethoxy]-5-methoxy-N-(1'-oxy-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide




This compound was prepared analogously to Example 199, using C-(1'-Oxy-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine trifluoroacetate salt.

Yield 12 mg.

MS (ES^+): m/e = 565 (M^+).

Example 229: 4-Chloro-3-[2-(4-chloro-phenyl)-ethoxy]-5-methoxy-N-(1'-oxy-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide




10

This compound was prepared analogously to Example 202, using C-(1'-Oxy-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine trifluoroacetate salt.

Yield 8.7 mg.

MS (ES^+): m/e = 530 (M^+).


15 Example 230: 4-Chloro-3-[2-(2,4-dichloro-phenyl)-ethoxy]-N-(1'-oxy-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



This compound was prepared analogously to Example 281, using C-(1'-Oxy-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine trifluoroacetate salt.

Yield 11 mg. MS (ES⁺): m/e = 535 (M⁺).


- 5 Example 231: 4-Chloro-3-[2-(4-chloro-phenyl)-ethoxy]-N-(1'-oxy-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



This compound was prepared analogously to Example 203, using C-(1'-Oxy-3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine trifluoroacetate salt.

- 10 Yield 16 mg. MS (ES⁺): m/e = 500 (M⁺).

- Example 232: 5-[2-(2,4-Dichloro-phenyl)-ethoxy]-N,N-diethyl-N'-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-isophthalamide



- 15 (i) 5-[2-(2,4-Dichloro-phenyl)-ethoxy]-N,N-diethyl-isophthalamic acid

0.5 g (1.41 mmol) of 5-[2-(2,4-Dichlorophenyl)-ethoxy]-isophthalic acid was dissolved in 5 ml of DMF and treated with 0.648 g (5.63 mmol) of NEM and 0.461 g (1.41 mmol) of TOTU and 0.103 g (1.41 mmol) of diethylamine. The solution was stirred for 16 h at RT. The compound was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt.

Yield 163 mg. MS (ES⁺): m/e = 410 (M⁺).

(ii) : 5-[2-(2,4-Dichloro-phenyl)-ethoxy]-N,N-diethyl-N'-(3,4,5,6-tetrahydro-2H-

[1,4']bipyridinyl-4-ylmethyl)-isophthalamide

0.05 g (0.12 mmol) of 5-[2-(2,4-Dichloro-phenyl)-ethoxy]-N,N-diethyl-isophthalamic acid was dissolved in 1 ml of DMF and treated with 0.140 g (1.22 mmol) of NEM and 0.04 g (0.12 mmol) of TOTU and 0.051 g (0.12 mmol) of C-(3,4,5,6-Tetrahydro-2H-


- 5 [1,4']bipyridinyl-4-yl)-methylamine. The solution was stirred for 16 h at RT. The compound was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product was obtained as its trifluoroacetate salt.

Yield 20 mg.

MS (ES⁺): m/e = 583 (M⁺).

10

Example 233: 3-[(2,4-Dichloro-benzylamino)-methyl]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



(i) 3-[(2,4-Dichloro-benzylamino)-methyl]-benzoic acid methyl ester

- 15 g (5.68 mmol) of 2,4-dichlorobenzylamine was dissolved in 20 ml of dichloromethane and treated with 2.94 g (22.7 mmol) of diisopropylethylamine and 1.43 g (6.25 mmol) of 3-bromomethyl-benzoic acid methyl ester. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure. The residue was chromatographed on silica gel eluting with ethyl acetate/n-heptane (1/4).

20 Yield 990 mg. MS (ES⁺): m/e = 324 (M⁺).

(ii) 3-{{[tert-Butoxycarbonyl-(2,4-dichloro-benzyl)-amino]-methyl}-benzoic acid methyl ester

0.98 g (3.02 mmol) of 3-[(2,4-Dichloro-benzylamino)-methyl]-benzoic acid methyl ester was dissolved in 20 ml of dioxan and treated with 0.659 g (3.02 mmol) of di-tert-butyl

- 25 pyrocarbonate. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure.

Yield 1.35 g. MS (ES⁺): m/e = 368 (M-tBu⁺).

(iii) 3-{{[tert-Butoxycarbonyl-(2,4-dichloro-benzyl)-amino]-methyl}-benzoic acid

0.85 g (2.00 mmol) of 3-{{[tert-Butoxycarbonyl-(2,4-dichloro-benzyl)-amino]-methyl}-benzoic acid methyl ester was dissolved in 20 ml of dioxan. 5 ml of water and 2N

30


aqueous NaOH was added to the solution to give a pH of 13. The reaction solution was stirred for 5 h then poured into water. The resulting solution was cooled to 0°C and concentrated hydrochloric acid was added to give a pH of 3. The product was extracted 3 times with ethyl acetate. The organic phase was dried over magnesium sulphate, filtered and the solvent was removed under reduced pressure.

5 Yield 0.77 g. MS (ES⁺): m/e = 354 (M-tBu⁺).
 (iv) (2,4-Dichloro-benzyl)-{3-[{(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)methyl}-carbamoyl]-benzyl}-carbamic acid tert-butyl ester
 10 0.15 g (0.37 mmol) of 3-{[tert-Butoxycarbonyl-(2,4-dichloro-benzyl)-amino]-methyl}-benzoic acid was dissolved in 2 ml of DMF and treated with 0.42 g (3.7 mmol) of NEM and 0.12 g (0.37 mmol) of TOTU and 0.195 g (0.37 mmol) of C-(3,4,5,6-Tetrahydro-2H-[1,4']bipyridinyl-4-yl)-methylamine trifluoroacetate salt. The solution was stirred for 3 h at RT. The compound was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid). After lyophilization the product
 15 was obtained as its trifluoroacetate salt.

Yield 128 mg. MS (ES⁺): m/e = 583 (M⁺).
 (v) 3-[(2,4-Dichloro-benzylamino)-methyl]-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide
 20 60 mg(0.1 mmol) of (2,4-Dichloro-benzyl)-{3-[{(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)methyl}- carbamoyl]-benzyl}-carbamic acid tert-butyl ester was dissolved in dichloromethane/TFA (1/1) and stirred for 45 min at RT. The solvent was removed under reduced pressure and the residue was dissolve in acetonitrile/water. After lyophilization the product was obtained as its trifluoroacetate salt.

25 Yield 44 mg. MS (ES⁺): m/e = 483 (M⁺).

Example 234: [4-(2-Chloro-5-[(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-yl)methyl]-carbamoyl]- phenoxy}-ethyl)-phenyl]-carbamic acid tert-butyl ester (S0103893)



(i) [4-(2-Hydroxy-ethyl)-phenyl]-carbamic acid tert-butyl ester

5g (36.4 mmol) of 2-(4-Amino-phenyl)-ethanol was dissolved in 25 ml of dioxan and treated with 7.95 g (36.4 mmol) of di-tert-butyl pyrocarbonate. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure.

5 Yield 8.5 g. MS (ES⁺): m/e = 238 (M+H⁺).


(ii) [4-(2-Chloro-5-[(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-carbamoyl]-phenoxy}-ethyl]-phenyl]-carbamic acid tert-butyl ester

This compound was prepared analogously to Example 203.

Yield 65 mg. MS (ES⁺): m/e = 565 (M⁺).

10


Example 235: [4-(2-Fluoro-5-[(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-carbamoyl]-phenoxy}-ethyl]-phenyl]-carbamic acid tert-butyl ester



This compound was prepared analogously to Example 212.

15 Yield 62 mg. MS (ES⁺): m/e = 548 (M⁺).

Example 236: 3-[2-(4-Amino-phenyl)-ethoxy]-4-chloro-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



20 62 mg (0.1 mmol) of [4-(2-Chloro-5-[(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-carbamoyl]-phenoxy}-ethyl]-phenyl]-carbamic acid tert-butyl ester was dissolved in dichloromethane/TFA (1/1) and stirred for 30 min at RT. The solvent was removed under reduced pressure and the residue was dissolve in acetonitrile/water.


After lyophilization the product was obtained as its trifluoroacetate salt.

Yield 36 mg.

MS (ES⁺): m/e = 465 (M+H⁺).

Example 237: 3-[2-(4-Amino-phenyl)-ethoxy]-4-fluoro-N-(3,4,5,6-tetrahydro-2H-

5 [1,4']bipyridinyl-4-ylmethyl)-benzamide



59 mg (0.1 mmol) of [4-(2-{2-Fluoro-5-[{(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-carbamoyl]-phenoxy}-ethyl)-phenyl]-carbamic acid tert-butyl ester was dissolved in dichloromethane/TFA (1/1) and stirred for 30 min at RT. The solvent was

10 removed under reduced pressure and the residue was dissolve in acetonitrile/water.


After lyophilization the product was obtained as its trifluoroacetate salt.

Yield 44 mg.

MS (ES⁺): m/e = 449 (M+H⁺).

Example 238: 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-5-methoxy-4-methyl-N-(3,4,5,6-

15 tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



(i) 3,5-Dihydroxy-4-methyl-benzoic acid methyl ester

4.8 g (28.6 mmol) of 3,5-Dihydroxy-4-methyl-benzoic acid was suspended in 100 ml of saturated methanolic HCl and stirred at room temperature for 16h. The solvent was

20 removed under reduced pressure, and the residue was dried under reduced pressure.

Yield 5.1 g. MS (ES⁻): m/e = 181 (M)⁻.

(ii) 3-Hydroxy-5-methoxy-4-methyl-benzoic acid methyl ester

5.1 g (28.2 mmol) of 3,5-Dihydroxy-4-methyl-benzoic acid methyl ester was dissolved in 100 ml of DMF and treated at 0°C with 7.8 g (56.4 mmol) of potassium carbonate and 4.0 g (28.2 mmol) of methyl iodide. The solution was stirred for 16 h at RT. The solvent was removed under reduced pressure, the residue was taken-up in ethyl acetate and the

5 solution was washed three times with water and twice with saturated aqueous sodium chloride. The organic phase was dried with magnesium sulphate, filtered and the solvent was removed under reduced pressure. The compound was purified by preparative RP-HPLC eluting with a gradient of 0 to 100% acetonitrile in water (+0.01% trifluoroacetic acid).

10 Yield 0.3 g. MS (ES⁻): m/e = 194 (M⁻).

(iii) 3-[2-(2,4-Dichloro-phenyl)-ethoxy]-5-methoxy-4-methyl-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide


This compound was prepared analogously to Example 199.

15 Yield 39 mg. MS (ES⁺): m/e = 528 (M⁺).

Example	Structure	MS (ES ⁺)
239		450
240		446

241		446
242		500
243		500

Example 244: 3-[2-(4-Cyano-phenyl)-ethoxy]-4-methoxy-N-(3,4,5,6-tetrahydro-2H-[1,4']bipyridinyl-4-ylmethyl)-benzamide



5 This compound was prepared analogously to Example 139.

Yield 12 mg. MS (ES⁺): m/e = 471.

Pharmacological testing

The ability of the compounds of the formula I to inhibit factor Xa or factor VIIa or other enzymes like thrombin, plasmin, or trypsin can be assessed by determining the

concentration of the compound of the formula I that inhibits enzyme activity by 50 %, i. e. the IC₅₀ value, which is related to the inhibition constant Ki. Purified enzymes are used in chromogenic assays. The concentration of inhibitor that causes a 50 % decrease in the rate of substrate hydrolysis is determined by linear regression after plotting the relative rates of hydrolysis (compared to the uninhibited control) versus the log of the concentration of the compound of formula I. For calculating the inhibition constant Ki, the IC₅₀ value is corrected for competition with substrate using the formula

$$Ki = IC_{50} / \{1 + (\text{substrate concentration} / Km)\}$$

wherein Km is the Michaelis-Menten constant (Chen and Prusoff, Biochem. Pharmacol.

10 22 (1973), 3099-3108; I. H. Segal, Enzyme Kinetics, 1975, John Wiley & Sons, New York, 100-125; which are incorporated herein by reference).

a) Factor Xa Assay

In the assay for determining the inhibition of factor Xa activity TBS-PEG buffer (50 mM Tris-HCl, pH 7.8, 200 mM NaCl, 0.05 % (w/v) PEG-8000, 0.02 % (w/v) NaN₃) was used.

15 The IC₅₀ was determined by combining in appropriate wells of a Costar half-area microtiter plate 25 µl human factor Xa (Enzyme Research Laboratories, Inc.; South Bend, Indiana) in TBS-PEG; 40 µl 10 % (v/v) DMSO in TBS-PEG (uninhibited control) or various concentrations of the compound to be tested diluted in 10 % (v/v) DMSO in TBS-PEG; and substrate S-2765 (N(α)-benzyloxycarbonyl-D-Arg-Gly-L-Arg-p-nitroanilide; 20 Kabi Pharmacia, Inc.; Franklin, Ohio) in TBS-PEG.

The assay was performed by pre-incubating the compound of formula I plus enzyme for 10 min. Then the assay was initiated by adding substrate to obtain a final volume of 100 µl. The initial velocity of chromogenic substrate hydrolysis was measured by the change in absorbance at 405 nm using a Bio-tek Instruments kinetic plate reader (Ceres

25 UV900HDI) at 25 °C during the linear portion of the time course (usually 1.5 min after addition of substrate). The enzyme concentration was 0.5 nM and substrate concentration was 140 µM.

b) Factor VIIa Assay

The inhibitory activity towards factor VIIa/tissue factor activity was determined using a 30 chromogenic assay essentially as described previously (J. A. Ostrem et al., Biochemistry 37 (1998) 1053-1059 which is incorporated herein by reference). Kinetic assays were conducted at 25 °C in half-area microtiter plates (Costar Corp., Cambridge, Massachusetts) using a kinetic plate reader (Molecular Devices Spectramax 250). A typical assay consisted of 25 µl human factor VIIa and TF (5 nM and 10 nM, respective

final concentration) combined with 40 µl of inhibitor dilutions in 10% DMSO/TBS-PEG buffer (50 mM Tris, 15 mM NaCl, 5 mM CaCl₂, 0.05 % PEG 8000, pH 8.15). Following a 15 minute preincubation period, the assay was initiated by the addition of 35 µl of the chromogenic substrate S-2288 (D-Ile-Pro-Arg-p-nitroanilide, Pharmacia Hepar Inc., 500 µM final concentration). The results (inhibition constants Ki (FXa) for inhibition of factor Xa) are shown in Table 1.


Table1:

Example	Ki(FXa) [µM]	Example	Ki(FXa) [µM]	Example	Ki(FXa) [µM]
1	0.600	24	1.128	85	0.304
2	1.540	28	0.960	86	0.026
3	5.410	31	9.340	87	0.070
4	0.298	32	0.970	88	0.140
5	0.167	54	6.515	89	0.044
6	0.050	55	0.650	91	1.393
7	2.820	56	4.327	92	0.028
8	0.106	57	6.217	93	0.188
9	0.306	60	1.051	94	0.760
10	0.061	61	0.057	95	29.734
11	1.378	66	1.484	97	3.497
12	3.005	67	0.018	99	3.709
13	1.412	68	3.040	100	0.298
14	2.184	77	0.076	101	0.057
15	2.221	78	0.037	102	0.636
16	4.219	79	0.029	117	0.588
17	0.407	80	0.050	118	0.316
18	6.200	81	0.241	119	1763
19	0.095	83	0.125	120	0.048
20	0.020	84	4.883	121	0.075

Example	Ki(FXa) [μ M]	Example	Ki(FXa) [μ M]	Example	Ki(FXa) [μ M]
128	40.95	198	5.004	232	0.192
129	25.18	199	0.01	233	0.275
132	0.054	200	0.108	234	4.531
133	0.020	201	0.314	236	0.420
134	0.037	202	0.025	237	1.554
140	69.50	203	0.013	238	0.013
143	38.79	204	0.036	239	3.839
144	0.041	205	0.102	240	1.345
145	0.591	206	0.124	241	2.168
165	0.950	207	0.068	242	2.939
166	0.110	208	1.552		
167	0.277	209	1.931		
168	0.024	210	2.494		
169	0.277	212	0.040		
170	1.796	213	0.071		
171	0.130	214	0.203		
172	6.450	215	0.059		
176	0.365	216	4.605		
177	0.226	217	0.206		
178	0.263	218	0.712		
179	0.086	219	3.348		
180	0.255	221	0.307		
181	0.041	222	0.072		
182	0.312	223	0.044		
183	0.233	224	0.020		
184	0.617	225	0.065		
185	0.039	226	0.082		
186	0.401	227	0.058		
187	0.964	228	0.220		
195	6.737	229	0.285		
196	4.265	230	0.649		
197	6.028	231	0.227		

Patent Claims

1. A compound of the formula I,



5 wherein

- R^0 is 1. a monocyclic or bicyclic 5- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^2 , or
2. a monocyclic or bicyclic 5- to 14-membered heteroaryl, containing zero, one, two, three or four heteroatoms chosen from nitrogen, sulphur or oxygen, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^2 ,

R^2 is halogen, $-NO_2$, $-CN$, $-C(O)-NH_2$, $-OH$, $-NH_2$, $-NH-C(O)$, $-NH-C(O)-(C_1-C_8)$ -alkyl, $-NH-C(O)-(C_1-C_8)$ -alkyl, $-(C_1-C_8)$ -alkyl, wherein alkyl in each case is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH_2 , $-OH$ or a methoxy residue, or $-(C_1-C_8)$ -alkyloxy, wherein alkyloxy is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH_2 , $-OH$ or a methoxy residue,

Q and Q' are independently of one another identical or different and are a direct bond, $-(CH_2)_r-O-CH_2)_s-$, wherein r and s are independently from each other the integers zero, 1, 2 or 3, $-C(O)-$; $-O-$, $-NR^{10}-$, $-C(O)-NR^{10}-$, $-NR^{10}-C(O)-$, $-S-$, $-S(O)-$, $-SO_2-$, $-NR^{10}-SO_2-$, $-SO_2-NR^{10}-$, $-(C_1-C_6)$ -alkylene, wherein alkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, NH_2 or $-OH$; or $-(C_3-C_6)$ -cycloalkylene, wherein cycloalkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, $-NH_2$ or $-OH$;

X is a direct bond, a 3- to 7-membered heteroaryl, $-(C_1-C_6)$ -alkylene, wherein alkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, $-NH_2$ or $-OH$; or $-(C_3-C_6)$ -cycloalkylene, wherein cycloalkylene is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, $-NH_2$ or $-OH$;

provided that when Q or Q' is $-(C_1-C_6)$ -alkyl then X is $-O-$, $-S-$, $-NR^{10}-$, $-C(O)-$, $-C(O)-NR^{10}-$, $-NR^{10}-C(O)-$, $-S(O)-$, $-SO_2-$, $-NR^{10}-SO_2-$ or $-SO_2-NR^{10}-$; with the proviso that if X is a direct bond, the fragment $-Q-X-Q'$ is not O-O, O-S, S-O, S-

S, SO₂-SO₂, SO-SO, SO-SO₂, SO₂-SO, SO₂-S, S-SO₂, SO-S, S-SO; with the proviso that if X is oxygen atom or sulphur atom, then Q and Q' are not oxygen atom or sulphur atom; and with the further proviso that if X is S(O) or SO₂, then Q and Q' are not oxygen atom or sulphur atom;

- 5 W is 1. a 5- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,
2. a 5- to 14-membered heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,
10 3. a 4-to 15 membered mono- or polycyclic group, wherein said mono- or polycyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹, or
4. a 4-to 15 membered mono- or polycyclic group, containing one, two, three or four heteroatoms, such as nitrogen, sulphur or oxygen, wherein said mono- or polycyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,
- 15 provided that if W is a six membered aryl or heteroaryl group, then Q' and U are not in an ortho position with respect to each other;

- R¹ is 1. halogen,
2. -NO₂,
20 3. -CN,
4. -NR⁴R⁵, wherein R⁴ and R⁵ are defined below,
5. -O-(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
25 6. -OH,
7. -SO₂-NH₂,
8. (C₁-C₈)-alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
9. (C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
30 10 (C₁-C₈)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
11. hydroxycarbonyl-(C₁-C₈)-alkylureido-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

12. (C_1-C_8)-alkyloxycarbonyl- (C_1-C_8) -alkylureido-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
- 5 13. (C_1-C_8)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
14. -NH-C(O),
15. -NH-C(O)- (C_1-C_8) -alkyl,
16. -NH-C(O)- (C_1-C_8) -alkyl,
17. -C(O)-NR⁴R⁵, wherein R⁴ and R⁵ are defined below,
- 10 18. -COOH;
19. -C(O)- (C_1-C_6) -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
20. -C(O)-O- (C_1-C_4) -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
- 15 21. -C(O)-NR¹¹R¹²,
22. -C(NH)-NH₂,
23. -NH-C(O)-NH₂,
24. -S- (C_1-C_8) -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,
- 20 25. -(C_1-C_8)-alkylthio, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , or
26. R¹¹R¹²N-, or

25 two R¹ residues bonded to adjacent ring carbon atoms together with the carbon atoms to which they are bonded form a dioxalane ring or an aromatic ring condensed to W, where the ring formed by the two R¹ residues is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,

30 R¹¹ and R¹² together with the nitrogen atom to which they are bonded form a saturated or unsaturated 5- to 6-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R¹¹ and R¹² can contain one or two identical or different ring heteroatoms chosen from oxygen, sulphur and nitrogen, and in which one or two of the ring carbon atoms can be substituted by oxo to form -C(O)- residue(s),

R¹³ is halogen, -NO₂, -CN, -OH, -(C₁-C₈)-alkyl, -(C₁-C₈)-alkyloxy, -CF₃, -C(O)-NH₂, -NH₂ or the residue V-G-M, wherein V, G and M are as defined below,

R¹⁰ is hydrogen atom or -(C₁-C₄)-alkyl,

U and G are independently of one another identical or different and are a direct bond,

-(CH₂)_m-, -(CH₂)_m-O-(CH₂)_n-, -(CH₂)_m-C(O)-NR¹⁰-(CH₂)_n-, -(CH₂)-SO₂-(CH₂)_n-,

-(CH₂)_m-NR¹⁰-C(O)-NR¹⁰-(CH₂)_n-, -(CH₂)_m-NR¹⁰-C(O)-(CH₂)_n-, -(CH₂)-S-(CH₂)_n-,

-(CH₂)_m-C(O)-(CH₂)_n-, -(CH₂)_m-SO₂-NR¹⁰-(CH₂)_n-, -(CH₂)_m-NR¹⁰-SO₂-(CH₂)_n-,

-(CH₂)_m-NR¹⁰-SO₂-NR¹⁰-(CH₂)_n-, -(CH₂)_m-CH(OH)-(CH₂)_n-,

-(CH₂)_m-O-C(O)-NR¹⁰-(CH₂)_n-, or -(CH₂)_m-NR¹⁰-C(O)-O-(CH₂)_n-,

n and m are independently of one another identical or different and are the integers zero, 1, 2, 3, 4, 5 or 6, wherein the alkylene residues which are formed by -(CH₂)_m- or -(CH₂)_n- are unsubstituted or mono-, di- or

trisubstituted independently of one another by -(C₁-C₄)-alkyl; -C(O)-OH,

-C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵, -SO₂, -NR⁴R⁵ or -(C₁-C₈)-alkylsulfonyl,

R⁴ and R⁵ are independently of one another identical or different and are hydrogen atom, -(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or tri-substituted independently of one another by R¹³, -(C₆-C₁₄)-aryl-(C₁-C₄)-alkyl-, wherein alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, -(C₆-C₁₄)-aryl-, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -(C₆-C₁₄)-heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³ or -(C₆-C₁₄)-heteroaryl-(C₁-C₄)-alkyl-, wherein alkyl and heteroaryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, or

R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a saturated 5- to 7-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R⁴ and R⁵ can contain one or two identical or different ring heteroatoms chosen from oxygen, sulphur and nitrogen;

wherein said heterocyclic ring is unsubstituted or mono-, di- or

trisubstituted independently of one another by R¹³,

V is 1. a direct bond,

2. $-(C_1-C_6)$ -alkylene, which is branched or unbranched and which is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, $=O$, $-CN$, $-OH$, $-NR^4R^5$, $-C(O)-OH$, $-C(O)-O-(C_1-C_4)$ -alkyl, $-SO_2-NR^4R^5$, $-C(O)-NR^4R^5$ or $-(C_1-C_8)$ -alkylsulfonyl,
- 5 3. a 3- to 7-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,
- 10 4. a 6- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} , or
- 15 5. a heteroaryl, wherein said heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,

R^{14} is R^1 , halogen, $-OH$, $-NR^4R^5$, $=O$, $-(C_1-C_4)$ -alkyl, $-(C_1-C_4)$ -alkoxyl, $-NO_2$, $-C(O)-OH$, $-CN$, $-C(O)-O-(C_1-C_4)$ -alkyl, $-C(O)-NR^4R^5$, $-(C_1-C_8)$ -alkylsulfonyl, $-O$ -heteroaryl, $-NR^{10}-C(O)-NH-(C_1-C_8)$ -alkyl, $-NR^{10}-C(O)-NH-[C_1-C_8]-alkyl]_2$, $-SO_2-NR^4R^5$, $-SR^4$, or $-SO_2$, wherein R^4 , R^5 and R^{10} are as defined above, and

- M is
- 20 1. a hydrogen atom,
2. $-(C_1-C_8)$ -alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,
3. $-C(O)-NR^4R^5$,
4. $-(C_6-C_{14})$ -aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,
- 25 5. $-(C_6-C_{14})$ -heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,
6. a 3- to 7-membered cyclic group, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,
- 30 7. a 3- to 7-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} , wherein R^{14} is defined above,
8. $-NH-CH(NA^1)(NA^2)$, wherein A^1 and A^2 are independently of one another identical or different and are hydrogen atom or $-(C_1-C_8)-$

alkyl, or A¹ and A² together with the nitrogen atom to which they are each bonded form a saturated 5- or 6-membered monocyclic heterocyclic ring, which is saturated or aromatic, or

9. -CH(NA¹)(NA²), wherein A¹ and A² are independently of one another identical or different and are hydrogen atom or -(C₁-C₈)-alkyl, or A² together with the nitrogen atom to which it is bonded forms a saturated 5- or 6-membered monocyclic heterocyclic ring, which contains 2 nitrogen atoms and is saturated or aromatic,
- in all its stereoisomeric forms and mixtures thereof in any ratio, polymorph forms and mixtures thereof in any ratio and its physiologically tolerable salts.

2. A compound of formula I as claimed in claim 1, wherein

R⁰ is phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R²,

pyridyl, wherein pyridyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R²,

pyrimidyl, wherein pyrimidyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R², or

naphthyl, wherein naphthyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R²,

R² is as defined above and wherein the alkyl- or alkyloxy residue is unsubstituted or mono-, di- or trisubstituted independently of one another by an amino residue or a methoxy residue,

Q and Q' are as defined above and wherein the alkylene- or cycloalkylene residue is unsubstituted or mono-, di- or trisubstituted independently of one another by -NH₂ or -OH;

X is as defined in claim 1,

W is phenyl, pyridyl, pyrimidyl, benzoxazole, benzthiazole, indole, benzo[1,3]dioxole, or naphthyl, wherein W is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,

provided that if W is a six membered aryl or heteroaryl group, Q' and U are not in an ortho position with respect to each other;

R¹, R¹⁰, R¹¹, R¹² and R¹³ are as defined in claim 1,

U and G are independently of one another identical or different and are a direct bond,

- $(\text{CH}_2)_m$ -, - $(\text{CH}_2)_m-\text{O}-(\text{CH}_2)_n$ -, - $(\text{CH}_2)_m-\text{C(O)-NR}^{10}-(\text{CH}_2)_n$ -,
- $(\text{CH}_2)_m-\text{NR}^{10}-\text{C(O)-NR}^{10}-(\text{CH}_2)_n$ -, - $(\text{CH}_2)_m-\text{NR}^{10}-\text{C(O)-(CH}_2)_n$ -, - $(\text{CH}_2)_m-\text{S-(CH}_2)_n$ -,
- $(\text{CH}_2)_m-\text{C(O)-(CH}_2)_n$ -, - $(\text{CH}_2)_m-\text{SO}_2-\text{NR}^{10}-(\text{CH}_2)_n$ -, - $(\text{CH}_2)_m-\text{NR}^{10}-\text{SO}_2-(\text{CH}_2)_n$ -,
- $(\text{CH}_2)_m-\text{NR}^{10}-\text{SO}_2-\text{NR}^{10}-(\text{CH}_2)_n$ - or - $(\text{CH}_2)_m-\text{CH(OH)-(CH}_2)_n$ -,

wherein n, m, R⁴ and R⁵ are as defined in claim 1,

V and M are as defined in claim 1.

- 10 3. A compound of formula I as claimed in claim 1 or 2, wherein
R⁰ is phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted
independently of one another by R²,
pyridyl, wherein pyridyl is unsubstituted or mono-, di- or trisubstituted
independently of one another by R²,
15 pyrimidyl, wherein pyrimidyl is unsubstituted or mono-, di- or trisubstituted
independently of one another by R², or
naphthyl, wherein naphthyl is unsubstituted or mono-, di- or trisubstituted
independently of one another by R²,
R² is halogen, -CN, -NH₂, -C(O)-NH₂, -(C₁-C₄)-alkyl, or -(C₁-C₄)-alkyloxy,
20 wherein the alkyl- or alkyloxy residue is unsubstituted or mono-, di- or
trisubstituted independently of one another by an amino residue or a
methoxy residue,
Q and Q' are independently of one another identical or different and are a direct
bond, -C(O)-; -O-, -NR¹⁰-, -C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -SO₂-, -NR¹⁰-SO₂-,
25 -SO₂-NR¹⁰-, -(C₁-C₄)-alkylene, wherein alkylene is unsubstituted or mono-,
di- or trisubstituted independently of one another by halogen; or -(C₃-C₆)-
cycloalkylene, wherein cycloalkylene is unsubstituted or mono-, di- or
trisubstituted independently of one another by halogen;
X is a direct bond, -(C₁-C₃)-alkylene, wherein alkylene is unsubstituted or
30 mono-, di- or trisubstituted independently of one another by halogen; or
-(C₃-C₆)-cycloalkylene, wherein cycloalkylene is unsubstituted or mono-, di-
or trisubstituted independently of one another by halogen;

provided that when Q or Q' is -(C₁-C₃)-alkylene then X is -O-, -NR¹⁰-, -C(O)-, -C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -SO₂-, -NR¹⁰-SO₂- or -SO₂-NR¹⁰-, with the proviso that if X is a direct bond, the fragment -Q-X-Q'- is not O-O, SO₂-SO₂, or SO-SO₂; and

5 with the proviso that if X is oxygen atom, then Q and Q' are not oxygen atom or sulphur atom; and

with the further proviso that if X is SO₂, then Q and Q' are not oxygen atom or sulphur atom;

W is phenyl, pyridyl, pyrimidyl, benzoxazole, benzthiazole, indole, 10 benzo[1,3]dioxole, or naphthyl, wherein W is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,

provided that if W is a six membered aryl or heteroaryl group, Q' and U are not in an ortho position with respect to each other;

R¹ is

- 1. halogen,
- 2. -NO₂,
- 3. -CN,
- 4. -NH₂,
- 5. (C₁-C₆)-alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
- 6. -OH,
- 7. -SO₂-NH₂,
- 8. (C₁-C₆)-alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
- 9. (C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
- 25 10 (C₁-C₆)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
- 11. hydroxycarbonyl-(C₁-C₆)-alkylureido-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
- 30 12. (C₁-C₆)-alkyloxycarbonyl-(C₁-C₆)-alkylureido-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
- 13. (C₁-C₆)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

14. bis[(C₁-C₆)-alkyl]amino, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
15. -C(O)-NH₂,
16. -C(O)-OH,
- 5 17. -C(O)-(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
18. -C(O)-NH-(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
19. -C(O)-NH-[(C₁-C₆)-alkyl]₂, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
- 10 20. -C(NH)-NH₂,
21. ureido,
22. -(C₁-C₆)-alkylthio, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, or
- 15 23. R¹¹R¹²N-, or

two R¹ residues bonded to adjacent ring carbon atoms together with the carbon atoms to which they are bonded form an aromatic ring condensed to W, where the ring formed by the two R¹ residues is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

20 R¹¹ and R¹² together with the nitrogen atom to which they are bonded form a saturated or unsaturated 5- to 6-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R¹¹ and R¹² can contain one or two identical or different ring heteroatoms chosen from oxygen, sulphur and nitrogen, and in which one or two of the ring carbon atoms can be substituted by oxo to form -C(O)- residue(s),

25 R¹³ is halogen, -CN, -(C₁-C₆)-alkyl, -(C₁-C₆)-alkyloxy, -CF₃, -C(O)-NH₂ or -NH₂,

R¹⁰ is hydrogen atom or -(C₁-C₄)-alkyl,

U and G are independently of one another identical or different and are a direct bond,

- 30 -(CH₂)_m-, -(CH₂)_m-O-(CH₂)_n-, -(CH₂)_m-C(O)-NR¹⁰-(CH₂)_n-,
 -(CH₂)_m-NR¹⁰-C(O)-NR¹⁰-(CH₂)_n-, -(CH₂)_m-NR¹⁰-C(O)-(CH₂)_n-, -(CH₂)-S-(CH₂)_n-,
 -(CH₂)_m-C(O)-(CH₂)_n-, -(CH₂)_m-SO₂-NR¹⁰-(CH₂)_n-, -(CH₂)_m-NR¹⁰-SO₂-(CH₂)_n- or
 -(CH₂)_m-NR¹⁰-SO₂-NR¹⁰-(CH₂)_n-,

n and m are are independently of one another identical or different and are the integers zero, 1, 2 or 3, wherein the alkylene residues are unsubstituted or mono-, di- or trisubstituted independently of one another by -(C₁-C₄)-alkyl; -C(O)-OH, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵, -SO₂, -NR⁴R⁵ or -(C₁-C₈)-alkylsulfonyl,

R⁴ and R⁵ are independently of one another identical or different and are hydrogen atom, -(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -(C₆-C₁₄)-aryl-(C₁-C₄)-alkyl-, wherein alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, -(C₆-C₁₄)-aryl-, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -(C₆-C₁₄)-heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³ or -(C₆-C₁₄)-heteroaryl-(C₁-C₄)-alkyl-, wherein alkyl and heteroaryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, or R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a

saturated 5- to 7-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R⁴ and R⁵ can contain one or two identical or different ring heteroatoms chosen from oxygen, sulphur and nitrogen;

wherein said heterocyclic ring is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

- V is
1. a direct bond,
 2. -(C₁-C₄)-alkylene, which is branched or unbranched and which is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, =O, -CN, -OH, -NR⁴R⁵, -C(O)-OH, -C(O)-O-(C₁-C₄)-alkyl, -SO₂, -NR⁴R⁵, -C(O)-NR⁴R⁵ or -(C₁-C₈)-alkylsulfonyl,
 3. a 5- to 7-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
 4. a 6- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or
 5. a heteroaryl, wherein said heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R¹⁴ is halogen, -OH, -NR⁴R⁵, =O, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkoxyl, -NO₂, -C(O)-OH, -CN, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵, -(C₁-C₈)-alkylsulfonyl, -C(O)-NR⁴R⁵, -SO₂-NR⁴R⁵, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH-[(C₁-C₈)-alkyl]₂, -NR¹⁰-C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH₂ or -NR¹⁰-C(O)-NH-[(C₁-C₈)-alkyl]₂, wherein R⁴, R⁵ and R¹⁰ are as defined above, and

- M is
1. a hydrogen atom,
 2. -(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
 3. -C(O)-NR⁴R⁵,
 4. -(C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
 5. -(C₆-C₁₄)-heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
 6. a 5- to 7-membered cyclic group, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or
 7. a 5- to 7-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, wherein R¹⁴ is defined above.

4. A compound of formula I as claimed in one or more of claims 1 to 3, wherein R⁰ is phenyl, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R², or pyridyl, wherein pyridyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R²,
- R² is halogen, -CN, -C(O)-NH₂, -(C₁-C₄)-alkyl, or -(C₁-C₄)-alkyloxy, wherein the alkyl- or alkyloxy residue is unsubstituted or mono-, di- or trisubstituted independently of one another by an amino residue or a methoxy residue,
- Q and Q' are independently of one another identical or different and are a direct bond, -C(O)-; -O-, -NR¹⁰-, -C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -SO₂-, -NR¹⁰-SO₂-, -SO₂-NR¹⁰-, or -(C₁-C₄)-alkylene,
- X is a direct bond or -(C₁-C₃)-alkylene,

provided that when Q or Q' is -(C₁-C₃)-alkylene then X is -O-, -NR¹⁰-, -C(O)-, -C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -SO₂-, -NR¹⁰-SO₂- or -SO₂-NR¹⁰-;

with the proviso that if X is a direct bond, the fragment -Q-X-Q'- is not O-O or SO₂-SO₂; and with the proviso that if X is oxygen atom, then Q and Q' are not oxygen atom or sulphur atom; and

with the further proviso that if X is SO₂, then Q and Q' are not oxygen atom or sulphur atom;

W is phenyl, pyridyl or pyrimidyl, wherein W is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,

provided that Q' and U are not in an ortho position with respect to each other;

R¹ is

1. halogen,
2. -NO₂,
3. -CN,
4. -NH₂,
5. (C₁-C₄)-alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
6. -OH,
7. -SO₂-NH₂,
8. (C₁-C₄)-alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
9. (C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
10. (C₁-C₄)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
11. hydroxycarbonyl-(C₁-C₄)-alkylureido-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
12. (C₁-C₄)-alkyloxycarbonyl-(C₁-C₄)-alkylureido-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
13. (C₁-C₄)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
14. bis[(C₁-C₄)-alkyl]amino, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
15. -C(O)-NH₂,

16. -C(O)-OH,
 17. -C(O)-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 18. -C(O)-NH-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 19. -C(O)-NH-[(C₁-C₄)-alkyl]₂, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 20. -C(NH)-NH₂,
 21. ureido,
 10 22. -(C₁-C₄)-alkylthio, wherein alkylthio is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, or
 23. R¹¹R¹²N-, or

two R¹ residues bonded to adjacent ring carbon atoms together with the carbon atoms to which they are bonded form an aromatic ring condensed to W, where the ring formed by the two R¹ residues is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
 15 R¹¹ and R¹² together with the nitrogen atom to which they are bonded form a saturated or unsaturated 5- to 6-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R¹¹ and R¹² can contain one or two identical or different ring heteroatoms chosen from oxygen, sulphur and nitrogen,

R¹³ is halogen, -CN, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkyloxy, -CF₃, -C(O)-NH₂ or -NH₂, R¹⁰ is hydrogen atom or -(C₁-C₄)-alkyl,

U and G are independently of one another identical or different and are 25 a direct bond,

-(CH₂)_m-, -(CH₂)_m-C(O)-NR¹⁰-(CH₂)_n-, -(CH₂)_m-NR¹⁰-C(O)-NR¹⁰-(CH₂)_n-,
 -(CH₂)_m-NR¹⁰-C(O)-(CH₂)_n-, -(CH₂)_m-C(O)-(CH₂)_n-, -(CH₂)_m-SO₂-NR¹⁰-(CH₂)_n- or
 -(CH₂)_m-NR¹⁰-SO₂-(CH₂)_n-,

n and m are independently of one another identical or different and are the 30 integers zero, 1, 2 or 3, wherein the alkylene residues are unsubstituted or mono-, di- or trisubstituted independently of one another by -(C₁-C₄)-alkyl; -C(O)-OH, -C(O)-O-(C₁-C₄)-alkyl or -C(O)-NR⁴R⁵,

R⁴ and R⁵ are independently of one another identical or different and are hydrogen atom, -(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -(C₆-C₁₄)-aryl-(C₁-C₄)-alkyl-, wherein alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, -(C₆-C₁₄)-aryl-, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -(C₆-C₁₄)-heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³ or -(C₆-C₁₄)-heteroaryl-(C₁-C₄)-alkyl-, wherein alkyl and heteroaryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, or R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a saturated 5- to 7-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R⁴ and R⁵ can contain one or two identical or different ring heteroatoms chosen from oxygen, sulphur and nitrogen; wherein said heterocyclic ring is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

V is

- 1. a direct bond,
- 2. -(C₁-C₄)-alkylene, which is branched or unbranched and which is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, =O, -CN, -OH, -NR⁴R⁵, -C(O)-OH, -C(O)-O-(C₁-C₄)-alkyl, -SO₂-NR⁴R⁵, -C(O)-NR⁴R⁵ or -(C₁-C₄)-alkylsulfonyl,
- 3. a 5- to 7-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
- 4. a 6- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or
- 5. a 6- to 14-membered heteroaryl, wherein said heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R¹⁴ is halogen, -OH, -NR⁴R⁵, =O, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkoxyl, -NO₂, -C(O)-OH, -CN, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵, -(C₁-C₈)-alkylsulfonyl, -C(O)-NR⁴R⁵, -SO₂-NR⁴R⁵, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH-[C₁-C₈]-

alkyl]₂, -NR¹⁰-C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH₂ or -NR¹⁰-C(O)-NH-[(C₁-C₈)-alkyl]₂, wherein R⁴, R⁵ and R¹⁰ are as defined above, and

- M is
- 1. a hydrogen atom,
 - 2. -(C₁-C₈)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
 - 3. -C(O)-NR⁴R⁵,
 - 4. -(C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
 - 5. -(C₆-C₁₄)-heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
 - 6. a 5- to 7-membered cyclic group, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or
 - 7. a 5- to 7-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, wherein R¹⁴ is defined above.

5. A compound of formula I as claimed in one or more of claims 1 to 4, wherein

20 R⁰ is phenyl, wherein phenyl is unsubstituted or mono- or disubstituted independently of one another by R², or

pyridyl, wherein pyridyl is unsubstituted or mono-, disubstituted independently of one another by R²,

25 R² is halogen, -CN, -C(O)-NH₂, -(C₁-C₃)-alkyl, or -(C₁-C₃)-alkyloxy, wherein the alkyl- or alkyloxy residue is unsubstituted or mono-, di- or trisubstituted independently of one another by an amino residue or a methoxy residue,

Q and Q' are independently of one another identical or different and are

a direct bond, -C(O)-; -O-, -NR¹⁰-, -C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -SO₂-,
-NR¹⁰-SO₂-, -SO₂-NR¹⁰-, or -(C₁-C₄)-alkylene,

30 X is a direct bond or -(C₁-C₃)-alkylene,

provided that when Q or Q' is -(C₁-C₃)-alkylene then X is -O-, -NR¹⁰-, -C(O)-,
-C(O)-NR¹⁰-, -NR¹⁰-C(O)-, -SO₂-, -NR¹⁰-SO₂- or -SO₂-NR¹⁰-;

with the proviso that if X is a direct bond, the fragment -Q-X-Q'- is not O-O or SO₂-SO₂; and with the proviso that if X is oxygen atom, then Q and Q' are not oxygen atom or sulphur atom; and

5 with the further proviso that if X is SO₂, then Q and Q' are not oxygen atom or sulphur atom;

W is phenyl, pyridyl or pyrimidyl, wherein W is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,

provided that Q' and U are not in an ortho position with respect to each other;

R¹ is 1. halogen,

10 2. -NO₂,

3. -CN,

4. -NH₂,

15 5. (C₁-C₄)-alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

6. -OH,

7. -SO₂-NH₂,

8. (C₁-C₄)-alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

9. (C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

20 10. (C₁-C₄)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

11. (C₁-C₄)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

25 12. bis [(C₁-C₄)-alkyl]amino, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

13. -C(O)-NH₂,

14. -C(O)-OH,

30 15. -C(O)-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

16. -C(O)-NH-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

17. -C(O)-NH-[(C₁-C₄)-alkyl]₂, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

18. $-\text{C}(\text{NH})\text{-NH}_2$,
19. ureido,
20. $-(\text{C}_1\text{-C}_4)\text{-alkylthio}$, wherein alkylthio is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , or
21. $\text{R}^{11}\text{R}^{12}\text{N-}$, or

5 two R^1 residues bonded to adjacent ring carbon atoms together with the carbon atoms to which they are bonded form an aromatic ring condensed to W, where the ring formed by the two R^1 residues is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,

10 R^{11} and R^{12} together with the nitrogen atom to which they are bonded form a saturated or unsaturated 5- to 6-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R^{11} and R^{12} can contain one or two identical or different ring heteroatoms chosen from oxygen or nitrogen,

15 R^{13} is halogen, $-\text{CN}$, $-(\text{C}_1\text{-C}_4)\text{-alkyl}$, $-(\text{C}_1\text{-C}_4)\text{-alkyloxy}$, $-\text{CF}_3$, $-\text{C}(\text{O})\text{-NH}_2$ or $-\text{NH}_2$, R^{10} is hydrogen atom or $-(\text{C}_1\text{-C}_4)\text{-alkyl}$,

U is a direct bond, $-(\text{CH}_2)_m-$, $-(\text{CH}_2)_m\text{-C}(\text{O})\text{-NR}^{10}\text{-}(\text{CH}_2)_n-$,
 $-(\text{CH}_2)_m\text{-NR}^{10}\text{-C}(\text{O})\text{-}(\text{CH}_2)_n-$, $-(\text{CH}_2)_m\text{-C}(\text{O})\text{-}(\text{CH}_2)_n-$,
 $-(\text{CH}_2)_m\text{-SO}_2\text{-NR}^{10}\text{-}(\text{CH}_2)_n-$ or $-(\text{CH}_2)_m\text{-NR}^{10}\text{-SO}_2\text{-}(\text{CH}_2)_n-$,

20 n and m are are independently of one another identical or different and are the integers zero, 1, 2 or 3, wherein the alkylene residues are unsubstituted or mono-, di- or trisubstituted independently of one another by $-(\text{C}_1\text{-C}_4)\text{-alkyl}$; $-\text{C}(\text{O})\text{-OH}$, $-\text{C}(\text{O})\text{-O-}(\text{C}_1\text{-C}_4)\text{-alkyl}$ or $-\text{C}(\text{O})\text{-NR}^4\text{R}^5$,

25 R^4 and R^5 are independently of one another identical or different and are hydrogen atom, $-(\text{C}_1\text{-C}_6)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , $-(\text{C}_6\text{-C}_{14})\text{-aryl-}(\text{C}_1\text{-C}_4)\text{-alkyl-}$, wherein alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R^{13} , $-(\text{C}_6\text{-C}_{14})\text{-aryl-}$, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} , $-(\text{C}_6\text{-C}_{14})\text{-heteroaryl}$, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} or $-(\text{C}_6\text{-C}_{14})\text{-heteroaryl-}(\text{C}_1\text{-C}_4)\text{-alkyl-}$, wherein alkyl and heteroaryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R^{13} , or

30

R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a
 saturated 5- to 7-membered monocyclic heterocyclic ring which in addition
 to the nitrogen atom carrying R⁴ and R⁵ can contain one or two identical or
 different ring heteroatoms chosen from oxygen, sulphur and nitrogen;
 5 wherein said heterocyclic ring is unsubstituted or mono-, di- or
 trisubstituted independently of one another by R¹³,

G is a direct bond, -(CH₂)_m-, -(CH₂)_m-O-(CH₂)_n-, -(CH₂)_m-C(O)-NR¹⁰-(CH₂)_n-,
 -(CH₂)_m-NR¹⁰-C(O)-NR¹⁰-(CH₂)_n-, -(CH₂)_m-NR¹⁰-C(O)-(CH₂)_n-,
 -(CH₂)-S-(CH₂)_n-, -(CH₂)_m-C(O)-(CH₂)_n-, -(CH₂)_m-SO₂-NR¹⁰-(CH₂)_n-,
 10 -(CH₂)_m-NR¹⁰-SO₂-(CH₂)_n-, -(CH₂)_m-NR¹⁰-SO₂-NR¹⁰-(CH₂)_n or
 -(CH₂)_m-SO₂-(CH₂)_n-,
 wherein n, m, and R¹⁰ are as defined above

V is 1. a direct bond,
 2. -(C₁-C₄)-alkylene, which is branched or unbranched and which is
 15 unsubstituted or mono-, di- or trisubstituted independently of one
 another by halogen, =O, -CN, -NR⁴R⁵, -C(O)-OH, -C(O)-O-(C₁-C₄)-
 alkyl, -SO₂-NR⁴R⁵, -C(O)-NR⁴R⁵ or -(C₁-C₄)-alkylsulfonyl,
 3. a 5- to 7-membered cyclic group, containing up to 1, 2, 3 or 4
 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said
 20 cyclic group is unsubstituted or mono-, di- or trisubstituted
 independently of one another by R¹⁴,
 4. a 6- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di-
 or trisubstituted independently of one another by R¹⁴, or
 25 5. a 6- to 14-membered heteroaryl, wherein said heteroaryl is
 unsubstituted or mono-, di- or trisubstituted independently of one
 another by R¹⁴,

R¹⁴ is halogen, -OH, -NR⁴R⁵, =O, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkoxyl, -NO₂,
 -C(O)-OH, -CN, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵, -(C₁-C₈)-alkylsulfonyl,
 -C(O)-NR⁴R⁵, -SO₂-NR⁴R⁵, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH-[(C₁-C₈)-
 30 alkyl]₂, -NR¹⁰-C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH₂ or -NR¹⁰-C(O)-NH-[(C₁-
 C₈)-alkyl]₂, wherein R⁴, R⁵ and R¹⁰ are as defined above, and

M is 1. a hydrogen atom,

2. $-(C_1-C_4)\text{-alkyl}$, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,
3. $-C(O)\text{-NR}^4R^5$,
4. $-(C_6-C_{14})\text{-aryl}$, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,
5. $-(C_6-C_{14})\text{-heteroaryl}$, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,
6. a 5- to 7-membered cyclic group, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} , or
- 10 7. a 5- to 7-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} , wherein R^{14} is defined above.

15

6. A compound of the formula I as claimed in one or more of claims 1 to 5, wherein R^0 is phenyl, wherein phenyl is unsubstituted or mono- or disubstituted independently of one another by R^2 , or
- 20 pyridyl, wherein pyridyl is unsubstituted or mono-, disubstituted independently of one another by R^2 ,

R^2 is halogen, $-CN$, $-C(O)\text{-NH}_2$, $-(C_1-C_3)\text{-alkyl}$, or $-(C_1-C_3)\text{-alkyloxy}$, wherein the alkyl- or alkyloxy residue is unsubstituted or mono-, di- or trisubstituted independently of one another by an amino residue or a methoxy residue, Q and Q' are independently of one another identical or different and are a direct bond, $-C(O)\text{-}$; $-O\text{-}$, $-NR^{10}\text{-}$, $-C(O)\text{-NR}^{10}\text{-}$, $-NR^{10}\text{-C}(O)\text{-}$, $-SO_2\text{-}$, $-NR^{10}\text{-SO}_2\text{-}$, $-SO_2\text{-NR}^{10}\text{-}$, or $-(C_1-C_4)\text{-alkylene}$,

X is a direct bond or $-(C_1-C_3)\text{-alkylene}$,

provided that when Q or Q' is $-(C_1-C_3)\text{-alkyl}$ then X is $-O\text{-}$, $-NR^{10}\text{-}$, $-C(O)\text{-}$, $-C(O)\text{-NR}^{10}\text{-}$, $-NR^{10}\text{-C}(O)\text{-}$, $-SO_2\text{-}$, $-NR^{10}\text{-SO}_2\text{-}$ or $-SO_2\text{-NR}^{10}\text{-}$;

25 with the proviso that if X is a direct bond, the fragment $-Q\text{-}X\text{-}Q'$ is not $O\text{-}O$ or $SO_2\text{-}SO_2$; and with the proviso that if X is oxygen atom, then Q and Q' are not oxygen atom or sulphur atom; and

30 with the further proviso that if X is SO_2 , then Q and Q' are not oxygen atom or sulphur atom;

W is phenyl or pyridyl, wherein W is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,

provided that Q' and U are not in an ortho position with respect to each other;

R¹ is 1. halogen,

5 2. -NO₂,

3. -CN,

4. -NH₂,

10 5. (C₁-C₄)-alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

6. -OH,

7. -SO₂-NH₂,

15 8. (C₁-C₄)-alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

9. (C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

20 10. (C₁-C₄)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

11. (C₁-C₄)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

25 12. bis[(C₁-C₄)-alkyl]amino, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

13. -C(O)-NH₂,

14. -C(O)-OH,

25 15. -C(O)-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

16. -C(O)-NH-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

30 17. -C(O)-NH-[(C₁-C₄)-alkyl]₂, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

18. -C(NH)-NH₂,

19. ureido,

20. -(C₁-C₄)-alkylthio, wherein alkylthio is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, or

21. R¹¹R¹²N-, or

two R¹ residues bonded to adjacent ring carbon atoms together with the carbon atoms to which they are bonded form an aromatic ring condensed to W, where the ring formed by the two R¹ residues is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, R¹¹ and R¹² together with the nitrogen atom to which they are bonded form a saturated or unsaturated 5- to 6-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R¹¹ and R¹² can contain one or two identical or different ring heteroatoms chosen from oxygen or nitrogen,

5 R¹³ is halogen, -CN, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkyloxy, -CF₃, -C(O)-NH₂ or -NH₂,

10 R¹⁰ is hydrogen atom or -(C₁-C₄)-alkyl,

U is a direct bond, -(CH₂)_m-, -(CH₂)_m-C(O)-NR¹⁰-(CH₂)_n-, -(CH₂)_m-NR¹⁰-C(O)-(CH₂)_n-, -(CH₂)_m-C(O)-(CH₂)_n-, -(CH₂)_m-SO₂-NR¹⁰-(CH₂)_n or -(CH₂)_m-NR¹⁰-SO₂-(CH₂)_n-,

15 n and m are independently of one another identical or different and are the integers zero, 1, 2 or 3, wherein the alkylene residues are unsubstituted or mono-, di- or trisubstituted independently of one another by -(C₁-C₄)-alkyl; -C(O)-OH, -C(O)-O-(C₁-C₄)-alkyl or -C(O)-NR⁴R⁵,

20 R⁴ and R⁵ are independently of one another identical or different and are hydrogen atom, -(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -(C₆-C₁₄)-aryl-(C₁-C₄)-alkyl-, wherein alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, -(C₆-C₁₄)-aryl-, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -(C₆-C₁₄)-heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³ or -(C₆-C₁₄)-heteroaryl-(C₁-C₄)-alkyl-, wherein alkyl and heteroaryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, or

25 R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a saturated 5- to 7-membered monocyclic heterocyclic ring which in addition to the nitrogen atom carrying R⁴ and R⁵ can contain one or two identical or different ring heteroatoms chosen from oxygen, sulphur and nitrogen;

30 wherein said heterocyclic ring is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

G is a direct bond, $-(CH_2)_m-$, $-(CH_2)_m-O-(CH_2)_n-$, $-(CH_2)_m-C(O)-NR^{10}-(CH_2)_n-$,
 $-(CH_2)_m-NR^{10}-C(O)-NR^{10}-(CH_2)_n-$, $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n-$, $-(CH_2)-S-(CH_2)_n-$,
 $-(CH_2)_m-C(O)-(CH_2)_n-$, $-(CH_2)_m-SO_2-NR^{10}-(CH_2)_n-$, $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n-$,
 $-(CH_2)_m-NR^{10}-SO_2-NR^{10}-(CH_2)_n-$ or $-(CH_2)_m-SO_2-(CH_2)_n-$,

wherein n, m, and R¹⁰ are as defined above

V is 1. a direct bond,

2. $-(C_1-C_4)$ -alkylene, which is branched or unbranched and which is unsubstituted or mono-, di- or trisubstituted independently of one another by halogen, =O, -CN, -NR⁴R⁵, -C(O)-OH, -C(O)-O-(C₁-C₄)-alkyl, -SO₂-NR⁴R⁵, -C(O)-NR⁴R⁵ or -(C₁-C₄)-alkylsulfonyl,

3. a 5- to 7-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

4. a 6- to 14-membered aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or

5. a 6- to 14-membered heteroaryl, wherein said heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R¹⁴ is halogen, -OH, -NR⁴R⁵, =O, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkoxyl, -NO₂, -C(O)-OH, -CN, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵, -(C₁-C₈)-alkylsulfonyl, -C(O)-NR⁴R⁵, -SO₂-NR⁴R⁵, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH-[(C₁-C₈)-alkyl]₂, -NR¹⁰-C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH₂ or -NR¹⁰-C(O)-NH-[(C₁-C₈)-alkyl]₂, wherein R⁴, R⁵ and R¹⁰ are as defined above, and

M is 1. a hydrogen atom,

2. -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

3. -C(O)-NR⁴R⁵,

4. -(C₆-C₁₄)-aryl, wherein aryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

5. -(C₆-C₁₄)-heteroaryl, wherein heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

6. a 5- to 7-membered cyclic group, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or
7. a 5- to 7-membered cyclic group, containing up to 1, 2, 3 or 4 heteroatoms chosen from nitrogen, sulphur or oxygen, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, wherein R¹⁴ is defined above.

- 5
7. A compound of formula I as claimed in one or more of claims 1 to 6, wherein
- 10 R⁰ is -(C₆-C₁₄)-aryl, wherein aryl is selected out of the group phenyl, naphthyl, biphenyl, fluorenyl and anthracenyl and is unsubstituted or mono- or disubstituted independently of one another by R², or -(C₆-C₁₄)-heteroaryl, wherein heteroarylaryl is selected out of the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, indole, isoindole, benzofuran, benzothiophene, 1,3-benzodioxole, indazole, chromane, benzimidazole, benzoxazole, benzothiazole, quinoline, isoquinoline, isochromane, cinnoline, quinazoline, quinoxaline, phthalazine, pteridine pyridyl, pyridopyridines, pyridoimidazoles, pyridopyrimidines and purine and is unsubstituted or mono- or disubstituted independently of one another by R²,
- 15
- 20
- 25
- R² is halogen, -CN, -C(O)-NH₂, -(C₁-C₃)-alkyl, or -(C₁-C₃)-alkyloxy, wherein the alkyl- or alkyloxy residue is unsubstituted or mono-, di- or trisubstituted independently of one another by an amino residue or a methoxy residue,
- Q is a direct bond
- 30
- Q' is -O-,
- X is -(C₁-C₃)-alkylene,
- W is -(C₆-C₁₄)-aryl, wherein aryl is selected out of the group phenyl, naphthyl, biphenyl, fluorenyl and anthracenyl, or

-(C₆-C₁₄)-heteroaryl, wherein heteroarylaryl is selected out of the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, indole, isoindole, benzofuran, benzothiophene, 1,3-benzodioxole, indazole, chromane, benzimidazole, benzoxazole, benzothiazole, quinoline, isoquinoline, isochromane, cinnoline, quinazoline, quinoxaline, phthalazine, pteridine pyridyl, pyridopyridines, pyridoimidazoles, pyridopyrimidines and purine, wherein W is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹,

provided that Q' and U are in a 1,2- or 1,3- substitution relationship with respect to each other; and further provided if Q' and U are in a 1,3- substitution relationship, the 2 position is unsubstituted,

R¹ is 1. halogen,

2. -NO₂,

3. -CN,

4. -NH₂,

5. (C₁-C₄)-alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

6. -OH,

7. -SO₂-NH₂,

8. (C₁-C₄)-alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

9. -(C₆-C₁₄)-aryl, wherein aryl is selected out of the group phenyl, naphthyl, biphenyl, fluorenyl and anthracenyl and is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

10. (C₁-C₄)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

11. (C₁-C₄)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

12. bis[(C₁-C₄)-alkyl]amino, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
13. -C(O)-NH₂,
14. -C(O)-OH,
- 5 15. -C(O)-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
16. -C(O)-NH-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
17. -C(O)-NH-[(C₁-C₄)-alkyl]₂, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,
- 10 18. -C(NH)-NH₂,
19. ureido,
20. -(C₁-C₄)-alkylthio, wherein alkylthio is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, or
- 15 21. R¹¹R¹²N-,

R¹¹ and R¹² together with the nitrogen atom to which they are bonded form a residue selected out of the group piperidine, morpholine, piperazine, thiomorpholine, pyrrolidine, pyrrolidinone and ketopiperazine

R¹³ is halogen, -CN, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkyloxy, -CF₃, -C(O)-NH₂ or -NH₂,

20 R¹⁰ is hydrogen atom or -(C₁-C₄)-alkyl,

U is -(CH₂)_m-C(O)-NR¹⁰-(CH₂)_n, wherein n and m are independently of one another identical or different and are the integers zero, 1 or 2,

R⁴ and R⁵ are independently of one another identical or different and are hydrogen atom, -(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -(C₆-C₁₄)-aryl-(C₁-C₄)-alkyl-, wherein aryl is as defined for W and alkyl and aryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, -(C₆-C₁₄)-aryl-, wherein aryl is as defined for W and is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -(C₆-C₁₄)-heteroaryl, wherein heteroaryl is as defined for W and is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³ or -(C₆-C₁₄)-heteroaryl-(C₁-C₄)-alkyl-, wherein heteroaryl is as defined for W and alkyl and heteroaryl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, or

R^4 and R^5 together with the nitrogen atom to which they are bonded form a residue selected out of the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine and 1,4-diazepine; wherein said residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{13} ,

G is a direct bond, $-(CH_2)_m$, $-(CH_2)_m-O-(CH_2)_n-$, $-(CH_2)_m-C(O)-NR^{10}-(CH_2)_n$, $-(CH_2)_m-NR^{10}-C(O)-NR^{10}-(CH_2)_n$, $-(CH_2)_m-NR^{10}-C(O)-(CH_2)_n$, $-(CH_2)_m-C(O)-(CH_2)_n$, $-(CH_2)_m-SO_2-NR^{10}-(CH_2)_n$, $-(CH_2)_m-NR^{10}-SO_2-(CH_2)_n$, $-(CH_2)_m-SO_2-(CH_2)_n$ or $-(CH_2)_m-NR^{10}-SO_2-NR^{10}-(CH_2)_n$,

wherein n , m , and R^{10} are as defined above

V is 1. a 5- to 7-membered cyclic group selected out of the group pyrroline, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, dihydropyridine,

tetrahydropyridine, piperidine, 1,3-dioxolane, 2-imidazoline, imidazolidine, 4,5-dihydro-1,3-oxazol, 1,3-oxazolidine, 4,5-dihydro-1,3-thiazole, 1,3-thiazolidine, perhydro-1,4-dioxane, piperazine, perhydro-1,4-oxazine, perhydro-1,4-thiazine, perhydroazepine, indoline, isoindoline, 1,2,3,4-tetrahydroquinoline and 1,2,3,4-tetrahydroisoquinoline, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,

2. $-(C_6-C_{14})$ -aryl, wherein aryl is selected out of the group phenyl, naphthyl, biphenyl, fluorenyl and anthracenyl and is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} , or

3. $-(C_6-C_{14})$ -heteroaryl, wherein heteroaryl is selected out of the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-

triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, indole, isoindole, benzofuran, benzothiophene, 1,3-benzodioxole, indazole, chromane, benzimidazole, benzoxazole, benzothiazole, quinoline, isoquinoline, isochromane, cinnoline, quinazoline, quinoxaline, phthalazine, pteridine pyridyl, pyridopyridines, pyridoimidazoles, pyridopyrimidines and purine, wherein said heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R^{14} ,

10 R¹⁴ is halogen, -OH, -NR⁴R⁵, =O, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkoxyl, -NO₂,
 -C(O)-OH, -CN, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵, -(C₁-C₈)-alkylsulfonyl,
 -C(O)-NH₂, -SO₂-NR⁴R⁵, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH-[(C₁-C₈)-alkyl]₂,
 -NR¹⁰-C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH₂ or -NR¹⁰-C(O)-NH-[(C₁-C₈)-alkyl]₂,
 wherein R⁴, R⁵ and R¹⁰ are as defined above, and

15 M is 1. a hydrogen atom,
2. -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
3. -C(O)-NR⁴R⁵,
4. a 5- to 7-membered cyclic group selected out of the group pyrrolidine, 20 pyrrolidone, tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, piperidine, 1,3-dioxolane, 2-imidazoline, imidazolidine, 4,5-dihydro-1,3-oxazol, 1,3-oxazolidine, 4,5-dihydro-1,3-thiazole, 1,3-thiazolidine, perhydro-1,4-dioxane, piperazine, perhydro-1,4-oxazine, perhydro-1,4-thiazine, perhydroazepine, 25 indoline, isoindoline, 1,2,3,4-tetrahydroquinoline and 1,2,3,4-tetrahydroisoquinoline, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
5. -(C₆-C₁₄)-aryl, wherein aryl is selected out of the group phenyl, naphthyl, biphenyl, fluorenyl and anthracenyl and is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
30 or
6. -(C₆-C₁₄)-heteroaryl, wherein heteroarylaryl is selected out of the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole,

isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, indole, isoindole, benzofuran, benzothiophene, 1,3-benzodioxole, indazole, chromane, benzimidazole, benzoxazole, benzothiazole, quinoline, isoquinoline, isochromane, cinnoline, quinazoline, quinoxaline, phthalazine, pteridine pyridyl, pyridopyridines, pyridoimidazoles, pyridopyrimidines and purine, wherein said heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

in all its stereoisomeric forms and mixtures thereof in any ratio, and its physiologically tolerable salts.

- 15 8. A compound of formula I as claimed in one or more of claims 1 to 7, wherein R⁰ is phenyl, wherein phenyl is unsubstituted or mono- or disubstituted independently of one another by R², or pyridyl, wherein pyridyl is unsubstituted or mono-, disubstituted independently of one another by R²,
- 20 R² is halogen or -CN,
Q is a direct bond
Q' is -O-,
X is ethylene,
- 25 W is phenyl or pyridyl, wherein W is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹, provided that Q' and U are in a 1,2- or 1,3- substitution relationship with respect to each other and the 2 position is unsubstituted,
- 30 R¹ is halogen, -NO₂, -CN, -NH₂, (C₁-C₄)-alkylamino-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -OH, -SO₂-NH₂, (C₁-C₄)-alkyloxy-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, (C₆-C₁₄)-aryl, wherein aryl is selected out of the group phenyl, naphthyl, biphenyl, fluorenyl and anthracenyl and is unsubstituted or mono-, di- or

trisubstituted independently of one another by R¹³, (C₁-C₄)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, (C₁-C₄)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

5 bis[(C₁-C₄)-alkyl]amino, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -C(O)-NH₂, -C(O)-OH, -C(O)-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -C(O)-NH-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

10 -C(O)-NH-[C(C₁-C₄)-alkyl], wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -C(NH)-NH₂, ureido, -(C₁-C₄)-alkylthio, wherein alkylthio is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, or R¹¹R¹²N-,

15 R¹¹ and R¹² together with the nitrogen atom to which they are bonded form a residue selected out of the group piperidine, morpholine, piperazine, thiomorpholine, pyrrolidine, pyrrolidinone and ketopiperazine

R¹³ is halogen, -CN, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkyloxy, -CF₃, -C(O)-NH₂ or -NH₂,

20 R¹⁰ is hydrogen atom or methyl,

U is -(CH₂)_m-C(O)-NR¹⁰-(CH₂)_n, wherein n is zero, 1 or 2, m is zero or 1,

R⁴ and R⁵ are independently of one another identical or different and are hydrogen atom, -(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -(C₆-C₁₄)-phenyl-(C₁-C₄)-alkyl-, wherein alkyl and phenyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, -(C₆-C₁₄)-phenyl-,

25 wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -(C₆-C₁₄)-heteroaryl, wherein heteroaryl is selected from the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine and 1,4-diazepine and is unsubstituted or mono-, di- or trisubstituted independently

of one another by R¹³ or -(C₆-C₁₄)-heteroaryl-(C₁-C₄)-alkyl-, wherein alkyl and heteroaryl are as defined above and independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, or

R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a residue selected out of the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine and 1,4-diazepine; wherein said residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

G is a direct bond, -(CH₂)_m, -(CH₂)_m-C(O)-NR¹⁰-(CH₂)_n, -(CH₂)_m-C(O)-(CH₂)_n, -(CH₂)_m-NR¹⁰-C(O)-NR¹⁰-(CH₂)_n, -(CH₂)_m-NR¹⁰-C(O)-(CH₂)_n, -(CH₂)_m-SO₂-NR¹⁰-(CH₂)_n or -(CH₂)_m-NR¹⁰-SO₂-(CH₂)_n,

wherein n, m, and R¹⁰ are as defined above

V is 1. a 5- to 7-membered cyclic group selected out of the group pyrrolidine, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, piperidine, 1,3-dioxolane, 2-imidazoline, imidazolidine, 4,5-dihydro-1,3-oxazol, 1,3-oxazolidine, 4,5-dihydro-

1,3-thiazole, 1,3-thiazolidine, perhydro-1,4-dioxane, piperazine, perhydro-1,4-oxazine, perhydro-1,4-thiazine, perhydroazepine, indoline, isoindoline, 1,2,3,4-tetrahydroquinoline and 1,2,3,4-tetrahydroisoquinoline, wherein said cyclic group is unsubstituted or

mono-, di- or trisubstituted independently of one another by R¹⁴,

2. -(C₆-C₁₄)-aryl, wherein aryl is selected out of the group phenyl, naphthyl, biphenyl, fluorenyl and anthracenyl and is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or

3. -(C₆-C₁₄)-heteroaryl, wherein heteroaryl is selected out of the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-

oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine, 1,4-diazepine, indole, isoindole, benzofuran, 5 benzothiophene, 1,3-benzodioxole, indazole, chromane, benzimidazole, benzoxazole, benzothiazole, quinoline, isoquinoline, isochromane, cinnoline, quinazoline, quinoxaline, phthalazine, pteridine pyridyl, pyridopyridines, pyridoimidazoles, pyridopyrimidines and purine, wherein said heteroaryl is unsubstituted or mono-, di- or trisubstituted independently of one 10 another by R¹⁴,

R¹⁴ is halogen, -OH, -NR⁴R⁵, =O, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkoxyl, -C(O)-OH, -CN, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵, -(C₁-C₈)-alkylsulfonyl, -C(O)-NH₂, -SO₂-NR⁴R⁵, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH-[(C₁-C₈)-alkyl]₂, wherein R⁴ or R⁵

15 are as defined above, and

- M is
1. a hydrogen atom,
 2. -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
 3. -C(O)-NR⁴R⁵,
 4. a 5- to 7-membered cyclic group selected out of the group pyrroline, pyrrolidine, tetrahydrofuran, tetrahydrothiophene, dihydropyridine, tetrahydropyridine, piperidine, 1,3-dioxolane, 2-imidazoline, imidazolidine, 4,5-dihydro-1,3-oxazol, 1,3-oxazolidine, 4,5-dihydro-1,3-thiazole, 1,3-thiazolidine, perhydro-1,4-dioxane, piperazine, perhydro-1,4-oxazine, perhydro-1,4-thiazine, perhydroazepine, indoline, isoindoline, 1,2,3,4-tetrahydroquinoline and 1,2,3,4-tetrahydroisoquinoline, wherein said cyclic group is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,
 5. -(C₆-C₁₄)-aryl, wherein aryl is selected out of the group phenyl, naphthyl, biphenyl, fluorenyl and anthracenyl and is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, or
 6. -(C₆-C₁₄)-heteroaryl, wherein heteroarylaryl is selected out of the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene,

dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole,
isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran,
thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-
oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-
triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-
diazepine, 1,4-diazepine, indole, isoindole, benzofuran,
benzothiophene, 1,3-benzodioxole, indazole, chromane,
benzimidazole, benzoxazole, benzothiazole, quinoline, isoquinoline,
isochromane, cinnoline, quinazoline, quinoxaline, phthalazine,
pteridine pyridyl, pyridopyridines, pyridoimidazoles,
pyridopyrimidines and purine, wherein said heteroaryl is
unsubstituted or mono-, di- or trisubstituted independently of one
another by R¹⁴,

in all its stereoisomeric forms and mixtures thereof in any ratio, and its
physiologically tolerable salts.

9. A compound of formula I as claimed in one or more of claims 1 to 8, wherein
R⁰ is phenyl, wherein phenyl is unsubstituted or mono- or disubstituted
independently of one another by R², or
20 pyridyl, wherein pyridyl is unsubstituted or mono-, disubstituted
independently of one another by R²,
R² is chlorine,
Q is a direct bond
Q' is -O-,
25 X is ethylene,
W is phenyl or pyridyl, wherein W is unsubstituted or mono-, di- or trisubstituted
independently of one another by R¹,
provided that Q' and U are in a 1,2- or 1,3- substitution relationship with respect to
each other and the 2 position is unsubstituted,
30 R¹ is halogen, -NO₂, -CN, -NH₂, (C₁-C₄)-alkylamino-, wherein alkyl is
unsubstituted or mono-, di- or trisubstituted independently of one another
by R¹³, -OH, -SO₂-NH₂, (C₁-C₄)-alkyloxy-, wherein alkyl is unsubstituted or
mono-, di- or trisubstituted independently of one another by R¹³, phenyl,

wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

(C₁-C₄)-alkyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, (C₁-C₄)-alkylsulfonyl-, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

bis[(C₁-C₄)-alkyl]amino, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -C(O)-NH₂, -C(O)-OH, -C(O)-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -C(O)-NH-(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³,

-C(O)-NH-[(C₁-C₄)-alkyl]₂, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -C(NH)-NH₂, ureido,

-(C₁-C₄)-alkylthio, wherein alkylthio is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, or R¹¹R¹²N-, R¹¹ and R¹² together with the nitrogen atom to which they are bonded form a residue selected out of the group pyridine, phenyl, pyrazine, pyrimidine, pyran, triazole, tetrahydropyridine, pyrrolidine, tetrazole, imidazole, imidazolin, furopyridine, cyclic guanidinium, pyrrolopyridine and oxadiazole,

R¹³ is halogen, -CN, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkyloxy, -CF₃, -C(O)-NH₂ or -NH₂,

R¹⁰ is hydrogen atom or methyl,

U is -(CH₂)_m-C(O)-NR¹⁰-(CH₂)_n, wherein n is zero, 1 or 2, m is zero or 1,

R⁴ and R⁵ are independently of one another identical or different and are hydrogen atom, -(C₁-C₆)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, -(C₆-C₁₄)-phenyl-(C₁-C₄)-alkyl-, wherein alkyl and phenyl independently from one another are unsubstituted or mono-, di- or trisubstituted by R¹³, -(C₆-C₁₄)-phenyl-, wherein phenyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, heteroaryl selected out of the group pyridine, pyrazine, pyrimidine, pyran, triazole, tetrahydropyridine, pyrrolidine, tetrazole, imidazole, imidazolin, furopyridine, cyclic guanidinium, pyrrolopyridine and oxadiazole, wherein heteroaryl is

unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³, or

R⁴ and R⁵ together with the nitrogen atom to which they are bonded form a residue selected out of the group aziridine, oxirane, azetidine, pyrrole, furan, thiophene, dioxole, imidazole, pyrazole, oxazole, isoxazole, thiazole, isothiazole, 1,2,3-triazole, 1,2,4-triazole, tetrazole, pyridine, pyran, thiopyran, pyridazine, pyrimidine, pyrazine, 1,2-oxazine, 1,3-oxazine, 1,4-oxazine, 1,2-thiazine, 1,3-thiazine, 1,4-thiazine, 1,2,3-triazine, 1,2,4-triazine, 1,3,5-triazine, azepine, 1,2-diazepine, 1,3-diazepine and 1,4-diazepine; wherein said residue is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹³

G is a direct bond, -(CH₂)_m, -(CH₂)_m-C(O)-NR¹⁰-(CH₂)_n, -(CH₂)_m-C(O)-NR¹⁰-(CH₂)_n, -(CH₂)_m-NR¹⁰-C(O)-(CH₂)_n, -(CH₂)_m-SO₂-NR¹⁰-(CH₂)_n or -(CH₂)_m-NR¹⁰-SO₂-(CH₂)_n,

wherein n, m, and R¹⁰ are as defined above


V is tetrahydropyridine, piperidine, phenyl, piperazine or wherein said groups are unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴,

R¹⁴ is halogen, -OH, -NR⁴R⁵, =O, -(C₁-C₄)-alkyl, -(C₁-C₄)-alkoxyl, -C(O)-OH, -CN, -C(O)-O-(C₁-C₄)-alkyl, -C(O)-NR⁴R⁵, -(C₁-C₈)-alkylsulfonyl, -C(O)-NH₂, -SO₂-NR⁴R⁵, -C(O)-NH-(C₁-C₈)-alkyl, -C(O)-NH-[(C₁-C₈)-alkyl]₂, wherein R⁴ or R⁵ are as defined above, and

M is a hydrogen atom, -(C₁-C₄)-alkyl, wherein alkyl is unsubstituted or mono-, di- or trisubstituted independently of one another by R¹⁴, -C(O)-NR⁴R⁵, or a residue out of the group consisting of pyridine, phenyl, pyrazine, pyrimidine, pyran, triazole, cyclohexyl, tetrahydropyridine, pyrrolidine, tetrazole, imidazole, imidazolin, fuopyridine, cyclic guanidinium, pyrrolopyridine or oxadiazole,

in all its stereoisomeric forms and mixtures thereof in any ratio, polymorph forms and mixtures thereof in any ratio and its physiologically tolerable salts.

10. A compound of formula II as claimed in one or more of claims 1 to 9,



wherein A is a carbon atom or a nitrogen atom, wherein the carbon atom can be unsubstituted or substituted by Cl, F or Br,

R1, R2 and R3 independent from each other are


hydrogen atom, F, Cl, -O-CH₃, -CH₃, -C(O)-N(CH₂-CH₃)₂, -C(O)-NH₂, or
-C(O)-NH-CH₂-piperidine-pyridine,

5

in all its stereoisomeric forms and mixtures thereof in any ratio, polymorph forms and mixtures thereof in any ratio and its physiologically tolerable salts.

11. A process for the preparation of a compound of the formula I as claimed in one or
10 more of claims 1 to 10, which comprises

a) wherein W is phenyl and U is -(CH₂)₀-C(O)NR¹⁰-(CH₂)₁-,
linking a compound of the formula XI,



15 wherein R⁰, Q, Q' and X are as defined in claims 1 to 9, or functional groups of the formula XI are precursor groups or are protected by protective groups, R^{1'}, R^{1''}, R^{1'''} and R^{1''''} are independently from each other hydrogen atom, R¹, which is as defined in formula I, precursor groups or can be protected by protective groups, and Y is a nucleophilically substitutable leaving group or a hydroxyl group, which may also be attached to a polystyrene resin,

20 with a compound of the formula XII



wherein R¹⁰, V, G and M are as defined in claims 1 to 9 or functional groups of the formula XII are precursor groups or protected by protective groups, or

- b) reacting a compound of the formula XII with a compound of the formula XIII
R⁰-Q-X-Q'-W-C(O)-Y (XIII)

wherein R⁰, Q, Q', X, W and Y are as defined in claims 1 to 9 or functional groups of the formula XIII are precursor groups or are protected by protective groups, and Y is a nucleophilically leaving group or a hydroxyl group, which may also be attached to a polystyrene resin.

10

12. A pharmaceutical preparation, comprising at least one compound of the formula I as claimed in one or more of claims 1 to 10 and/or its physiologically tolerable salts and a pharmaceutically acceptable carrier.

- 15 13. The use of a compound of the formula I as claimed in one or more of claims 1 to 10 and/or their physiologically tolerable salts and/or their prodrugs for the production of pharmaceuticals for inhibition of factor Xa and/or factor VIIa or for influencing blood coagulation or fibrinolysis.

- 20 14. The use as claimed in claim 13 for influencing blood coagulation, inflammatory response, fibrinolysis, cardiovascular disorders, thromboembolic diseases, restenoses, abnormal thrombus formation, acute myocardial infarction, unstable angina, acute vessel closure associated with thrombolytic therapy, thromboembolism, percutaneous, pathologic thrombus formation occurring in the veins of the lower extremities following abdominal, knee and hip surgery, transluminal coronary angioplasty, transient ischemic attacks, stroke, disseminated systemic intravascular coagulopathy occurring in vascular systems during septic shock, a risk of pulmonary thromboembolism, certain viral infections or cancer, intravascular coagulopathy occurring in vascular systems during septic shock, coronary heart disease, myocardial infarction, angina pectoris, vascular restenosis, for example restenosis following angioplasty like PTCA, adult respiratory distress syndrome, multi-organ failure, stroke and disseminated intravascular clotting disorder, thromboses like deep vein and proximal vein thrombosis which can occur following surgery.

25

30

INTERNATIONAL SEARCH REPORT

Inte	nal Application No
PCT/EP	01/14842

A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 C07D401/00 C07D213/30 C07D333/16 C07D333/58 A61K31/38
A61K31/435

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, WPI Data, PAJ, BIOSIS, BEILSTEIN Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category ^a	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HANESSIAN S S ET AL: "Exploring the chiral space within the active site of alpha-thrombin with a constrained mimic of d-Phe-Pro-Arg - design, synthesis, inhibitory activity, and X-ray structure of an enzyme-inhibitor complex" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 3, February 2000 (2000-02), pages 243-247, XP004188826 ISSN: 0960-894X *Scheme 3* abstract; examples 18-21 ---	1-14 -/-

Further documents are listed in the continuation of box C.

Patent family members are listed in annex.

^a Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

Date of the actual completion of the international search

1 March 2002

Date of mailing of the international search report

11.05.02

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Härtinger, S

INTERNATIONAL SEARCH REPORT

Inte	Application No
P	01/14842

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HOEKSTRA ET AL: "Potent, Orally Active GPIIb/IIIa Antagonists Containing a Nipecotic Acid Subunit. Structure-Activity Studies Leading to the Discovery of RWJ-53308" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 42, no. 25, 1999, pages 5254-5265, XP002142349 ISSN: 0022-2623 page 5254, left-hand column; examples 2,3; table 2 --- CAMPILLO N ET AL: "Novel Arylpyrazino[2,3-c][1,2,6]thiadiazine 2,2-Dioxides as Platelet Aggregation Inhibitors. 2." JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 42, 1999, pages 3279-3288, XP002181373 ISSN: 0022-2623 table 1 --- WALSER A ET AL: "TRIAZOLOBENZO- AND TRIAZOLOTHIENODIAZEPINES AS POTENT ANTAGONISTS OF PLATELET ACTIVATING FACTOR" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 34, no. 3, 1991, pages 1209-1221, XP000942214 ISSN: 0022-2623 example 1; tables --- DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER WISSENSCHAFTEN, FRANKFURT, DE; BRN 146145, XP002181378 abstract --- DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER WISSENSCHAFTEN, FRANKFURT, DE; BRN 8523212, XP002181379 abstract --- DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER WISSENSCHAFTEN, FRANKFURT, DE; BRN 4301943, XP002181380 abstract ---	1-14 1-14 1-14 1-14 1-14 1-14 1-14 1-14 1-14

INTERNATIONAL SEARCH REPORT

Inte	al Application No
PCT	P 01/14842

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	CHOI-SLEDESKI Y M ET AL: "Aminoisoquinolines: Design and Synthesis of an Orally Active Benzamidine Isostere for the Inhibition of Factor XA" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, no. 17, 6 September 1999 (1999-09-06), pages 2539-2544, XP004188859 ISSN: 0960-894X page 2540, line 1 - line 9; table 1 ---	1-14
X	MAIGNAN S J ET AL: "Crystal Structures of Human Factor Xa Complexed with Potent Inhibitors" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY, WASHINGTON, US, vol. 43, 24 August 2000 (2000-08-24), pages 3226-3232, XP002181374 ISSN: 0022-2623 table 1 ---	1-14
X	DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER WISSENSCHAFTEN, FRANKFURT, DE; BRN 95671, XP002181381 abstract ---	1-14
X	DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER WISSENSCHAFTEN, FRANKFURT, DE; BRN 8639815, XP002181382 abstract ---	1-14
Y	HE W ET AL: "Nonbenzamidine compounds as selective factor xa inhibitors" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 15, 7 August 2000 (2000-08-07), pages 1737-1739, XP004213235 ISSN: 0960-894X table 1 ---	1-14
X	OGINO T ET AL: "Discovery of FR115092: a novel antinephritic agent" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 8, no. 1-6, 6 January 1998 (1998-01-06), pages 75-80, XP004136626 ISSN: 0960-894X table 1 ---	1-14

-/-

INTERNATIONAL SEARCH REPORT

Int	nal Application No
F	EP 01/14842

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER WISSENSCHAFTEN, FRANKFURT, DE; BRN 7813412, XP002181383 abstract ---	1-14
X	DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER WISSENSCHAFTEN, FRANKFURT, DE; BRN 8658351, XP002181384 abstract ---	1-14
X	DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOEDERUNG DER WISSENSCHAFTEN, FRANKFURT, DE; BRN 1430606, XP002181385 abstract ---	1-14
X	DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOEDERUNG DER WISSENSCHAFTEN, FRANKFURT, DE; BRN 3069936, XP002181386 abstract ---	1-14
Y	PITTS W J ET AL: "Isoxazolines as Potent Antagonists of the Integrin alpha v beta 3" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, 2000, pages 27-40, XP002181375. ISSN: 0022-2623 figure 2; examples 3,15; table 1 ---	1-14
X	HERRON D K ET AL: "1,2-Dibenzamidobenzene Inhibitors of Human Factor Xa" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 43, 9 March 2000 (2000-03-09), pages 859-872, XP002181376 ISSN: 0022-2623 figure 1; examples 1-10; table 1 ---	1-14
	-/-	

INTERNATIONAL SEARCH REPORT

Int'l Application No
EP 01/14842

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	FUJIO M ET AL: "N-[1-(2-Phenylethyl)pyrrolidin-3-yl]-1-adamantanecarboxamides as novel 5-HT2 receptor antagonists" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 21, 6 November 2000 (2000-11-06), pages 2457-2461, XP004224239 ISSN: 0960-894X table 1 ---	1-14
X	EP 0 019 589 A (PENTAPHARM AG) 26 November 1980 (1980-11-26) example 29 ---	1-14
X	BAILEY P D ET AL: "How to make Drugs Orally Available" ANGEWANDTE CHEMIE. INTERNATIONAL EDITION, VERLAG CHEMIE. WEINHEIM, DE, vol. 39, no. 3, 4 February 2000 (2000-02-04), pages 506-508, XP002184168 ISSN: 0570-0833 example 4; table 1 ---	1-14
X	DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER WISSENSCHAFTEN, FRANKFURT, DE; BRN 8665019, XP002181387 abstract ---	1-14
X	OKADA Y ET AL: "Development of plasmin and plasma kallikrein selective inhibitors and their effect on M1 (melanoma) and ht29 cell lines" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 10, no. 19, 2 October 2000 (2000-10-02), pages 2217-2221, XP004212007 ISSN: 0960-894X table 2 ---	1-14
X	DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER WISSENSCHAFTEN, FRANKFURT, DE; BRN 8360262, XP002181446 abstract ---	1-14
	-/-	

INTERNATIONAL SEARCH REPORT

In Application No.
 PCT/EP 01/14842

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER WISSENSCHAFTEN, FRANKFURT, DE; BRN 8564005, XP002181447 abstract ---	1-14
Y	ROUSSEL P ET AL: "Inhibition of the Tissue Factor/Factor VIIa Complex - Lead Optimisation Using Combinatorial Chemistry" TETRAHEDRON, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 55, no. 19, 7 May 1999 (1999-05-07), pages 6219-6230, XP004164552 ISSN: 0040-4020 figure 2 ---	1-14
Y	DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER WISSENSCHAFTEN, FRANKFURT, DE; BRN 8511019, XP002181448 abstract ---	1-14
X	GB 2 011 892 A (SUMITOMO CHEMICAL CO) 18 July 1979 (1979-07-18) table 1 ---	1-11
X	US 4 309 212 A (TAKEMOTO ICHIKI ET AL) 5 January 1982 (1982-01-05) tables ---	1-11
X	DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER WISSENSCHAFTEN, FRANKFURT, DE; BRN 869622, XP002181449 abstract ---	1-11
X	DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER WISSENSCHAFTEN, FRANKFURT, DE; BRN 7062387, XP002181450 abstract ---	1-11
X	DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER WISSENSCHAFTEN, FRANKFURT, DE; BRN 8653610, XP002181451 abstract ---	1-11
		-/-

INTERNATIONAL SEARCH REPORT

Int'l Application No.
F 01, LP 01/14842

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER WISSENSCHAFTEN, FRANKFURT, DE; BRN 8326226, XP002181452 abstract -----	1-12
X	DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER WISSENSCHAFTEN, FRANKFURT, DE; BRN 8331996, XP002181453 abstract -----	1-12
X	DATABASE CROSSFIRE BEILSTEIN [Online] BEILSTEIN INSTITUT ZUR FOERDERUNG DER WISSENSCHAFTEN, FRANKFURT, DE; BRN 3582913, XP002191875 abstract -----	1-14

INTERNATIONAL SEARCH REPORT

tional application No.
PCT/EP 01/14842

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely:

2. Claims Nos.: **1(part)-14(part)** because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

see additional sheet

1. As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

1 (part) - 14 (part)

Remark on Protest

- The additional search fees were accompanied by the applicant's protest.
 No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 1(part)-14(part)

The initial phase of the search revealed a very large number of documents relevant to the issue of novelty. So many documents were retrieved that it is impossible to determine which parts of the claims may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT). For these reasons, a meaningful search over the whole breadth of the claims is impossible, and consequently, the search has been restricted.

Moreover, the present claims relate to an extremely large number of possible compound classes, ranging from peptides (eg. R QXQ'W = phe-pro) to nonpeptides, and from natural products (eg. QXQ'W = O-glucose) to synthetic compounds. Support within the meaning of Art. 5 PCT is to be found, however, for only a very small portion of the compounds claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported by the individual examples. With reference to the fact that the application lacks unity of invention, only those parts have been searched, which belong to the first mentioned group of inventions named in the annex to this search report. Within this already restricted group of the first group of inventions, the initial phase of the search revealed again a very large number of documents relevant to the issue of novelty, such that it is impossible to determine which parts of the claims may be said to define subject-matter for which protection might legitimately be sought (Article 6 PCT).

For the reasons given above the search had to be restricted to compounds of the Formula I or II, where R is selected from phenyl or pyridyl; QXQ' is an alkylene-oxygen linker; W is selected from phenyl and pyridyl.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1(part)-14(part)
compounds (I) of the type R -alkylene-O-W-UVGM
2. Claims: 1(part)-14(part)
compounds (I) of the type R -W-UVGM
3. Claims: 1(part)-14(part)
compounds (I) of the type R -CO-W-UVGM
4. Claims: 1(part)-14(part)
compounds (I) of the type R -S02-W-UVGM
5. Claims: 1(part)-14(part)
compounds (I) of the type R -S02NH-alkylene-W-UVGM
6. Claims: 1(part)-14(part)
compounds (I) of the type R -CONH-W-UVGM
7. Claims: 1(part)-14(part)
compounds (I) of the type R -O-W-UVGM
8. Claims: 1(part)-14(part)
compounds (I) of the type R -alkylenen-W-UVGM
9. Claims: 1(part)-14(part)
compounds (I) of the type R -alkylene-NHCO-W-UVGM
10. Claims: 1(part)-14(part)
peptide compounds (I) having W = prolyl
11. Claims: 1(part)-14(part)

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

compounds (I) of the type R -alkylene-O-alkylene-W-UVGM

12. Claims: 1(part)-14(part)

compounds (I) wherein QXQ' is different from above groups

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No	
PCT/EP 01/14842	

Patent document cited in search report	Publication date		Patent family member(s)	Publication date
EP 0019589	A 26-11-1980		AT 5254 T AU 547872 B2 AU 5990480 A CA 1161431 A1 WO 8002559 A1 DE 3065506 D1 DK 155781 A ,B, DK 509788 A ,B, EP 0019589 A1 ES 491376 D0 ES 8105865 A1 JP 1616944 C JP 2044839 B JP 62294695 A JP 1616945 C JP 2044840 B JP 62294696 A JP 1616946 C JP 2044518 B JP 62296899 A JP 1450372 C JP 57002253 A JP 62057197 B NO 811510 A ,B, IL 60000 A ZA 8002779 A	15-11-1983 07-11-1985 03-12-1980 31-01-1984 27-11-1980 15-12-1983 07-11-1981 13-09-1988 26-11-1980 16-05-1981 01-09-1981 30-08-1991 05-10-1990 22-12-1987 30-08-1991 05-10-1990 22-12-1987 30-08-1991 04-10-1990 24-12-1987 11-07-1988 07-01-1982 30-11-1987 09-11-1981 30-12-1983 24-06-1981
GB 2011892	A 18-07-1979		JP 54088231 A DE 2855699 A1 FR 2412520 A1 IT 1102412 B PL 212041 A1	13-07-1979 28-06-1979 20-07-1979 07-10-1985 25-02-1980
US 4309212	A 05-01-1982		JP 1349455 C JP 54115347 A JP 61013704 B JP 54117436 A JP 1303744 C JP 54079249 A JP 60030307 B AR 229391 A1 AU 522936 B2 AU 4105878 A BG 33731 A3 BR 7807054 A CA 1108184 A1 CH 641770 A5 CS 201516 B2 DD 139711 A5 DE 2846723 A1 DK 478078 A ES 474581 A1 ES 480717 A1 ES 480718 A1 FR 2407201 A1 GB 2010244 A ,B HU 177145 B IT 1160892 B	28-11-1986 07-09-1979 15-04-1986 12-09-1979 28-02-1986 25-06-1979 16-07-1985 15-08-1983 01-07-1982 01-05-1980 15-04-1983 10-07-1979 01-09-1981 15-03-1984 28-11-1980 16-01-1980 03-05-1979 27-04-1979 16-01-1980 16-08-1980 16-01-1980 25-05-1979 27-06-1979 28-07-1981 11-03-1987

INTERNATIONAL SEARCH REPORT

Information on patent family members

In: International Application No

I...EP 01/14842

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 4309212	A	MX	5191 E	21-04-1983
		NL	7810700 A	01-05-1979
		PL	210522 A1	11-02-1980
		US	4690709 A	01-09-1987
		YU	250478 A1	30-04-1983
		BE	871562 A1	26-04-1979
		ZA	7806041 A	31-10-1979